

SUBJECT REVIEW

The Dystonias

Edith G. McGeer and Patrick L. McGeer

Can. J. Neurol. Sci. 1988; 15: 447-483

Contents

1. Introduction
2. Histopathological and brain imaging studies
3. Sleep and other physiological studies
4. Chemical pathology
 - Brain studies
 - CSF studies
 - Blood studies
 - Urine studies
 - Fibroblast studies
 - Miscellaneous
5. Therapy
6. Iatrogenic dystonia
7. Possible animal models of dystonia
8. Summary

1. INTRODUCTION

Dystonia is a difficult problem for both the clinician and the scientist. It is sufficiently common to be seen by almost all physicians, yet uncommon enough to prevent any physician from gaining broad experience in its diagnosis and treatment. Each case represents a difficult challenge even to the specialist. The basic scientist is faced with investigating a disorder that is without relevant animal models and which is so rare that obtaining suitable tissue for study is a major obstacle. Dystonia may be idiopathic, or associated with lesions from many sources, including a variety of rare diseases. If idiopathic, it may be genetically transmitted or sporadic. If genetically transmitted, it may be generalized or focal, with symptoms varying in different members of the same family. It may be refractory to treatment, or it may respond to any one of a number of individual drugs that have very different mechanisms of action. For idiopathic dystonias, no clear method of genetic transmission has been established and no consistent pathology identified.

This review is intended for both the practitioner and the scientist. Its purpose is to summarize current knowledge regarding the various forms of dystonia, as well as the pathology known to produce the syndrome in specialized circumstances.

The low incidence of the disorder, its prolonged course, and the difficulty of accurate diagnosis has precluded the type of systematic investigation that is possible with many other disorders. Yet such systematic investigation is essential if the mysteries surrounding dystonia are to be unravelled and methods of treatment improved.

Dystonia has been defined by the Scientific Advisory Board of the Dystonia Medical Research Foundation as a syndrome of sustained muscle contraction, frequently causing twisting and repetitive movements, or abnormal posture. It is a clinical term and not a disease description. It refers to all anatomical forms, whether they involve generalized musculature or only focal groups. Although dystonia appears as part of the syndrome in a number of disease states, it is idiopathic dystonia, where inheritance is a major factor, that has aroused the greatest medical interest. This review emphasizes recent literature and those aspects which may contribute to an understanding of the underlying mechanisms of dystonic movement. Excellent reviews giving much more detail on historical aspects, clinical classification, differential diagnosis and therapy are available.^{e.g. 1-3}

One problem in the dystonic literature is the frequent existence of alternative names for the same syndrome; to help the reader with this problem we have described some of this nomenclature in Table 1.

Idiopathic Forms

Idiopathic forms may be familial or sporadic. The most important form of idiopathic dystonia is torsion dystonia (TD) which tends to be familial. The name is preferred to the classical term dystonia musculorum deformans (DMD).³⁹ It usually starts in childhood as a focal disorder which progresses overall but, in common with almost all dystonias, it is subject to exacerbations and remissions. The incidence of generalized dystonia is generally thought to be about 2-3 per million (Table 2) but this incidence can be expected to show considerable regional variation depending upon the genetic make-up of the population

From the Kinsmen Laboratory of Neurological Research, Department of Psychiatry, University of British Columbia, Vancouver

Reprint requests to: Edith G. McGeer, Kinsmen Laboratory of Neurological Research, Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall, Vancouver, British Columbia, Canada V6T 1W5

Table 1: Some Dystonia Subtypes and Alternative Nomenclature.

Adult-onset focal foot dystonia:	Much rarer than adult-onset dystonia of the upper limbs but does occur. ⁴⁻⁶ It may be a presenting feature in Parkinson's disease (see Table 3).
Azorean disease:	see Joseph's disease.
Blepharospasm:	Age of onset usually 5-6th decade, Female:Male ratio, 3:1 in 250 patients studied. ⁷ For review on etiology, diagnosis and treatment see Elston ⁸ .
Brueghel's syndrome:	see Meige's disease.
Cranial/cervical dystonia:	see Meige's disease.
Dystonic stridor:	Frequently thought hysterical but may be a form of segmental dystonia involving the vocal cords - seen in 2 cases of DOPA-treated Parkinsonism along with other symptoms of dystonia, ⁹ and in a case of idiopathic generalized dystonia. ¹⁰
Joseph's disease (Machado-Joseph disease, Azorean disease):	A familial, autosomal dominantly inherited disease with dystonia as a prominent symptom which was originally described in Portuguese families; may be associated with striatonigral and rubro-dentato degeneration. ¹¹ A number of variants may exist (see text and Table 3).
Grisel's syndrome (nasopharyngeal torticollis):	Nontraumatic atlanto-axial dislocation following inflammation in the naso-oro-pharyngeal region. ¹²
Machado-Joseph disease:	see Joseph's disease.
Manto syndrome:	Spasmodic torticollis with thoracic outlet syndrome. ^{13,14}
Meige's disease (Brueghel's syndrome, adult-onset idiopathic blepharospasm and/or oromandibular dystonia, focal cranial dystonia, cranial/cervical dystonia):	Meige's disease is probably most commonly used but is argued against because others, such as Brueghel, Wood and Black, each described it independently. ¹⁵⁻¹⁸ Age of onset generally after 50, more common in women than men, no defined pathology, symptoms disappear during sleep. ¹⁹ In 100 cases Jankovic and Ford ²⁰ found average age of onset 51.7, 60% female, and a high correlation with essential tremor, ²¹ other movement disorders and positive family histories. ²² It frequently begins with or involves other dystonic symptoms such as torticollis; the legs are seldom if ever involved. Tolosa ²³ reports not only a family history of dystonia or other extrapyramidal disorders but a high incidence of prior depression.
Musician overuse syndrome:	Focal dystonia in hand where pain is not present. It must be distinguished from muscle tendon overuse with pain. ²⁴⁻²⁹
Oromandibular dystonia:	See Meige's disease.
Pisa syndrome:	Tonic flexion to one side and slight rotation of the trunk, unaccompanied by other dystonic symptoms, sometimes seen after butyrophenones ^{30,31} or phenothiazines. ³²
Segawa's disease:	A fluctuating, usually hereditary dystonia with diurnal rhythm, responsive to DOPA and usually accompanied by parkinsonian symptoms (see text).
Spasmodic dysphonia:	Believed to be almost always a laryngeal/paralaryngeal movement disorder, frequently associated with Meige's disease. ³³⁻³⁵
Writer's cramp:	Again often associated with other features of segmented or generalized dystonia. ^{29,36-38}

Table 2: Prevalence and Incidence Figures for Idiopathic Dystonias*.

Region and Reference	Prevalence (Total Cases/million)			All Focal Dystonias	Incidence (New Cases Per Year/million)			
	Torsion Dystonia		Gen. Pop.		Torsion Dystonia		All Focal Dystonias	
	Ash. Jews	Sep. Jews			Ash. Jews	Sep. Jews	Gen. pop.	
U.S. ⁴⁰	25.2		2.99					
U.S. ⁴¹	59							
Israel ⁴²					4.82	1.05		
Israel ⁴³	22	1.5	10.8		0.98	0.11	0.43	
	52.5							
Israel ⁴⁴	43.5	8.6	24.2					
Rochester, Minn ⁴⁵			18	248			2	24

* Adapted from unpublished summary prepared by S.G. Diamond and C.H. Markham.

in question. In the generalized form, there may be widespread and differing dystonic movements and postures. However, the dystonic appearance in each body area is distinctive. "The eyes may screw shut (blepharospasm); the jaw may be forced open or closed with spasms of the mouth (oromandibular dystonia); the neck may twist (torticollis, retrocollis or antecollis); the trunk may bend (scoliosis, lordosis, or flexion); the arm may adopt a characteristic posture of hyperpronation, with flexed wrist and extended fingers, particularly during the act of writing (dystonic writer's cramp); or the leg may be extended with the plantar flexed and inverted, particularly when walking (the dystonic foot)".⁴⁶ Although torsion spasms (prolonged sustained muscle spasms which produce characteristic dystonic postures) or slow, sinuous writhing of distal parts of the limbs (athetosis) are often considered characteristic of dystonia, more rapid, irregular or repetitive movements (myorhythmia) or even brief, rapid, myoclonic jerks may occur.⁴⁷⁻⁴⁸ Postural or action tremor is also often seen. Although dystonic movements usually cease during sleep, certain postures may persist.

Autosomal dominant, autosomal recessive, X-linked recessive and sporadic forms of torsion dystonia have been described.⁴⁹⁻⁵⁰ It was initially felt that the Ashkenazim form was autosomal recessive⁵¹ but at present there is no consensus about the inheritance pattern, with many workers interpreting the evidence in both Jewish and non-Jewish families as being consistent with an autosomal dominant with reduced penetrance.^{44,45,52,53} Others interpret the evidence as indicating a recessive gene that shows "pseudodominance".⁵⁴ It is possible that both types of dystonic gene exist.⁵⁵ Bressman et al.⁵⁶ recently studied the pedigrees of 79 Ashkenazi patients with onset before age 27 and found the data for this early onset pattern consistent with an autosomal dominant transmission but with a minimum penetrance of only 31%. These hereditary cases typically begin in childhood and are usually progressive although Eldridge et al.⁴⁹ described a prolonged spontaneous remission in one identical twin of a 61 year female pair with a probable autosomal recessive form of the disease. Although the

maximum prevalence probably occurs in the Ashkenazim (Table 2), familial patterns have been described in American Indians, Japanese, Chinese, Arabs, South African colored⁵⁷ and Mexicans.⁵⁸

Considerable searching for an identifiable genetic marker in dystonia has taken place without success to date. Bressman et al.⁵⁹, assuming an autosomal recessive mode of inheritance for TD, found no linkage in 5 families, each including two affected siblings, with 18 marker systems, including HLA. Breakfield et al.⁶⁰ have used restriction length polymorphisms to work through about one-third of the human genome without finding evidence of linkage in families with TD. This, of course, cannot be taken as evidence against a genetic basis for the disease; it only indicates that possible genes have not yet been identified.

The X-linked form is clearly distinguishable on a genetic basis from the autosomal forms even though the clinical symptoms overlap. This form is relatively rare and has been described only on the Philippine Islands.⁶¹

In some families where a clear autosomal dominant form of inheritance can be established, affected children may have the generalized disease while some of the adults may present only with a focal dystonia.⁴⁶ Such mild, late onset cases are clearly a forme fruste of TD. Occasional cases have also been reported where more than one family member suffers from a form of focal dystonia such as writer's cramp⁶² or Meige's syndrome^{22,63} (Table 1). Severe dystonia was found in one family accompanied by ataxia telangiectasi.⁶⁴ The dystonia in this family, but not the ataxia, responded to bromocriptine. Tremor is frequent in affected families^{20,21,65} and may occur along with focal dystonia in individual patients.⁶⁶ Rare adult-onset forms are thought to be inherited as an autosomal dominant or to be sporadic.⁶⁷ In situations where there is late onset of focal dystonia, the disease tends not to spread to generalized dystonia.

Idiopathic spasmodic torticollis⁶⁸⁻⁷⁰ is the most common form of primary dystonia. An incidence of 3/10,000 is often quoted.⁷¹ Familial cases occasionally occur and an association with both benign essential tremor and Parkinson's disease has

been noted. Of 200 patients with essential tremor seen at an Italian Movement Disorder Center, 2 also had dystonia and 10 had buccolinguo-fascial dyskinesias.^{72,73}

In summary, every case of dystonia, including focal and late onset forms, should be investigated for a possible familial pattern. It can be anticipated that restriction fragment length polymorphic markers (RFLPs) will be identified for at least some forms of dystonia in the future and these will help to clarify the inheritance problem. Discovery of additional dystonia pedigrees would greatly assist in this endeavor.

Other Inherited or Idiopathic Movement Disorders with Dystonic Symptoms Idiopathic torsion and focal dystonias must be differentiated from other inherited movement disorders with a dystonic component, as well as from acquired cases. The latter may be a consequence of encephalitis, toxins or drugs (see Section 6); focal or generalized cerebral injury; infarcts; brain tumors; or even spinal malformations (see Section 2).^{74,75}

A syndrome of hereditary progressive dystonia with marked diurnal variations and frequent parkinsonian symptoms was first described by Segawa et al.⁷⁶ and is sometimes called the Segawa syndrome. It responds dramatically to L-DOPA and shows minimum progression in adult life, suggesting it is distinct from other forms of primary dystonia. Others have now reported similar cases in both juveniles and adults.⁷⁷⁻⁹² Some of the cases vary somewhat in the rhythm of fluctuation and symptomatology and may represent variant forms of the Segawa syndrome; all show the characteristic marked improvement on DOPA. Segawa originally postulated autosomal dominant inheritance with low penetrance for this disease. One family, which included five generations of members with juvenile dystonia-parkinsonism, appeared to conform to such a pattern.⁹⁴ Deonna⁹⁵ reported 9 sporadic and 11 familial juvenile cases with pedigrees that neither confirmed nor refuted Segawa's hypothesis.

Familial paroxysmal dystonia choreoathetosis (FPDC), a rare autosomal dominant disorder characterized by episodes of sustained generalized dystonic contractions of muscles without loss of consciousness, has been described in 6 families with over 73 affected members.⁹⁶⁻¹⁰² One of the victims in one family also had familial ataxia.¹⁰² Graff-Radford¹⁰³ described a possibly related family with recessively inherited ataxia and dystonic episodes. Plant et al.¹⁰⁴ reported still another family in which both mother and daughter showed paroxysmal dystonia induced by exercise though not by sudden movement; EEG recordings were normal during these attacks.

Willemse¹⁰⁵ reported 4 cases of idiopathic dystonia with onset in the first year of life; in contrast to childhood onset TD, the course for these infants was benign. He proposed that an imbalance in neurotransmitter development may be the underlying cause. Other cases of benign paroxysmal torticollis in infancy have also been reported¹⁰⁶⁻¹¹⁰ but they need to be carefully distinguished from iatrogenic forms which are particularly common in children¹¹¹ (see Section 6).

"Nocturnal paroxysmal dystonia" (NPD) is the name given to a syndrome characterized by sleep-related, short or long duration seizures with choreoathetoid, dystonic and ballistic movements.^{112,113} It has been identified in 14 patients. Lee et al.¹¹⁴ described a family with dystonic spasms occurring during non-REM sleep that may be another example of this disorder.

There is some debate as to whether this is a form of epilepsy or a new dystonic syndrome.¹¹⁵ EEG studies in a case reported by Godbout et al.¹¹⁶ favor the epileptic hypothesis but 5 cases reported by Lugaresi and Cirignotta¹¹⁷ showed no EEG abnormalities either during sleep or wakefulness.

In addition to these idiopathic dystonia variants, the syndrome may occur in association with other diseases (Table 3), including many which are genetically determined. It is a prominent symptom in Hallervorden-Spatz disease¹³⁴ and in Joseph's disease,^{11,217} two other hereditary, progressive neurodegenerative disorders. Dystonic symptoms are also frequently seen in various forms of gangliosidosis and in juvenile cases of Leigh's disease (an X-linked disorder of purine metabolism sometimes called infantile bilateral striatal necrosis).^{145,218-225} They have also been reported in some cases of homocystinuria^{167,168} as well as some other enzyme deficiency conditions (Table 3). As indicated in Table 3, several of these conditions have been linked to chromosomes X, especially the Xq28 region. Whether this has any relevance to the possible genetic linkage of any form of primary idiopathic dystonia remains to be determined. Table 3 also lists a variety of other conditions such as Wilson's disease, Parkinson's disease and progressive supranuclear palsy where associated dystonic symptoms have been reported. In instances where only one or two cases have been reported, coincidental association of rare diseases may be the explanation.

In summary, there are a number of identifiable variants of inherited dystonia to be considered in diagnosis, as well as its appearance as part of some disease with more generalized pathology.

Acquired

Delayed onset dystonia may appear 1 to 14 years after a non-progressive cerebral insult such as perinatal anoxia, trauma or cerebral infarction. Tudehope et al.²²⁶ reported that 18 of 117 babies with birth weight less than 1500 g showed dystonia. Symptoms resolved in 13 of them by 8-12 months, but 5 had major neurologic/intellectual problems at that age. Such delayed-onset dystonia following perinatal anoxia is an important diagnostic alternative to TD in childhood cases.^{227,228} Burke et al.²²⁹ suggested that the diagnosis of TD should not be made in the absence of a family history but that MRI scans may reveal striatal pathology in cases of dystonia consequent upon perinatal anoxia. Similarly, dystonia may develop late in cases of cerebral palsy.²³⁰ According to Kyllerman et al.²³¹⁻²³² dystonia occurred in 70% of a series of 116 cerebral palsy cases, with the rate for the dystonic form being 0.17/thousand births. Both Burke et al.²²⁹ and Treves and Korczyn²³⁰ suggested that a genetic tendency towards dystonia may also be triggered or worsened by perinatal factors.

Painful torticollis is seen in Grisel's syndrome where the underlying cause appears to be an infection in the nasopharyngeal region; this rare condition was seen somewhat more frequently in the pre-antibiotic period.^{12,233-235}

Epidemics of an acute torticollis have occurred in eastern and northern China since 1975, particularly among farmers in rural areas where it may affect up to 3% of the population. The individual episodes of spasmodic torticollis last generally for about 10 minutes but may persist for up to 24 hours; the episodes in most cases were seen over a 5-10 day period. The

Table 3: Some Other Diseases in Which Dystonic Symptoms Occur.

Joseph's disease (Machado-Joseph disease; Azorean disease)	A dominantly inherited multisystem disorder that occurs primarily in people of Azorean descent but has been described in non-Portuguese families. ^{118,119} Dystonia is seen as a variable symptom. ^{11,118-121} In single cases pathology is reported in CP, ¹¹ GP, ¹¹⁹ SNC, ¹¹ red n., ^{11,119} cerebellar dentate n. ^{11,119} and subthalamus. ¹¹⁹ Brain glutamate dehydrogenase and malate dehydrogenase activities are not abnormal. ¹²²
Lesch-Nyhan syndrome (and some other X-linked conditions)	Torsion dystonia seen in 8 patients; 1 on autopsy showed no brain histopathology but no HPRT activity. ¹²³ Testicular atrophy and partial failure of the 11 β -hydroxylation of steroids in 7 cases. ^{124,125} The HPRT gene has been assigned to locus Xq26-27.3. ¹²⁶ The closely related Xq28 is reportedly the locus for a syndrome of torticollis, cryptorchidism, keloids and renal dysplasia described by Goeminne ¹²⁷ in a large family and believed an X-linked, incomplete dominant. ¹²⁸ The Xq position has also been linked to Charcot-Marie-Tooth disease ¹²⁶ which is a hereditary motor and sensory neuropathies sometimes indexed under dystonia although it is not clear how frequent dystonic symptoms are seen. Others ^{129,130} have linked it to chromosome 1 and it may be a heterogeneous collection of genetic diseases of peripheral nerves.
Rett syndrome	An X-linked disease occurring in females, 1/8 cases showed progressive dystonia and the "hand-washing" automatisms characteristic of the disease ¹³¹ . More than 1000 cases have been recognized. ¹³² A genetic defect in synapsin I, a neuron-specific protein, has been suggested. ¹³³
Hallervorden-Spatz (HS)	Dystonia is an important feature. Involves deposition of iron-containing pigment and degeneration in GP and SN ¹³⁴ as well as red n. and dentate n. ¹³⁵ GP pathology is believed key. ¹³⁵⁻¹³⁸ Some cases also show putaminal pathology. ^{138,139} Sethi et al. ¹³⁶ suggested the syndrome may be more common than currently believed and that MRI may be helpful in making the diagnosis, but the occasional case with dystonic and parkinsonian symptoms may have normal CT and MRI. ¹⁴⁰ Cysteine accumulation in GP and cysteine dehydrogenase and GABA low only in GP in 2 cases. ¹⁴¹ One case with dystonia showed marked loss of DA in basal ganglia with no loss in limbic areas. ¹⁴²
Leigh's disease¹⁴³ Subacute necrotizing encephalopathy	Generalized TD is a frequent and may be the only ¹⁴⁴ symptom. Pathology in putamen ¹⁴⁵⁻¹⁴⁹ and may also involve whole CP ^{144,150} GP and SN. ¹⁵⁰ Clinical symptoms often divergent but histopathology always found in the caudate and sometimes the lenticular n., the mesencephalic tectum, tegmentum and periaqueductal gray. ¹⁴³ Plasma pyruvate and lactate elevated; ¹⁴⁴ four siblings described with no abnormality of pyruvate metabolism in serum or fibroblasts but marked elevation of CSF pyruvate and lactate, suggesting defect in oxidative metabolism limited to brain. ¹⁵¹ Cytochrome c deficiency appears important factor. ^{152,153}
Type III (adult) GM¹-gangliosidosis	Foot dystonia is often presenting symptom, progressing to generalized dystonia; improved markedly on trihexyphenidyl. In this condition there is a hereditary lack of lysosomal β -galactosidase. ¹⁵⁴ Dystonic symptoms seen in 3 members of a family with adult disease, pathology in autonomic neurons. ¹⁵⁵
Type III (juvenile)	Takamoto et al. ¹⁵⁶ report a case of juvenile β -galactosidase deficiency with dystonic movements, pyramidal symptoms and mental deficiency.
GM₂ gangliosidosis (hexosaminidase deficiency) (Tay-Sachs disease)	A 24 year old man presenting with dystonia, dementia, amyotrophy, choreoathetosis and ataxia was found to have a partial hexosaminidase deficiency. A review of the literature in this paper ¹⁵⁷ is used to suggest that dystonia and choreoathetosis may be neglected symptoms of chronic GM ₂ gangliosidosis and some cases have been reported with progressive dystonia as the dominant ¹⁵⁸ symptom or presenting ¹⁵⁹ symptom. Sibling of case of typical Tay-Sachs disease had normal hexosaminidase but microencephaly vera, progressive motor neuron disease and nigral degeneration associated with dystonia and an action tremor. ¹⁶⁰ Elwes & Saunders ¹⁶¹ report occurrence of torsion dystonia, focal dystonia and Sandhoff disease (a hexosaminidase deficiency) in a single family but this may represent chance association of rare diseases.
Ataxia-telangiectasia	Ten yr old male with familial disease and severe, progressive dystonic posturing ¹⁶² . cf64, 102, 103.
Schwartz-Jampel syndrome Metachromatic leucodystrophy	Blepharospasm and other abnormalities. Family reported indicates autosomal recessive. ¹⁶⁸ Dystonic symptoms seen in 3 siblings of Iranian ancestry ¹⁶⁴ and in a Jewish lady, ¹⁶⁵ biopsies proved reduced arylsulfatase A.
Triosephosphate isomerase deficiency	Two siblings had prominent progressive dystonia plus tremor, pyramidal signs and evidence of spinal cord motor neuron involvement as well as hemolytic anemia. Poll-The et al. ¹⁶⁶ reviewed 14 other cases in the literature and suggested specific involvement of basal ganglia, brainstem and/or spinal cord structures.
Homocystinuria	Occasional dystonic symptoms have been attributed to multiple multiinfarcts in the basal ganglia. ^{167, 168}
Glutaric acidemia (glutaryl-CoA-dehydro- genase deficiency)	Dystonia may be seen in this inherited disease characterized by defective metabolism of lysine, hydroxylysine and tryptophan ¹⁶⁹ 14/16 cases of this autosomal recessive disorder showed debilitating dystonia; 4 studied by CT (including 2 symptom-free cases) all showed bilateral frontotemporal atrophy. ¹⁷⁰ Loss of striatal neurons shown in 1 case on autopsy. ¹⁷¹

Progressive familial encephalopathy	Eight cases reported in infants showing bilateral spasticity and dystonia, acquired microcephaly, a rapid course to death, and various combinations of basal ganglia calcification and white matter densities with persistent lymphocytosis in the CSF. ¹⁷²
Methylmalonic acidemia	Child with bilateral dystonic posturing associated with lucencies in the GP. ¹⁷³
Hartnup disease	One case with dystonic posturing showed Purkinje and cortical neuronal loss. ¹⁷⁴ 17 month old reported with focal intermittent dystonia. ¹⁷⁵
Niemann-Pick disease (dystonic lipidosis)	⁷ / ₈ had low skin fibroblast sphingomyelinase. ¹⁷⁶ Variant in 43 yr old male ¹⁷⁷ and 2 siblings ¹⁷⁸ with dystonic symptoms but normal sphingomyelinase. Siblings showed pathology in many nuclei including cortex, basal ganglia and brainstem.
Familial apoceruloplasmin deficiency	Case of 52 yr old woman with blepharospasm and retinal degeneration, accumulation of Fe but not Cu in brain and liver shown. ¹⁷⁹
Wilson's disease	Of 31 patients, 65% show dystonia. Frequent MRI lesions in CP, midbrain, pons and subcortical white matter - dystonia correlated with putaminal lesions. ¹⁸⁰ PET-FDG study indicated less involvement of caudate than in HD but no involvement of putamen or GP. ¹⁸¹ Occurrence of generalized dystonia and whispering dysphonia. ¹⁸² Dystonia in single cases improved with trihexyphenidyl ¹⁸³ and worsened on initial penicillamine therapy. ¹⁸⁴ Others ^{185,186} observed cases of TD where there was cupruria and cases of TD occur in the same family with Wilson's disease and spasmodic stiff neck. ¹⁸⁷
Other disorders of Cu metabolism	10 yr old non-Jewish child with non-familial TD who had normal ceruloplasmin, only slight cupraemia but the brain on autopsy contained 3 times the normal amount of Cu - there was lipofuscin in cortical and CP neurons, chromatolysis and vacuolization of neurons in the basal nuclei, VL thalamus, cerebellar dentate and fronto-parietal cortex. ¹⁸⁸ A 15 year old with dystonic posturing and low serum and urine Cu, also low blood glutathione but no Kayser-Fleischer rings. ¹⁸⁹
Tyrosinosis	Infant showing blepharospasm and finger movements had markedly elevated (>4-fold) MHPG and HVA (>2-fold) levels in the CSF. ¹⁹⁰
Progressive supranuclear palsy (PSP, Steele-Richardson-Olszewski disease)	Review emphasizes axial dystonia as one of main symptoms - male predominance (60:40), average age of onset 60 years. ¹⁹¹ 8/30 show progressive limb dystonia ¹⁹² which may be an early symptom, ¹⁹³ as may blepharospasm. ^{194,195} PSP pathology involves basal ganglia, brainstem and cerebellum. ^{194,195} Several case reports suggesting that multiinfarcts involving the CP, GP, internal capsule, or midbrain (SN and subthalamus), especially in parkinsonian patients, may produce PSP symptoms. ^{196,197} Excessive yawning frequently seen is reduced or abolished by dopaminergic drugs; ¹⁹⁸ such yawning may indicate brainstem involvement. ¹⁹⁹
Parkinson's disease	Case having also hyperkalemic periodic paralysis (a dominantly inherited disorder). ²⁰⁰ A focal foot ²⁰¹ or other form of dystonia ²⁰² is sometimes seen as presenting feature. In some cases where dystonic symptoms occur first, they have been reported to decrease as the parkinsonism progresses and the two respond differently to DOPA. ^{203,204} Parkinsonian and dystonic features frequently occur together in Segawa's disease.
Tourette	28/29 Tourette patients had blepharospasm ²⁰⁵ and occasional cases with dystonia (4 out of 1377 reviewed) also show vocalizations similar to those in Tourette's disease. ²⁰⁶
Shy-Drager	Two cases of laryngeal stridor; histological examination ruled out motoneuron loss as cause — believe CNS defect. ²⁰⁷
Multiple sclerosis	Paroxysmal dystonia as initial manifestation in 8 patients with other symptoms developing as long as 10 years later. ²⁰⁸ 2 cases with bilateral blepharospasm. ²⁰⁹
Central pontine myelinolysis	Lesion in basal pons; case developed segmental dystonia several months after initial clinically apparent insult. ²¹⁰
Whipple's disease	Dystonic eye and jaw movements seen in two middle aged cases. ²¹¹
Paraneoplastic myeloradiculoneuropathy	Single case with retrocollis. ²¹²
Albinism	4 cases with torticollis and nystagmus. ²¹³
Scoliosis, camptodactyly	Occur in case of torticollis ²¹⁴
Multisystem mitochondrial cytopathy	¹ / ₂ cases had torsion dystonia but characteristic triad is ophthalmoplegia, retinitis pigmentosa and heart conditions. ^{215,216}

Abbreviations used: CP, caudate/putamen; GP, globus pallidus; SN, substantia nigra; SNC, SN, pars compacta; DA, dopamine; HPRT hypoxanthine-guanine phosphoribosyl transferase; HD, Huntington's disease; MHPG, 3-methoxy-4-hydroxyphenylglycol; HVA, homovanillic acid.

Table 4: Histopathological changes found by CT, MRI*, Histopathology or Pneumoencephalopathy*** in cases with Dystonic Symptoms (see also Table 3 for pathology in cases of dystonia associated with other diseases).**

Area of Lesion	Type of Case and Apparent Cause.
Calcification through brain, including basal ganglia	Female, aged 53, with idiopathic hypoparathyroidism showed writhing movements and parkinsonism. ²⁵⁹
Striopallidodentate calcification	1 case aged 5 had dystonia and normoparathyroidism, case aged 51 had hypoparathyroidism but no dystonia. ^{260**}
Basal ganglia calcification	In cases of paroxysmal dystonic choreoathetosis; ^{261**262**} in family showing TD with normal parathyroid function; ^{263**} in 2 of 12 children showing dystonia after perinatal anoxia; ²⁶⁴ in 70 yr female with bilateral dystonia and ballism; ²⁶⁵ in 23 yr old male with progressive hemidystonia after a head injury; ²⁶⁶ and in 2 sisters with autosomal recessive TD (see Section 6 for chemistry). ²⁶⁷ Rapid development with onset of abnormal movements in 58 yr old following anesthetic anoxia. ²⁶⁸
Corpus striatum, symmetrical infarcts	Young man with blepharospasm following hypoxic encephalopathy. ²⁶⁹
Basal ganglia infarcts	Children with hemidystonia after head injuries. ²⁷⁰
Basal ganglia hematoma	64 yr man with post-traumatic transient Meige which disappeared as hematoma resolved. ²⁷¹
Dorsal caudate and putamen	Filipino man, age 50, with 6 yr history of progressive dystonia. ^{272**}
Bilateral caudate, extending into putamen	Female with compulsive movements of hand. ²⁷³
Right lentiform n. and left basal ganglia infarcts	Left hemidystonia developed 2 yrs postinfarct in case later showing systemic lupus erythematosus. ²⁷⁴
Mild atrophy in frontal cortex, dentate, VL thalamus & CP	Case of torsion dystonia - no family history. ^{275**}
Caudate calcification	30 yr old man with progressive hemidystonia after a head injury. ²⁷⁶
Bilateral putaminal cystic lesions	30 yr old man with bradykinetic dystonia following methanol poisoning. ²⁷⁷
Bilateral putaminal hypodensities	3 cases with generalized dystonia; ²⁷⁸ 31 yr old man. with progressive generalized dystonic paraplegia and mental deficiency; not Wilson's disease. ²⁷⁹
Putaminal infarct	Progressive hemidystonia in 4 children ^{280,282} and 8 adults. ^{147*,281*,283-285}
Putamen, unilateral but extensive	Bilateral tardive dystonic movements in 61 yr M, probably an old infarction. ²⁸⁶
Astrocytoma in lentiform nucleus	Hemidystonia in 8 yr old. ²⁸⁷
Lentiform n., thalamus & borders of internal capsule	Young man with torsion dystonia following CO poisoning. ²⁸⁸
Left putamen & mild left frontal atrophy	2 cases of posthemiplegic hemidystonia. ²⁸⁹
Subdural hematoma	Hemidystonia. ²⁹⁰
Arteriovenous malformation (AVM) in contralateral cerebral hemisphere	2 cases of progressive hemidystonia; in only 1 did the AVM obviously involve the basal ganglia. ²⁹¹
Cortex & (in 1 case) PL thalamus, not striatum	2 cases of posthemiplegic dystonia. ²⁹²
Mildly atrophic cortex	Spasmodic torticollis. ^{293***}
Mildly atrophic frontal cortex	3 of 5 cases of Meige. ^{294***}
Slight cortical atrophy	7/15 cases of spasmodic torticollis. ²⁹⁵
PL thalamic infarction	22 yr F with delayed onset hemidystonia. ²⁹⁶
Thalamic atrophy, no basal ganglia pathology	3 adults with posthemiplegic dystonia. ²⁸⁴
Thalamus, not striatum	Posttraumatic focal hemidystonia. ^{297**}
Unilateral thalamic infarct	Bilateral blepharospasm + hemidystonia in hand. ²⁹⁸
Bilateral PL thalamic	9 yr M with delayed onset dystonia. ²⁹⁹

Area of Lesion	Type and Apparent Cause.
Medial longitudinal fasciculus with hematoma	Post-traumatic dystonic posture. ³⁰⁰
Rostral brainstem infarcts	4 cases with bilateral blepharospasm. ²⁰⁹
Paraneoplastic brainstem	Acute dystonia. ³⁰¹
Brainstem	29 yr old man with TD had numerous neurofibrillary tangles (NFT) and mild neuronal loss in locus coeruleus, as well as some NFT in SNC, pedunculopontine n. and dorsal raphe; a 68 yr old man with Meige's syndrome had moderate to severe neuronal loss in several brainstem nuclei including those four. ^{255**}

torticollis is almost always preceded by chills, fever, malaise and increases in white blood cell count; thus, although the etiology is unknown, a viral infection is suspected. The EEG in all cases is normal.²³⁶ Fox²³⁷ reported a single case in a 3.5 year old female American which seemed to have a similar clinical course. The dystonia signs in the Chinese victims are usually dramatically relieved by intramuscular diazepam.

Komandenko et al.²³⁸ said that, in a series of 35 cases which included 28 patients with spastic torticollis and 7 with other extrapyramidal hyperkineses, one of the most frequent causes was a chronic encephalitis or other infectious process causing damage to extrapyramidal structures. The best treatment they found was repeated courses of dexamethasone in combination with antibiotics and vitamins. A number of cases of transient post-varicella lingual mandibular dystonia have been described²³⁹ and progressive dystonia is also seen in Sydenham's chorea.²⁴⁰

Association of Meige's disease or essential blepharospasm²⁴¹ with autoimmune disorders, including Sjogren's syndrome, has been reported. Blepharospasm may also occur or be exacerbated during worsening of underlying autoimmune disorders such as systemic lupus erythematosus²⁴² or myasthenia gravis.²⁴³ Some AIDS cases also show dystonia, accompanied by MRI-apparent lesions in the thalamus or frontal lobe.²⁴⁴

Stress is often a precipitating factor in blepharospasm,^{245,246} spasmodic torticollis,²⁴⁷ and other forms of dystonia, including neuroleptic-induced iatrogenic dystonia.²⁴⁸ This precipitating effect of stress may explain why dystonia is often seen shortly after peripheral trauma.^{249,250}

Dystonia has often been misdiagnosed as being of psychological origin.²⁵¹ Although most cases seem clearly neurological, occasional cases of factitious or hysterical dystonia are still reported.²⁵²⁻²⁵³

In summary, the possibility must be considered that in any given case the dystonia has been permanently or transiently acquired as a result of perinatal or other vascular, anoxic or traumatic lesion; or as a result of infection, autoimmune disease, stress, or even hysteria.

2. HISTOPATHOLOGICAL AND BRAIN IMAGING STUDIES

No consistent neuropathological abnormalities have yet been reported in the brains of patients who have died with idiopathic dystonias, whether hereditary or sporadic, generalized or focal.^{18,50,254,255} For example, Hornykiewicz et al.²⁵⁶ reported

no important histological changes in the basal ganglia, cortex, higher brainstem nuclei, locus coeruleus or raphe in two non-Jewish cases who began to develop dystonia at the ages of 5 and 7.5, one of whom had a family history of dystonia. There were some chemical abnormalities (see Section 4). Jankovic and Svendsen²⁵⁷ derived data consistent with the findings of Hornykiewicz et al. from a 68 year old woman who developed blepharospasm at age 61 with progressive development of other forms of cranial-cervical dystonia (Meige's syndrome). H & E, Bielschowsky's and Luxol fast blue stains of the cortex, hippocampus, striatum, globus pallidus, hypothalamus, thalamus, midbrain, pons, medulla and cerebellum revealed no abnormality.

While CT scans and postmortem pathological examinations have repeatedly found no abnormalities in most cases of either idiopathic dystonia²⁵⁸ or spasmodic torticollis,⁷¹ cases have been identified which are clearly associated with putaminal or thalamic lesions. Mild cortical atrophy or a brainstem lesion has been reported in other cases (Table 4).

In a review on dystonia with emphasis on Spanish contributions, Gimenez-Roldan and Barraquer-Bordas³⁰² said that Lopez-Aydllo and Sanz-Ibanez correlated symptomatic dystonia with contralateral putamen-caudate infarctions in 1956. Marsden et al.³⁰³ described 28 patients with focal (arm or leg) hemidystonia due to tumor, arteriovenous malformation, infarction, hemorrhage or hemiatrophy and reviewed 13 other such cases in the literature. In all cases the lesion responsible, as defined by CT scan or pathological examination, was in the contralateral caudate, lentiform nucleus (particularly the putamen), thalamus, or a combination of these structures.

Jankovic³⁰⁴ described a parkinsonian case with blepharospasm following thalamotomy and reviewed the literature on 14 cases of blepharospasm associated with basal ganglia, thalamus or brainstem lesions.

Lesions of the basal ganglia and/or thalamus are also prominent in many of the diseases which are associated with dystonic symptoms (cf Table 3). For example, CT and/or MRI scans have shown putaminal lesions in a number of cases of familial and spasmodic generalized dystonia with symptoms of other diseases such as Leigh's disease,^{145,147,149} or pigmentary degeneration of the retina (probably Hallervorden-Spatz).¹³⁹

Basal ganglia lesions may be more common than indicated by CT scanning. Quinn et al.³⁰⁵ reported a case of hemidystonia where the CT scan showed only minor asymmetry of the lateral ventricles, but where an MRI scan clearly revealed a large, well

defined, unilateral lesion affecting the basal ganglia.

Putaminal or striatal lesions do not always produce dystonia. For example, Larsen et al.³⁰⁶ described a family with a dominantly inherited condition that produced both dystonia and extensive calcification of the basal ganglia. However, calcification occurred without dystonia in some members, and dystonia without calcification in others. Caraceni et al.²⁶³ reviewed the literature on basal ganglia calcification and pointed out that not all of the cases showed dystonic symptoms.

Although dystonia seems the more usual symptom of putaminal pathology, Mas et al.³⁰⁷ reported a case of hemiballism with a CT-documented lacunar infarct in the contralateral lenticular nucleus, Gross³⁰⁸ described a case of hemiparkinsonism showing CT evidence of a giant aneurysm in the left lentiform region, and House and Hodges³⁰⁹ a male with large infarctions of the putamen and globus pallidus but no dystonic symptoms. In many cases where dystonic symptoms do appear as a result of basal ganglia lesions, there may be a delay of years between the insult and onset of symptoms. This implies the necessity of additional changes to a primary lesion being necessary to produce the decompensation causing dystonia.

Another possible site of involvement, particularly for spasmodic torticollis, is the vestibular complex. The occurrence of vestibular abnormalities in more than 70% of 35 patients with this form of dystonia in the absence of other otological or neurological symptoms has been considered as evidence of a primary involvement of the vestibular system.³¹⁰ Diamond et al.³¹¹ reported ocular counterrolling abnormalities in each of 8 patients with spasmodic torticollis; such abnormalities had previously been seen only in persons with brainstem problems. Since some of the patients also showed spontaneous vestibular nystagmus in the dark, Diamond et al. suggested an abnormality in central vestibular connections. Similar findings in Machado-Joseph disease have also been interpreted as indicating vestibular involvement.³¹² In animals vestibular lesions cause striking derangement of head position (Section 7).

Jankovic and Patel²⁰⁹ reported several cases of blepharospasm associated with rostral brainstem lesions and suggested a mechanism similar to that postulated for palatal myoclonus. Reports of further cases in which blepharospasm is associated with palatal myoclonus,^{313,314} communicating hydrocephalus,³¹⁴⁻³¹⁶ or other rostral brainstem disorders³¹⁷ reinforce their suggestion. Janati¹⁹⁴ argued that occurrence of both blepharospasm and torticollis in a 76 year old man with progressive supranuclear palsy indicates that these two forms of focal dystonia have a common pathophysiology involving the striatum and brainstem.

Dystonia may also occur as a result of peripheral lesions. In some patients with focal dystonia of the hand, electrophysiological studies have indicated the existence of a peripheral nervous system lesion.^{e.g.318-321} Many cases of torticollis are associated with congenital muscular problems or with spinal abnormalities.^{e.g.326-329} In some cases, the dystonia may be the cause rather than the effect. For example, spinal abnormalities may result from dystonic posturing rather than being responsible for producing it.^{e.g.330-332} Torticollis is sometimes associated with hiatus hernia and disappears on surgical repair of the hernia.³³³ Head tilt is often seen in cases with posterior fossa tumors³³⁴ and torticollis has been described with upper spinal

cord tumors, syringomyelia^{335,336} or as a posttraumatic sequel to insertion of a ventriculoperitoneal shunt.³³⁷

Torticollis in children may be caused by hemi-aplasia or hypoplasia of the atlas. It was reported to be corrected by surgery in 17 cases.³³⁸ Bagolini et al.^{339,cf340} described four cases of ocular torticollis resulting from plagiocephaly - i.e. premature union of the coronal sutures on one side.

Positron emission tomography (PET) studies with [¹⁸F]-fluoro-2-deoxyglucose (FDG) on 8 cases of asymmetric idiopathic dystonia showed no abnormality in 6; 3 of these patients had spasmodic torticollis and 3 had mild dystonia of the distal extremities. Two with severe dystonia involving the upper trunk and neck showed no abnormality in the caudate, putamen or thalamus but did show asymmetries of 18 and 21% in the sensorimotor cortex, with lower metabolism contralateral to the symptomatic side.³⁴¹ A further possible indication of involvement of the sensorimotor cortex is the report that regional cerebral blood flow, measured by PET, is consistently increased in that region contralateral to vibrotactile hand stimulation by 25±5% over that seen at rest in normal subjects, but only by 16±3% in dystonic patients.³⁴²

Another PET study with FDG on 16 cases of idiopathic spasmodic torticollis revealed no consistent significant focal abnormality but there was a bilateral breakdown of the normal relationships between the thalamus and basal ganglia, suggesting possible disruption of the pallidothalamic projections.³⁴³

A patient with trauma-induced hemidystonia showed decreased oxygen extraction and increased blood flow by PET in the contralateral basal ganglia.³⁴⁴

PET scanning of a case of hemidystonia with a well defined left basal ganglia lesion, revealed by MRI,³⁰⁵ showed enhanced radioactive uptake of ¹¹C-spiperone in that area, suggesting an increased density of dopamine receptors.

In one patient with a stroke-induced right putaminal lesion revealed by MRI, producing contralateral hemidystonia, the ¹⁸F-fluorodopa PET scan revealed only background activity in the lesioned putamen but normal activity in the ipsilateral caudate and entire contralateral striatum.²⁸⁵

In summary, idiopathic dystonia occurs in the absence of any lesion which can be defined either by standard postmortem pathological investigation or in vivo imaging. Some cases of dystonia show clear evidence of basal ganglia or thalamic lesions, but lesions of these areas do not always produce dystonia and, in circumstances where they do, there can be a prolonged time delay between appearance of the lesion and onset of symptoms. Dystonia can also be produced by peripheral lesions, and possibly by cortical or brainstem lesions.

3. SLEEP AND OTHER PHYSIOLOGICAL STUDIES

Dystonic movements, like most abnormal movements, generally cease during sleep. This is also true for acute neuroleptic-induced dystonia although such dystonic movements usually persist during lighter daytime sleep.²⁴⁸

Polysomnographic studies in 9 adults with TD and 9 healthy volunteers indicated that the patients slept poorly compared with controls. They showed pronounced high amplitude spindles that were continuous for all stage 2 and portions of stage 3 sleep, instead of spindles that became less frequent. The spin-

dles also did not show the characteristic diminution in amplitude with age. Other sleep parameters were also disturbed.^{345,346} In a case of TD showing similar poor sleep and spindle activity, a clinically successful unilateral thalamic operation led to a normalization of sleep parameters and a reduction of the high amplitude spindles.³⁴⁷

In a study of 27 cases of TD, patients were found to be slow in falling asleep and frequently wakened during the night. There was also a significant reduction in eye movements during REM sleep.³⁴⁸

Narayan et al.³⁴⁹ studied multimodality evoked potentials in 10 patients with idiopathic spasmodic torticollis. They found no abnormalities and concluded that the lesion does not discernibly involve the visual, auditory or somatosensory pathways. However, Disertori et al.^{13,14} studied auditory evoked potentials (BAEPs) in a case of apparent methylparathion toxicity which produced spasmodic torticollis with thoracic outlet syndrome, and found evidence of severe brainstem involvement. Both the neurophysiological and clinical pictures improved on 5-hydroxytryptophan. Abnormalities were also found in the BAEPs in 13 patients with tardive dystonia, suggesting pathology in the caudal or rostral pons, midbrain and/or thalamus. Patients on long-term neuroleptics without tardive dystonia had no such abnormalities.³⁵⁰ EEG changes in 32 patients with facial paraspasm were also interpreted to indicate involvement of nonspecific portions of the pontomesencephalic brainstem.³⁵¹

In patients with spasmodic dysphonia, Schaefer³⁵ reported evidence of impairment of somatic and visceral brainstem pathways; both the clinical signs and the brainstem findings appeared to stabilize after 3-5 years.

One case of paroxysmal dystonic choreoathetosis was shown to have a photically inducible epileptiform discharge, suggesting an epileptogenic basis for the disorder³⁵² but normal EEGs have been reported in other cases.¹⁰⁴

Some patients with an autosomal dominant inherited form of myoclonic dystonia had widespread symmetrical cortical events in the EEG which were time-locked to the muscle jerks. Ethanol gave dramatic relief.³⁵³

Blink rate, a reportedly useful index of central dopamine activity in parkinsonism and supranuclear palsy, is normal in dystonia.³⁵⁴

EMG studies have been reported to be normal in many cases of Meige's syndrome, spasmodic torticollis and other forms of dystonia, e.g.³⁵⁵⁻³⁵⁸ Thus, for example, normal electrophysiology in the corticomotoneuron path, as well as normal muscle spindles, were found in five cases of TD,³⁵⁹ indicating that the symptoms in TD result from delivery of abnormal central motor commands.

In summary, a few mild and poorly defined changes in physiological measures have been recorded in TD related to brainstem function but they have not been focussed on any specific lesion or any distinct anatomical region.

4. CHEMICAL PATHOLOGY

The literature on chemical pathology in dystonia is very sparse. Routine laboratory studies on blood, urine and CSF have been done in many cases without revealing any abnormality. Only two chemical studies appear to have been done on post-

mortem brain tissue and both were largely limited to the catecholamines. A few measurements of choline acetyltransferase (ChAT), glutamate and GABA in the cortex and basal ganglia were made in two cases. Even the literature on CSF and blood studies is almost entirely concerned with the aromatic amine neurotransmitters; hence an enormous amount of exploration remains to be done.

Brain Studies

In two non-Jewish TD cases with onset at ages 5 and 7.5, Hornykiewicz et al.²⁵⁶ reported ChAT, GABA and glutamic acid to be within the control ranges in the cerebral cortex and basal ganglia. However, noradrenaline (NA) levels in the lateral and posterior hypothalamus, mammillary body, subthalamic nucleus and locus coeruleus showed a marked and consistent decrease while those of the septum, thalamus, colliculi, red nucleus and dorsal raphe were increased. The serotonin (5HT) level was subnormal in the dorsal raphe but high in the globus pallidus, subthalamus and locus coeruleus. The dopamine (DA) level was subnormal in the nucleus accumbens and, in one of the two cases, in the striatum. The level of the 5HT metabolite, 5-hydroxyindoleacetic acid (5HIAA), was high in the globus pallidus, subthalamus and nuclei raphe centralis inferior and obscurus. The level of the DA metabolite, homovanillic acid (HVA), showed little consistent change in the regions examined. Unfortunately the interpretation of these data may be confused by the fact that both cases had been subjected to bilateral thalamotomies which were therapeutically ineffective.

Jankovic and Svendsen²⁵⁷ reported somewhat similar data from a 68 year old woman who showed blepharospasm at age 61 and progressive development of other forms of cranial-cervical dystonia (Meige's syndrome). Measurements of the monoamines suggested that both DA and NA might be markedly (3- and 2-fold, respectively) elevated in the red nucleus, NA might be elevated 4-fold in the substantia nigra (SN) and both DA and NA might be reduced (to about 40%) in some cortical areas. The levels of 5HT, 5HIAA, and HVA seemed about normal in all areas measured and 3-methoxy-4-hydroxyphenylglycol (MHPG, a NA metabolite) was normal in the putamen, red nucleus, SN and lateral globus pallidus but may have been elevated (2.5-fold) in the medial globus pallidus and in one cortical area (2-fold). In all of these cases, routine histopathology revealed no abnormalities.

It has been suggested that these abnormalities in the NA system may reflect an abnormal initial number of NA neurons. Another possibility is that the normal developmental pruning of some NA projections does not occur.

The report that most cases of idiopathic spasmodic torticollis show rotation of the head to the left³⁶⁰ has been taken to indicate that abnormal asymmetries in DA systems may be involved;³⁶¹ no experimental evidence relevant to this suggestion has yet been obtained.

Abnormal brain chemistry has been reported in some situations where dystonic symptoms occur as part of various inherited or acquired neurological diseases but the changes observed are not generally in specific neurotransmitter systems (see Table 3).

CSF Studies

Again, most studies have concentrated on the aromatic

amines and their metabolites and the results on lumbar fluid have generally indicated no consistent abnormality. Many peptides have not been measured in CSF and the reports on bipterin and neopterin abnormalities deserve more attention despite some inconsistent findings. The studies on ventricular fluid may be of special interest since some believe ventricular levels reflect primarily brain metabolism while lumbar levels emphasize spinal cord metabolism.

(1) Aromatic Amines and Metabolites: Low levels of DA and NA metabolites (HVA, MHPG) have been reported in ventricular fluid from cases of childhood-onset dystonia, with normal levels in other forms of dystonia (Table 5A).

A number of investigators have studied the levels of these metabolites (and of SHIAA) in lumbar fluid and, while there is some ambiguity, most appear to find normal levels (Table 5B).

(2) GABA: Based on a radioreceptor assay, CSF GABA levels in 6 cases of sporadic torticollis were found not to be significantly different from the levels in a group of 34 controls.³⁷⁶ In TD, no significant abnormality in CSF levels has been found for any of the commonly determined amino acids, including GABA,^{368,373} except for a modest reduction in ornithine.³⁷⁷

(3) Peptides: Thal et al.³⁷⁸ reported data on the concentration of somatostatin (SOM) in ventricular fluid (Table 6) which indicate significantly low levels in childhood onset dystonia. Cramer et al.³⁷⁹ found the concentrations of SOM in lateral ventricular fluid to be significantly lower in patients with dystonia or parkinsonism than in those with essential tremor. Since Fahn³⁷² has data indicating that lumbar CSF SOM levels are not abnormal in childhood onset dementia, Thal et al.³⁷⁸ suggested these results indicate a SOM abnormality limited to the basal ganglia. They also provided evidence in rats that SOM does not cross the blood/brain barrier. No correlation was found in any group between SOM levels and age. Levels of some other peptides (AVP, TRH, ACTH and CCK) in the CSF in TD appear to be normal.³⁷²

(4) Other: Cullis et al.³⁸⁰ reported that a CSF protein pattern differing from controls was seen in 11 out of 12 patients with spasmodic torticollis. In 2 of the cases there appeared to be abnormal staining for IgG bands and in 7 there was abnormal staining for ceruloplasmin.

LeWitt et al.^{381,382} found CSF levels of total bipterin substantially lower in 8 untreated patients with dystonia (aged 20-

Table 5: Studies on Aromatic Amine Metabolites in CSF.

A. Ventricular Fluid (nmol/liter; number of cases in parentheses).

Disease	MHPG ³⁶²	HVA	SHIAA
Dystonia:			
Childhood onset	8.7 ± 0.6* (9)	1510 ± 478(14) ³⁶³	429 ± 125(14) ³⁶³
Adult Onset	11, 14	984 ± 368(6) ³⁶³	340 ± 120(6) ³⁶³
Unclassified	11.3 ± 0.3 (3)		
Symptomatic	10.8 ± 1.9 (5)		
TD - mainly hyperkinetic		1031 ± 89 ³⁶⁵	
- other		393 ± 51 ³⁶⁵	
Cerebral palsy	15.7 ± 1.8* (6)	1280 ± 77(7) ³⁶⁴	387 ± 68(7) ³⁶⁴
Parkinsonism		227 ± 17 ³⁶⁵	
		654 ± 209(5) ³⁶⁴	408 ± 152(5) ³⁶⁴
Controls	11.7 ± 1.1 (9)	1275 ± 192(7) ³⁶⁶	
		1346 ± 504(37) ³⁶⁷	

B. Lumbar Fluid**

Type of Case	HVA	DOPAC	MHPG	DBH	SHIAA	Ref.
9 cases, all non-familial	N	N	N		N	368
5 cases, idiopathic dystonia-parkinsonism	N				N	87
7 cases, sporadic juvenile distal dystonia	N			N	N	369
8 cases, dystonia			N			370
3 cases, torsion dystonia	N				N	371
many, torsion dystonia	N	N	N		N	372
1 case, childhood onset			L			373
1 infant, benign idiopathic dystonia	H?		N		N	105
1 case, action-induced rhythmic dystonia	H				L	378
5 Joseph disease and 1 family member at risk	L					11
1 Segawa disease	L				L	375

* Significantly different from control.

** Examples of literature, more exists. N = normal, L = low, H = high, H? = possibly high but control values not available for age group.

Table 6: Concentration of SOM in ventricular and lumbar fluid³⁷⁸

Disease	Age	N	SOM pg/ml, mean \pm SEM
Dystonia, childhood onset	19 (7-66)	18	20.1 \pm 1.6*
adult onset	45 (33-56)	12	30.3 \pm 3.5
symptomatic	29 (16-56)	6	37.9 \pm 5.8
Multiple sclerosis with tremor	37 (21-66)	18	23.6 \pm 4.0
Parkinson's	57 (41-72)	33	25.9 \pm 1.8
Epilepsy	24 (22-28)	8	26.0 \pm 4.9
Epilepsy (lumbar fluid)	30 (16-71)	12	23.3 \pm 3.0
Multiple sclerosis (lumbar)	41 (19-60)	21	27.6 \pm 3.3
Alzheimer's disease (lumbar)	65 (49-79)	18	34.2 \pm 3.4
Controls (lumbar)	40 (16-78)	9	35.4 \pm 3.8

* $p < 0.001$ vs symptomatic dystonia and lumbar controls; $p < 0.01$ vs adult onset dystonia and $p < 0.05$ vs Parkinson's disease.

63 years) than in normal controls (ages 20-77 years (12.6 ± 0.9 vs 20.5 ± 1.5 pmol/ml). However, others^{372,383} found normal levels in TD with the exception of one family. Williams et al.³⁸⁴ had previously described low tetrahydrobiopterin levels in some cases of inherited dystonia but normal levels in torticollis.³⁸⁵ Generalized dystonia with marked diurnal fluctuations like these in Segawa's syndrome has been associated with a significant biopterin deficiency in five cases; four of these also showed low CSF neopterin levels. The HVA and 5HIAA levels were either normal or reduced.⁹³ Tanaka et al.³⁸⁶ found large amounts of neopterin with only a trace of biopterin in a 27 year old man with deficient dihydrobiopterin synthesis who showed dystonia along with mild mental retardation, rigid spasticity, hyperreflexia and myoclonus. CSF levels of HVA and 5HIAA were low.

Mehta et al.³⁸⁷ reported a family in which association of hyperuricaemia and increased CSF uric acid was noted in two members who had classical TD. Other members of the family with no clinical evidence of TD, however, also showed increased serum and CSF uric acid. It is possible that these were cases of the Lesch-Nyhan syndrome (Table 3). Disturbed purine metabolism is part of that disorder. Coleman³⁸⁸ described a case with a mixed movement disorder, predominantly of a dystonic type, but also including choreic symptoms, who showed hyperuricaemia.

Trace element concentrations in CSF are reported as normal in TD.³⁷²

Blood Studies

Early reports^{389,390} of elevated blood DBH in dystonics aroused considerable interest but subsequent data suggest this is not a consistent finding and the results may have depended on other factors. It is known that DBH is under close genetic control and unaffected family members, as well as patients with both the non-Jewish ("dominant") and Jewish ("recessive") forms of the syndrome, were reported to have higher DBH activities than age- and sex-matched normal school children.³⁹¹ Plasma DBH and melatonin and urinary melatonin were measured in 10 Jewish and 9 non-Jewish patients with idiopathic TD and in 22 nondystonic family members; there was no signif-

icant difference between the groups.³⁹² Other studies have found plasma DBH in dystonics to be high, normal or low. Korczyn et al.³⁹³ found normal levels in 25 Jewish patients suffering from TD, Eldridge et al.⁴⁹ reported normal levels of NA and DBH in the plasma of 2 twins with a probable autosomal recessive form of TD, and Busard et al.³⁶⁹ found normal levels in 7 cases of sporadic juvenile distal dystonia. However, Hirase et al.²⁶⁷ reported low plasma DBH in two sisters with autosomal recessive TD. Friedman and Mendlewicz³⁹⁴ studied plasma DBH in the probands with spasmodic torticollis and sibs in 4 families. They found normal values in 3 families having only one affected member, while in one family with two affected siblings, the plasma DBH was higher in the probands than in the non-affected sibs (145.5 and 125.5 vs 65.5 nmol/ml-min). They suggested there might be two forms of spasmodic torticollis: a genetic form probably linked to familial TD with altered DBH, and a non-familial sporadic form with normal DBH.

Platelet 5HT concentration and uptake was studied in 11 Jewish cases of idiopathic TD. Levels and the V_{max} for uptake were normal, as was the K_i for inhibition of uptake by imipramine, but the K_m for uptake was significantly higher in dystonics as compared with controls (2.59 ± 0.86 vs 1.40 ± 0.39 mM).³⁹⁵

Erythrocyte acetylcholinesterase has been reported as normal in dystonia.³⁹⁶

Serum calcium levels were normal in 17 psychotic patients exhibiting neuroleptic-induced acute dystonic reactions.³⁹⁷ Borisova³⁹⁸ reported that blood Mn levels were high in 23 cases of TD, while Fe and Zn appeared normal.

Gannushkina et al.³⁹⁹ counted T- and B-cells in blood of 37 patients with various hereditary diseases of the nervous system including TD and 22 healthy controls. They found in all the diseases a drop in the content of thymus-dependent lymphocytes and an increase in the capacity of lymphocytes for complementary rosette formation. They proposed the existence of a secondary immunodeficient state, possibly determined by metabolic abnormalities, in hereditary nervous system diseases. Moore et al.⁴⁰⁰ also reported a significant decrease of both helper and suppressor lymphocytes in 11 cases of spasmodic torticollis.

In a study of 67 cases of idiopathic dystonia, no significant linkage was found with any of the HLA A, B and C subtypes; however, 13 patients with idiopathic TD showed a trend towards the DR3 subtype.^{401,cf59}

Urine Studies

According to Aggarwal et al.⁸⁸, cases of TD showed no increase in HVA or VMA and little increase in DOPAC after a dose of L-DOPA, while a case of progressive dystonia with marked diurnal fluctuations showed increases in HVA and DOPAC but little or no change in VMA and 5HIAA.

A Russian group⁴⁰² reported decreased DOPA excretion in most cases of TD while others^{403,404} report decreased excretion of DA metabolites in some but not all types. Iadgarov⁴⁰⁵ said there was increased excretion of DA in TD with a possible disruption in the diurnal excretion rhythm.^{cf404}

Phenylacetylglutamine (PAG) is a major product of phenylalanine. Melnichuk et al.⁴⁰⁶ measured it in urine of various kinds of hyperkinetic children and found:

Controls 200 mg/day Torsion dystonia 274 ± 60 (N=15)
Tourette 47 ± 5; (N = 26) Tic hyperkinesia 232 ± 40 (N=15)
Infantile cerebral palsy with dystonia 250 ± 20 (N=15)

They interpreted these data to indicate excessive utilization of phenylalanine in the metabolic route to tyrosine and catecholamines in Tourette and under-utilization in TD, resulting in the changes seen in the alternative PAG route. Therefore they gave phenylalanine to Tourette cases to act as a feedback inhibitor of both phenylalanine and tyrosine hydroxylases and glutamine to TD cases to try to detoxify excess phenylpyruvic acid. They claimed improvement in both situations. Note, however, that dystonic symptoms are frequently seen in the Tourette syndrome and the link between the results reported and changes in DA synthesis are highly speculative.

A complication of dystonia may be myoglobinuria from excessive muscular use.⁶⁵

Fibroblast Studies

Average activity of catecholamine-0-methyltransferase (COMT), a DA and NA metabolizing enzyme, in cultured skin fibroblasts from 8 patients with inherited TD did not differ significantly from the average in 16 controls and, in the controls, no variation was found with age or sex. Average activity of monoamine oxidase-A (MAO-A), another aromatic amine metabolizing enzyme, in 12 cell lines from patients with TD did not differ significantly from the average found in age- and sex-matched controls.⁴⁰⁷ Edelstein et al.⁴⁰⁸ had reported that MAO activity in cultured fibroblasts from dystonics tended to be low normal.

Cultured skin fibroblasts from patients with hereditary ("recessive") TD or adult-onset sporadic dystonia and from healthy volunteers were compared with respect to total cellular cholesterol, total phospholipids and phospholipid composition. Differences that could be attributed specifically to dystonia were not detected.⁴⁰⁹ And studies on samples from 4 patients with TD indicated no abnormality in the phosphoprotein phosphatase activity in fibroblast membranes.⁴¹⁰

Preliminary gel electrophoretic studies on 2 patients with Joseph's disease suggest possible abnormalities in the fibroblast proteins.¹¹

Miscellaneous

Korein^{411,412} said that dystonic disorders were rare among non-Caucasians and hypothesized that susceptibility might be linked to decreased melanin metabolism. In a study of 153 Caucasians with torticollis and other dystonias, he found significantly more light eyed than brown eyed people as compared with various control groups (Parkinsonians, cerebrovascular accidents, normals, tardive dyskinesics). In all the control groups except the last, there were more brown-eyed than blue/green/grey/hazel eyed subjects but in the dystonic group, the light eyes occurred in more than two-thirds of the total population of 153. The difference was the same if subgroups of Jewish or British descent were considered.⁴¹³

Lang et al.⁴¹⁴ studied dystonics and non-dystonics of British descent and found a greater proportion of light eyes in all groups. They felt their results did not support those of Korein although there was a significantly higher percentage of light eyes in the dystonics (82%) than in the controls (64%). But there was no significant difference between the dystonics and a group of Parkinsonians (71% light-eyed).

Nutt et al.⁴¹⁵ found a far greater percentage of thyroid disorders (both hypo- and hyper-) in 25 women with Meige's disease (51%) than in a similar group of age-matched women seen in a medical clinic (15%). No males in either group had thyroid disease. Lang⁴¹⁶ reported a family in which 5 of 7 siblings who survived into the 6th decade had a thyroid disorder and two of them had Meige's disease. Rosenfeld et al.³⁴ described hypothyroidism in a case of spasmodic dysphonia (often associated with Meige's syndrome). It is suggested that thyroid dysfunction may predispose one to Meige's disease. Possibly relevant findings are the occurrence of hypoplasia in rats showing a permanent movement disorder after a single peripheral dose of dimethylaminohexone reductase (Section 7), the association of basal ganglia calcification with parathyroid dysfunction (Table 4), and the report⁴¹⁷ that latent idiopathic TD may be provoked by thyrotoxicosis.

5. THERAPY

Pharmacological treatment of the dystonias is unpredictable and often disappointing. A wide variety of drugs - dopamine agonists and antagonists, acetylcholine agonists and antagonists, GABA agonists and miscellaneous compounds - have been tried in the primary dystonias; in general each type is successful in a small proportion of cases but the results are variable and improvement is often only transient. A few exceptions do, however, exist to this generally disappointing scene. First, dystonias of the paroxysmal type, lasting a matter of minutes and sometimes called "basal ganglia epilepsy," usually respond to phenytoin, carbamazepine or clonazepam.⁴¹⁸

Secondly, cases of juvenile dystonia parkinsonism or progressive dystonia with marked diurnal fluctuations (sometimes called the Segawa syndrome), show a dramatic response to DOPA and are also amenable to anticholinergic therapy⁴¹⁹ (Tables 1, 7). This, plus the usually minimal progression in adult life, has led to speculations that there is a fundamental difference between this and other primary dystonias⁹⁴ and that it may be an aberrant juvenile parkinsonism.⁴²⁰ Even in adult life, dystonia is frequently a presenting symptom of parkinsonism. A

common form is foot dystonia which may occur as an early symptom in parkinsonism, either idiopathic²⁰¹ or MPTP-induced,⁴²¹ or (in 20-40% of cases) as an iatrogenic response to prolonged L-DOPA therapy. The pharmacological responses are often similar to those seen in juvenile dystonia-parkinsonism but are far less consistent. For example, Poewe and Lees⁴¹⁹ reported cases where the dystonia is abolished by scopolamine and exacerbated by physostigmine. But, according to Klawans and Paleologos,⁴²² in 11 patients presenting first with dystonia (4 spasmodic torticollis, 2 hemidystonia, 4 Meige's syndrome and 1 writer's cramp), who later developed parkinsonism, DOPA often exacerbated the underlying dystonia while direct DA agonists were less apt to do so. LeWitt et al.⁴²³ reported similar experience in 10 patients.

Thirdly, high doses of anticholinergics (e.g. trihexyphenidyl) have been found to be well tolerated by dystonic children and to a lesser extent by adults.⁴²⁴⁻⁴²⁶ They have become the regimen of choice for the treatment of idiopathic TD. They are not effective in all cases, however. Burke et al.⁴²⁶ reported a clinically significant response in 71% of 31 patients completing a prospective, double blind crossover study. After a mean follow-up of 2.4 years, 68% of the patients continued to take the drug and 42% continued to show a considerable or dramatic benefit. Marsden et al.⁴²⁷ concluded high dose trihexyphenidyl is the first treatment of choice in children with severe dystonia (they found improvement in 52% without marked side effects) but is less useful in adults (improvement in 41% but most had side effects). In severe axial dystonia in adults, a regimen of tetra-benzazine, plus pimozide and trihexyphenidyl as necessary to control side effects and add benefit, was helpful in 75% of the cases. This regimen also benefited 1 out of 2 children with life threatening generalized dystonia. Pakkenberg and Pedersen⁴²⁸ said that anticholinergics, while the most effective, are tolerated in, and give benefit to, less than 50% of cases. They recommended a combination of an anticholinergic, a benzodiazepine and a third drug (antidopaminergic, carbamazepine or fluperlapine). One adult case of idiopathic torticollis benefited from high dose trihexyphenidyl plus bethanechol to diminish peripheral anticholinergic side effects.⁴²⁹

Lang⁴³⁰ reported high dose anticholinergics to be more effective in idiopathic than "symptomatic" dystonia and to be more useful in children than in adults. In most adult-onset focal dystonias they seem of little benefit.^{431,432}

In dystonics on high dose anticholinergics, the acute anticholinergic side effects paralleled the rise and fall of serum anticholinergic levels but the response to dystonia did not.^{433,434}

A brief indication of some of the drugs tried in the treatment of various forms of dystonia is given in Tables 7 and 8. Treatment of iatrogenic dystonia is included in these tables but is discussed in Section 7.

The reported efficacy of baclofen (which often acts by inhibiting glutamate/aspartate release) in several cases of hemifacial spasm or Meige syndrome suggests that some of the NMDA antagonists, such as MK-801, now becoming available might well be tested.⁵⁴⁷ This suggestion is reinforced by the recent discovery that trihexyphenidyl, and some other antiparkinsonian agents, resemble MK-801 in that they act as antagonists at the σ type of binding site which modulates the NMDA-type excitatory amino acid receptors.⁵⁴⁸

The effectiveness of therapeutic interventions must be evaluated in light of the spontaneous remissions that are known to occur in spasmodic torticollis. In a review of 116 patients, remissions lasting longer than 1 year were observed in 14 patients (12%). This included 1 out of 11 cases with a familial history of dystonia. Spontaneous remissions seem to be more frequent in cases with early onset and usually occur during the first year.⁵⁴⁹ Other reports in the literature, reviewed in this paper, indicate a spontaneous remission rate ranging from 7-50%.^{cf439,550} In 26 patients with spasmodic torticollis followed for an average of 12 years, the frequency of sustained remission was 23% with the median duration of remission 8 years.⁵⁵¹

Local injections of botulinum toxin into affected muscles is now widely used for the temporary (2-3 month) relief of focal dystonias,⁵⁵² including blepharospasm,^{17,553-556} hemifacial spasm,^{554,556} age-related entropion,⁵⁵⁴ torticollis,⁵⁴⁷ and writer's cramp.⁵⁴⁸ A flood of similar reports have appeared. Infiltration of a local anesthetic (pancuronium bromide) gives relief for at least 3 weeks in patients with acute torticollis but only for 2-3 hours in patients with a chronic problem.⁵⁵⁹ Little light on the underlying pathology of the conditions is, however, given by such treatments, or by the reported effectiveness of EMG (bio-) feedback in some cases,^{e.g.500} or chronic spinal stimulation which has been said to give some relief in 68-78% of cases of spasmodic torticollis^{e.g.560,561} but to have little benefit in idiopathic (primary) dystonia.⁵⁶² Even acupuncture has been tried.^{e.g.563}

Surgical lesions of the brain have also been used for symptomatic relief.^{e.g.564} At one time, some dentectomies were done⁵⁶⁵ but the more generally chosen site is the thalamus. Cooper was the most ardent exponent of such surgery and he argued from work on over 400 patients in a 20 year period that dystonia "is a manifestation of abnormal sensory communication involving cerebropetal pathways from basal ganglia, cerebellum and reticular substance. A possible role for the red nucleus must be considered."⁵⁶⁶ Kandel⁵⁶⁷ said that stereotaxic operations for spasmodic torticollis aimed at the ventrolateral (VL) thalamus, subthalamus or interstitial nucleus of Cajal (INC) gave marked or stable improvement in 50% of the cases and Vasin et al.⁵⁶⁸ favored destruction of the INC in the rigid form. Others^{e.g.569,570} found thalotomy of benefit in a smaller proportion of cases than reported by Cooper. Namba et al.⁵⁷¹ reported that 21 cases of spasmodic torticollis given VL thalotomy did not do any better than 25 cases treated conservatively. Because of the side effects, especially with the bilateral operations needed in generalized dystonia, such operations are generally regarded as a last resort. But such work does provide possible clues to the anatomical basis of dystonia. Peripheral surgery used in some cases of torticollis^{e.g.572,573} contributes little to an understanding of the etiology.

Stahl et al.⁴⁵⁴ argued from the pharmacology that various movement disorders are due to imbalances in basal ganglia dopamine/acetylcholine systems as indicated below:

Syndromes of dopamine excess and acetylcholine deficiency

Tardive dyskinesia	Tourette syndrome
Huntington disease	L-DOPA dyskinesia

Syndromes of dopamine deficiency and acetylcholine excess

Parkinson disease	Acute drug-induced dystonia
Drug-induced parkinsonism	Torsion dystonia

Table 7. Summary of some of the Literature on the Number where Dystonic Symptoms Improved or (Worsened) on Treatment with Some Relatively Commonly Used Drugs¹

Type of Drug	TYPE OF DYSTONIA										Overall Percent	References	
	Probably idiopathic		Iatogenic		Associated with		Birth Anoxia Trauma	Overall Percent	References				
	TD or General	Torti-collis	Meige focal	Other focal	Neuro-leptic	Dopa				H-S			L-N
DA agonists ²													
Dopa/sinemet	70/158 (24/121)	9/49 (3/9)	3/51 (7/23)	0/2 (3/3)		10/10 ³		0/8 (1/1)	2/7 (2/7)				123,134,202,256,258,272, 294,375,381,420,428,441-59
Lisuride	4/16	16/23	40/68	4/26	2/3	8/9		0/8	0/4	0/4			202,449,460-9
Other	24/135 (13/66)	33/113 (8/67)	24/64 (5/10)	1/15				0/8 (1/8)	1/1	0/1			123,202,272,428,451,454-6, 463,465-7,470-5
DA antagonists ³	4/21 (4/4)	18/26	28/135 (2/11)	3/9	1/84	4/13		0/8					123,202,256-8,272,283,294, 428,444,448-9,454-6,458,472 477-83
Cholinergics													
Anti-AChE	0/4 (3/3)	(1/1)	0/6 (7/7)		0/42	0/9 (7/9)							0% (90%) 474 428,444,449,483-6 487
Choline/deanol			6/19	3/8	few/42					1/1			
Nicotine													
Anticholinergics ⁴	12/20	9/19 (2/5)	53/116 (3/3)	7/12	18/45	7/9		2/3	2/6 (1/6)				134,202,257-8,272,424,428, 433-4,444,449,455,458,472-3, 475,479,481-3,485,488-500
Lithium	1/3	0/2	0/2		0/1	7/7							272,483,501-5
Amine releasers ⁵	12/23 (2/19)	0	43/133 (9/57)	20/54 (17/33)	9/58 (1/15)								7,257,272,428,449,479,483, 506-11
Benzodiazepines ^{2,6}	7/14	0	15/47	5/6	0/42			0/8		0/1			100,102,123,201,256-8,272,282, 428,479,483,492,513-5

1) Abbreviations used: TD, torsion dystonia; DA, dopamine; AChE, acetylcholinesterase; H-S, Halloverden-Spatz; L-N, Lesch-Nyhan; Park, parkinsonism. General reviews on therapy may be found in references 46, 427, 428 and 435. The percentages of cases showing improvement must be taken as rough approximations since much depends upon the criteria used by various investigators and the literature reviewed is by no means complete. The figures are probably over-optimistic since many of the references found are to uncontrolled studies. Double blind, placebo controlled studies in most cases show lower rates of improvement, and many negative clinical results are not reported.

2) All cases of fluctuating dystonia are said to respond very well to DOPA, 76,77,79,83,84,87,90-92,94,95,436,437 lisuride or bromocriptine,^{87,437} the few cases tried have also shown a response to tetrahydrobiopterin³⁸¹ or benzodiazepines, and some show an improvement on anticholinergics.^{87,438} See Lang⁴³⁹ for a general review on therapy with DA agonists. In 1973 Eldridge et al.⁴⁴⁰ reviewed the responses of 203 dystonic patients to levodopa: 21% improved, 70% were unchanged and 9% worsened.

3) Tardive complications are seen in about 5% of patients with idiopathic dystonia treated with DA antagonists.⁴⁷⁶

4) Anticholinergics appear more generally useful, especially in young cases, than indicated by these figures (see text). The dramatic improvement in 2 siblings with Halloverden-Spatz syndrome on benzotropine, in contrast to the ineffectiveness of other anticholinergics, is attributed to an augmentation of DA release in the caudate overcoming the presumed hypoactive DA system.¹³⁴

5) See reference 506 for discouraging review.

6) In an attempt to raise brain GABA levels, Korein et al.⁵¹² gave a mixture of L-glutamine, isoniazid, pyridoxine and diazepam to a group of patients who had proven refractory to other therapy and reported marked improvement in some of those with spasmodic torticollis.

Table 8: Other Drugs Reported to Have Some Use or No Benefit in Various Forms of Dystonia (Many Tested in Only a Few Cases).

Drug	References Reporting	
	Some Cases Benefit	No benefit
5-HTP	Manto's disease (13)	(514)
5-HTP + carbidopa + clomipramine		(123)
Methysergide		(272)
Tizanidine	Stiff man syndrome (515)	(516)
ACTH	(517)	
Baclofen	(479,518,519)	Iatrogenic(483,520)
Valproate	(282,428,521)	(522)
Valproate + baclofen	(523-526)	
Dantrolene	(282)	(272,484)
γ -VinylGABA		(527-529)
Isoniazid		(376)
Progabide		(530); essential tremor (531)
Carbamazepine	(112,428,446)	
Acetazolamide	(102)	
Phenytoin		(483)
Propranolol	(428,479)	(257,272)
Clonidine		(483,532)
Antihistamines*	(483)	(272)
MAO inhibitors	(479)	(483)
Sedatives.		
meprobamate		(256)
phenobarbital		(256,483)
Cannabidiol	(534,535)	
Ethanol	(353,536-538)	
Nitrous Oxide	(430,539,540)	
Ethyl chloride	(541)	
Naloxone		Worsens (542)
Benzhydrol	(487)	
Ca ²⁺ channel blockers.		
verapamil	Iatrogenic (543)	Not lasting
diltiazem	Iatrogenic (544)	(545)
Calcitonin	(451)	
Oxiperamide		(483)
Mepiridine		(483)
Chlormezanone	Wry neck (546)	
Piribedil	(282)	

*May be initially fluctuating response to antihistamines.⁵³³

Syndrome of dopamine excess - acetylcholine excess

Idiopathic orofacial dyskinesia (Meige's syndrome)

In support of this view, Ortiz⁵⁷⁴ reported a case of Meige that responded best to a combination of haloperidol and benztpropine, but the pharmacologic results in general are too erratic to support such a simple postulate (Tables 7-9) and it seems clear that the many other neurotransmitter systems in the basal ganglia (and rest of brain) must be taken into account in explaining the spectrum of pharmacological responses in dystonia.

6. IATROGENIC DYSTONIA

Iatrogenic forms of dystonia have been induced by many different types of drugs (Table 9) and can take a variety of forms such as torticollis, blepharospasm and oromandibular dystonia. Dystonic movements of facial or throat muscles seem to be frequently involved.

The dystonic reactions are idiosyncratic, occurring only in susceptible patients, with the susceptibility decreasing with age.

No consistent picture emerges as to what central neurotransmitter systems might be involved. Dystonic reactions occur most frequently in persons treated with DA receptor blockers and are usually promptly relieved by anticholinergics or antihistamines. This has been taken to indicate that the basic mechanism is a relative DA deficiency (analogous to that in parkinsonism). However, such DA blockers are occasionally useful in the treatment of idiopathic dystonia with similar symptomatology.^{e.g.586} Dystonic reactions also occur following DOPA treatment and even, occasionally, following treatment with the same antihistamines and anticholinergics useful in the treatment of iatrogenic dystonic reactions. Moreover, some drugs not known to effect any of these systems occasionally produce dystonic symptoms (Table 9).

Rupniak et al.⁶⁵⁵ estimated the incidence of acute dystonic reactions in patients treated with neuroleptics to be 2-3%, but some authors give rates closer to 50%⁶⁵⁶ (Table 10). The incidence is particularly high (50-63%) in children or young adults⁶⁶³⁻⁶⁶⁵ and some have advocated that such patients be giv-

en concurrent benzotropine during the first week of neuroleptic treatment as a prophylactic measure.⁶⁶⁵⁻⁶⁶⁸ Others have indicated that dystonic reactions may occur on high dose neuroleptics even with concurrent anticholinergic therapy. They have suggested that lower doses of neuroleptics (200-400 chlorpromazine equivalents daily) should be used.^{248, 669}

Acute dystonic reactions occurred in 6 out of 7 young cocaine addicts after 1-2 doses of haloperidol suggesting the effects of cocaine addiction rendered the subjects particularly sensitive to dystonia induced by dopaminergic blockers⁶⁷⁰

(cocaine is a DA uptake inhibitor and chronic use may produce subsensitivity of DA receptors). Prior abuse³⁹⁷ or current use⁶⁷¹ of alcohol may also be a precipitating factor. However, incidences of acute dystonic reactions following antipsychotic administration as high as those seen in the cocaine users have also been reported in some other groups of young adults⁶⁶⁶ and alcohol is said to relieve some dystonic symptoms (Table 8). Stress is also said to be a factor in precipitating these reactions^{672,673} and patients with a history of birth trauma or childhood convulsions may be particularly at risk.⁵⁹² Gosper and

Table 9: Some Drugs Causing Acute Dystonia and Some Reported Pharmacology.†

Eliciting Agent	Drugs Reported to Alleviate, (Not Affect) Or [Worsen]
Dopamine blockers*, ⁴⁸ Neuroleptics ⁵⁷⁵⁻⁸ (e.g. chlorpromazine, ⁵⁷⁹⁻⁵⁸² prochlorperazine, ⁵⁸³ haloperidol, ^{582,584-586} pimozide, ^{584,587} thietilperazine, ⁵⁸⁸⁻⁹ promethazine, ⁵⁹⁰ fluphenazine, ⁵⁹¹ flupenthixol, ⁵⁹²) Antiemetics (e.g. metoclopramide, ⁵⁹³⁻⁶⁰⁰ domperidone, ⁶⁰¹⁻⁶⁰³ Tigan ⁶⁰⁴)	Withdrawal of neuroleptic ³¹ , 605 diphenhydramine, ⁵⁷⁶⁻⁸ 584,587,594 benzotropine, ⁵⁷⁶⁻⁸ diazepam; ^{584,587,599} baclofen ⁶⁰⁶ Diphenhydramine, benzotropine
Amine depleters Tetrabenazine ⁶⁰⁷ Tetrabenazine+ α -methyl-p-tyrosine ⁶⁰⁸	[Diphenhydramine, haloperidol] ⁶⁰⁸
DA uptake inhibitor (normifensine ⁶⁰⁹)	Withdrawal of drug ⁶⁰⁹
Tricyclic antidepressants (e.g. amitriptyline, ⁶¹⁰ trazodone, ⁶¹¹ amoxapine ⁶¹²⁻³ (also a DA, blocker) ⁶¹⁴	
Anticonvulsants Carbamazepine, ⁶¹⁵⁻⁹ Tegretol, ⁶¹⁵⁻⁷ Phenytoin ⁶¹⁹⁻²³ Dilantin ⁶²¹⁻²³ diphenylhydantoin, ⁵⁹³ diazepam ⁶²⁴⁻⁶	(Anticholinergics)
Antihistamines (e.g. Benadryl, ⁶²⁷⁻⁸ oxatomide, ⁶¹⁶ , 629 diphenhydramine, ^{627,630-1} azatadine ⁶³²)	Neuroleptics; ^{627,630,631} benzotropine ⁶³²
Decongestants (chronic) ⁶³³ Dimotrop elixir (acute) ⁶³⁴⁻⁶	Haloperidol
Ketamine ⁶³⁷ Lithium ⁶³⁸⁻⁹ (Reinduces neuroleptic malignant syndrome in 2 patients ⁶⁴⁰) L-DOPA* ^{48,641-643}	Diphenylhydantoin*; dopamine agonists ^{48,202,204,644} Anticholinergics ^{48,202} Baclofen ^{634,636} Chlorpromazine*
Antimalarial drugs (e.g. chloroquine), ^{645*} Anticholinergics (benzotropine ⁶⁴⁶), Cholinomimetics (bethanechol) ⁶⁴⁷ Ergot ⁶⁴⁸ Methylparathion ¹³ Carbon monoxide ²⁸⁸ Manganese poisoning ⁶⁴⁹	5-Hydroxytryptophan ¹³ Haloperidol + diazepam or L-DOPA + benseramide ⁶⁴⁹
Verapamil, ⁶⁵⁰ nifedipine ⁶⁵¹ (Ca ²⁺ influx inhibitors). Chloroxazone ⁶⁵² Caffeine + aminophylline ⁶⁴³ Anti-cancer drugs. Tegafur (furan-5-fluorouracil) ⁶⁵⁴	Diazepam, benzotropine ⁶⁵³

† Often reports of single cases in children.

*See text for additional references. Case report of dystonia precipitated in a child who was on methylphenidate + phenothiazine when the phenothiazine was stopped⁵⁷⁶

Table 10: Some Incidence Figures on Iatrogenic Dystonia.

Neuroleptic malignant syndrome	0.4-0.5% of patients, M: F, 2:1 ⁶⁵⁷ 0.5-1.4% of patients, M:F, 1.4:1; median. age of onset 36 ⁶⁵⁸ <0.2% of hospitalized patients on neuroleptics ⁶⁵⁹
Metochlorpromide-induced	28.6/million prescriptions, F:M, 1.8:1, mostly in young; in women aged 12-19 incidence is 191/million ⁶⁶⁰
Prochlorperazine-induced	2.7/million prescriptions ⁶⁶¹
Haloperidol-induced	14.7/million prescriptions ⁶⁶¹
Neuroleptic-induced dystonia	36% of 135 cases, especially in young males ⁶⁶² 33% of 120 cases ⁶⁵⁷

Jankovic⁶⁰⁶ report rapid onset of dystonia during thioridazine therapy in a patient with neuronal ceroid-lipofuscinosis and suggest patients with certain degenerative diseases of the nervous system may be at increased risk; the dystonia was refractory to most drugs but improved on baclofen.

The acute dystonic reaction may take the form of a laryngeal-pharyngeal dystonia. This can lead to death through asphyxiation but, if recognized, is easily controlled with diphenhydramine or benztropine. Such reactions have been seen in isolated cases after haloperidol,⁶⁷⁴⁻⁶⁷⁶ thiothixene⁶⁷⁷ or droperidol.⁶⁷⁸

Acute dystonic reactions can also be induced in non-human primates by neuroleptics⁶⁵⁵ (Section 7).

Acute dystonic reactions to neuroleptics usually occur 24-72 hours after initiation of the antipsychotic therapy but they can occur at any time during maintenance therapy. In either case they are generally relieved by diphenhydramine or benztropine.^{665,679,680} Occasionally, however, the dystonic symptoms persist despite treatment with benzodiazepines or anticholinergics.⁵⁹² Acute reactions must be distinguished from the late-onset and persistent dystonia seen in many cases treated with neuroleptics. The latter is known as tardive dystonia.^{681,682} Tardive dystonia has to be distinguished from another, more common movement disorder, classic tardive dyskinesia. This is a choreic disorder that predominantly affects the oral region. Patients with tardive dystonia may or may not benefit either from treatment with anticholinergics or by withdrawal of neuroleptics.⁶⁸³ By contrast, patients with tardive dyskinesia usually experience an exacerbation of their abnormal movements when withdrawn from neuroleptics or given anticholinergics to counteract their movement disorder.⁶⁸⁴ The two conditions also differ in age and sexual prevalence. In contrast to tardive dyskinesia, tardive dystonia decreases with age and shows no female preponderance.⁶⁸⁵ The incidence of tardive dystonia in one population of chronic hospitalized patients was 1.5%.⁶⁸⁶ Risk factors in this small population appeared to be mental retardation and convulsive therapy. On the other hand, Kwentus et al.⁶⁸⁷ reported an improvement in tardive dystonic symptoms in a patient who received ECT for depression.

Burke et al.⁴⁸³ described 42 patients with tardive dystonia with the age of onset being from 13-60 years and the time of

antipsychotic treatment before onset ranging from 3 days to 11 years. Younger patients tended to show more generalized dystonia although some showed Meige-like symptoms.⁶⁸⁸ In a few patients, spontaneous remission occurred, but in most the dystonia persisted for years. In adults, some cases diagnosed as Meige's syndrome may be tardive dystonia.⁶⁸⁹

Kang et al.⁶⁹⁰ retrospectively reviewed data on 67 patients with tardive dystonia and found no predilection for any particular age group or sex. Tetrabenazine and reserpine were the most effective drugs in controlling the dystonic reaction, having an improvement rate of over 50%; anticholinergics diminished the dystonia in 46%.

Dystonic reactions must also be distinguished, though they may be part of, the neuroleptic malignant syndrome which involves mainly fever, labile blood pressure, tachycardia and muscular rigidity. It is particularly common in young men.^{691,692} Bromocriptine and damrolene are helpful while anticholinergics, benzodiazepines and ECT are not. In a fatal case of the neuroleptic malignant syndrome, acute myopathic features with absence of muscle glycogen and neutral lipid were found, suggesting that the primary biochemical abnormality responsible for uncontrolled heat production might be muscular rather than central (hypothalamic).⁶⁹¹

Metoclopramide and droperidol, which are dopaminergic blockers commonly used as antiemetics in cancer patients undergoing irradiation, can also induce acute dystonic reactions. Selective 5-HT₃ receptor antagonists are being tested for such antiemetic use and it is thought that they will be unlikely to cause dystonic reactions.⁶⁹⁴ The dystonic reactions seen after the dopaminergic blockers are usually controlled by diphenhydramine or benztropine. The incidence is relatively rare in adults (4-7%) but is much more common in children.⁶⁹⁵⁻⁶⁹⁷ According to Bateman et al.⁶⁹⁸ the pharmacokinetics of metoclopramide are the same in children showing dystonic reactions as in other children or in healthy adults. The risk of such reactions is increased by concomitant administration of chloroquine.⁵⁹⁵ A rapidly fatal outcome was described in a 49 year old female receiving metoclopramide after hexamethylmelamine, a drug known to produce a parkinsonian-like disease and tremor.⁶⁹⁹

Episodes of blepharospasm have been reported in 2 out of 3

cases of MPTP-induced parkinsonism during drug "holidays" when they were not receiving dopa.⁷⁰⁰

Marsden and Jenner⁷⁰¹ suggested that acute dystonia might be due to DA activation rather than blockade. Korczyn,⁷⁰² on the other hand, proposed that the iatrogenic dystonia produced by DA blockers was due to a relative noradrenergic hyperactivity. This hypothesis was based upon reports (later contested, see Section 4c) of high DBH levels in patients with the dominant form of dystonia, coupled with an absence of reports of dystonia in any patients given DA depletors such as reserpine or tetrabenazine. However, Burke et al.⁶⁰⁸ reported dystonic symptoms in a Huntington's disease case during treatment with tetrabenazine and α -methyl-p-tyrosine; the dystonic symptoms in this case were worsened by diphenhydramine or haloperidol. Subsequently, the same group⁶⁰⁷ reported acute dystonic reactions in four patients being treated with tetrabenazine.

The confusing picture painted by drug-induced dystonias is evident in a review by Rupniak et al.⁶⁵⁵ They point out that not only can neuroleptics produce such reactions but that L-DOPA also does in a proportion of parkinsonians^{202,703-706} (Table 9). This proportion is particularly high in older patients.⁷⁰⁷ Such patients may have painful dystonic spasms before the first dose of DOPA each day, during off-periods, or at the beginning, peak, or end of the effectiveness of a DOPA dose.⁷⁰⁸ Off-period dystonia has been said to be by far the most common drug-induced dystonia encountered in Parkinson's disease, with an overall incidence varying from 20-33% of patients receiving DOPA treatment for more than 3 years.^{636,709,710} The off-period dystonia, usually involving prolonged abnormal postures and torsion spasms, may be relieved by challenge doses of DOPA or a DA agonist.²⁰² On the other hand, these drugs may worsen some dystonic movements, usually writhing of the neck and cranial dystonia, which occur at the peak action of DOPA; this again suggests that the different types of movement grouped under the term dystonia may have different neurochemical bases. It may be of significance that DOPA-induced dyskinesias are said to occur more often in parkinsonians (50% of cases) than in TD, Hallervorden-Spatz or Huntington's disease cases being similarly treated (11%).⁷¹¹

Although DOPA-induced dystonia has been reported to be relieved with diphenylhydantoin,⁷¹² this and other anticonvulsants may induce dystonia in intoxicated epileptic patients⁷¹³ (Table 9); phenytoin has been reported to cause dystonia in some epileptics⁶²³ and also occasionally in parkinsonians. Symptoms disappeared when carbamazepine was substituted for phenytoin.⁷¹⁴ Antimalarial agents such as chloroquine and amodiaquine can provoke acute florid oro-bucco-linguo-facial dyskinesias^{645,715-717} and this chloroquine-induced dystonia is relieved by chlorpromazine.⁶⁴⁵ Even antihistamines such as diphenhydramine, which relieve neuroleptic-induced acute dystonia, can themselves produce dystonias which are relieved by neuroleptics (Table 9).

Although cholinomimetics do not in themselves generally induce acute dystonic reactions in humans (but see Section 7), Shafrir et al.⁶⁴⁷ reported such an episode induced in a 10 month old infant with bethanechol. This infant also had acute dystonic reactions following both metoclopramide and a phenothiazine. A brother had a similar reaction to metoclopramide at the age of 2 years.

7. POSSIBLE ANIMAL MODELS OF DYSTONIA

Idiopathic

The most useful model of idiopathic torsion dystonia may be the Sprague-Dawley rat mutant dystonic (dt) which follows an autosomal recessive pattern of inheritance. Clinical signs begin to appear about postnatal day 10 and include twisting of the axial musculature, hyperflexion of the trunk, self-clasping of forelimbs and hindlimbs and poor placement of the limbs during locomotion. No morphological lesions have been observed with routine light microscopy in whole brain or on Golgi-impregnated striatal sections. A very interesting recent finding is that such animals exhibit markedly abnormal σ_h binding in whole brain, with a B_{max} more than twice normal and a k_d more than four times normal.⁷¹⁸ The σ_h site is a haloperidol-sensitive receptor site which is non-dopaminergic and non-opiate. It is found in many brain areas involved in motor function, including particularly the cerebellum, red nucleus, locus coeruleus and substantia nigra pars compacta (SNC).⁷¹⁹ Exploration of σ_h binding in the dystonic rat was based upon the discovery that microinjection of a selective σ_h ligand (1,3-di-o-tolylguanidine) into the SNC of normal rats produced circling, and injections into the red nucleus produced dystonic movements.^{720,721} Dystonic (dt) rats show normal DA levels and turnover, normal dopaminergic and muscarinic binding parameters, and the normal response of increased locomotion after apomorphine or amphetamine. However, the development of a cataleptic response to haloperidol was decreased, although it was normal after morphine.^{721,722} These results suggest that defective σ_h receptors may underlie this and perhaps other forms of dystonia.

Earlier work on these dystonic rats had revealed some cerebellar abnormalities. Cerebellar NA levels were significantly elevated, although cerebellar levels of MHPG and of β -adrenergic binding sites, as well as the levels of NA in other terminal fields of the locus coeruleus were similar to those in normal littermates.^{723,724} The mutants showed not only high cerebellar NA levels but a reduction in sensitivity to the NA-depleting effects of reserpine, a change also confined to the cerebellum. GAD activity was found to be abnormally high in the deep cerebellar nuclei but normal in other regions examined (vermis, cerebellar hemisphere, caudate and globus pallidus). The abnormality in GAD was confined to the nucleus interpositus at 16 days of age but was present in all 3 cerebellar nuclei (fastigial, interpositus and dentate) at 20 days of age.⁷²⁵ Treatment with diazepam significantly reduced the frequency of dystonic movements.⁷²⁶ There were also lower levels of cerebellar 3',5'-cGMP, a biochemical marker of Purkinje cells, under both basal and harmaline-stimulated conditions and a failure to show tremor after administration of harmaline. The dystonic rats, like normal rats, did show tremor after oxotremorine.⁷²⁷

No differences in the pattern or density of NA innervation of the cerebellum were apparent using histofluorescent techniques and cerebellar morphology appeared normal except for a reduction in Purkinje cell size. On the basis of this morphological finding, and the biochemical abnormalities in GAD and 3',5'-cGMP, it was suggested that the alteration in cerebellar NA may be secondary to a functional change in the target Purkinje neurons.⁷²³ Nevertheless, some amelioration of the abnormal movements was reported on clonidine administration.⁷²⁸

Dystonic mouse mutants have also been described. One was due to a mutant autosomal recessive gene occurring spontaneously in a random bred strain.⁷²⁹ Homozygous animals began to show incoordination and mild posturing during the second week of life. There was a rapidly progressive course leading to severe ataxia and overall writhing motions. Pathology was seen mainly in the sensory pathways leading from the spinal cord encephalad to the thalamus. Histochemical studies of selected lysosomal hydroxylases in animals 5-28 days old suggested an early defect of axonal transport in primary sensory neurons. Segmental demyelination, axon swelling and degeneration was also seen in peripheral nerves, including motor fibers.^{730,731} Schwann cell counts in peripheral nerves,⁷³² as well as transplant studies of peripheral nerves between affected and normal littermates suggested that an underlying Schwann cell defect existed.⁷³³ Such defects do not occur in idiopathic human dystonia which suggests that these mice may not be good models of the disorder.

A number of alleles of this mutant have appeared in other stocks of mice. Dramatic pathological changes are seen not only in sensory afferents, including prominent degeneration of large neurons in the dorsal root ganglion, but also in the large neurons of the caudal red nucleus. Reported neurochemical changes in the CNS include a reduced capacity for GABA synthesis in the striatum and substantia nigra but not in the hypothalamus,⁷³⁴ an increased turnover of NA (high MHPG and tyrosine hydroxylase but normal NA) in the cerebellum with normal DA, HVA, DOPAC and tyrosine hydroxylase in the striatum,⁷³⁵ and decreases in glutamate, aspartate, glycine and GABA in the cerebellar vermis with increases in the taurine/glutamate ratio in the cerebellar hemispheres. These changes in amino acids have been said to be more comparable to those occurring in Friedreich's ataxia than dystonia.⁷³⁶ There is no evidence of Purkinje cell pathology and cGMP-dependent protein kinase, a Purkinje cell-specific marker, is normal.⁷³⁵ A reduction of NGF in salivary glands and sciatic nerve has been reported.⁷³⁷

The pathology in the red nucleus may be of importance.⁷³⁸ Stanley et al.⁷³⁹ report that allelic differences exist in the age of onset and severity of this pathology. The magnocellular neurons of the Jackson allele (*dt¹*) almost completely disappear prior to 4 weeks of age, while some of these cells are retained in the adult of the Albany strain (*dt^{A1b}*). In the latter strain, however, acetylcholinesterase staining suggests that the remaining rubral neurons are non-functional.

A form of idiopathic torticollis in ducks was reported by Gopalakrishnakone^{740,741} but no pathological examination of the CNS was made; the neck muscles showed myodegeneration with an inflammatory reaction that consisted of an infiltration of lymphocytes, monocytes and macrophages. Neuromuscular junctions had degenerated mitochondria and large accumulations of glycogen granules.

Dystonia Acquired Following Peripheral Drugs or Infections

Dystonia has been reported in two out of 6 monkeys receiving L-DOPA as a successful therapy for severe MPTP-induced parkinsonian symptoms.⁷⁴²

Administration of neuroleptics to primates results in acute dystonic reactions very similar to those seen in a proportion of psychiatric patients. The time course and pharmacology has

been reviewed by Rupniak et al.⁶⁵⁵ The acute neuroleptic-induced dystonias in man or non-human primate are easily reversed by neuroleptic withdrawal or treatment with an anticholinergic. Identical dystonic reactions can be induced in haloperidol-primed monkeys with either selective D1 or D2 antagonists.⁷⁴³ Anticholinergics are effective in either case. In accord with the apparent role of cholinergic systems, physostigmine worsens neuroleptic-induced dystonia in primates.^{744,745} Cholinergic agonists can induce dystonia in monkeys primed with haloperidol⁷⁴⁶ or by direct injection of the agonist into the neostriatum.^{747,748} Four out of five monkeys given sulpiride to reduce persistent neuroleptic-induced dyskinesia developed acute dystonia which had to be reversed by anticholinergic medication.⁷⁴⁹

The effect of drugs acting upon monoamine or GABA systems is more controversial. Haloperidol-induced dystonia in cebus monkeys, which was readily relieved by an anticholinergic, was only slightly reduced by the 5HT antagonist methysergide. Other 5HT blockers (minanserin, ketanserin, ritanserin) and a specific 5HT uptake inhibitor (citalopram) had no significant effect.⁷⁵⁰ The tyrosine hydroxylase inhibitor, α -methyl-tyrosine (AMPT), was found not to alter neuroleptic-induced dystonia in baboons when given alone,^{744,751} but pretreatment with reserpine plus AMPT reduced the intensity and duration of neuroleptic-induced dystonia.⁷⁴⁴ In monkeys, however, AMPT was found to worsen neuroleptic-induced dystonia⁷⁴⁵ and even to induce acute dystonia by itself.⁷⁴⁶ As in man, DA agonists, such as apomorphine,⁷⁴⁵ or L-DOPA⁷⁴⁶ may alleviate neuroleptic-induced dystonia even though L-DOPA is itself capable of producing an acute dystonic reaction in monkeys.⁷⁵²⁻⁷⁵⁴ Benzodiazepines⁷⁴⁶ are also beneficial. Pargyline has been reported to reduce or prevent the neuroleptic-induced acute dystonia in monkeys.⁷⁵⁵ In one study, both picrotoxin and muscimol increased the severity of neuroleptic-induced dystonia.⁷⁴⁵ However, treatment with the GABA_B agonist, baclofen, is reported to have either no or an opposite, beneficial effect.^{746, 756}

Liebman and Neale⁷⁵⁶⁻⁷⁵⁸ found that an acute dystonic reaction could also be induced in squirrel monkeys by treatment with tetrabenazine, but the syndrome differed from the neuroleptic-induced symptoms in being reversible by D-amphetamine.

Biochemical studies on the brains of such neuroleptic-treated dystonic monkeys are few but Haggstrom et al.⁷⁵⁹ reported a reduction in nigral GAD in the brains of cebus monkeys treated chronically with haloperidol. The monkeys showed acute dystonic behavior lasting several hours after the last neuroleptic dose, followed by tardive dyskinesia as the acute dystonia subsided.⁷⁶⁰ The reduction in nigral GAD seemed more related to the emergence of tardive dyskinesia than to the acute dystonia.

Rupniak et al.⁶⁵⁵ reviewed the chewing movements in rats evoked by neuroleptics. These may constitute a rodent model of acute dystonia but the relationship is not completely clear.

The head shakes, vertical neck dyskinesia and random circling behavior induced in rats by chronic administration of iminodipropionitrile have been said to resemble closely spasmodic torticollis. The behavioral syndrome is inhibited by ketanserin, suggesting that serotonin (5HT₂) receptors are involved.⁷⁶¹

Prenatal exposure to the fungicide dinocap causes behavioral

torticollis as well as ballooning and cleft palate in mice but not in rats or hamsters.⁷⁶²

The only other report noted of a possibly related movement disorder following peripheral administration of a drug is the permanent circling with head tossing syndrome produced in mice or rats by single oral or parenteral doses of dimethylaminohexose reductone. Symptoms are ameliorated by chlorpromazine or thiouracil. Thyroid hypoplasia has been reported in affected rats. Central pathology has not been described.^{763,764}

Rabbits often show torticollis after diseases which lead to central infection - e.g. with *Psoroptes cuniculi*, *Pasteurella multocida* and *Encephalitozoon cuniculi*. No common pathology is reported.⁷⁶⁵

CNS Lesions and Chemical Injections

The barrel rotation in rats, first described after intraventricular injection of SOM, and also observed following intraventricular injection of substance P, arginine-vasopressin or chlorpromazine methiodide (CPZMI) has been called a form of "experimental dystonia". It is not associated with activation of cortical EEG and is therefore not a convulsive phenomenon.⁷⁶⁶ Using stereotaxic injections of CPZMI into various nuclei bordering the 4th ventricle, Burke and Fahn⁷⁶⁷ found that only injections into the vestibular nuclear complex produced the effect; injections into the locus coeruleus, for example, did not. A specific neuroanatomical basis involving vestibular mechanisms is suggested for this barrel rotation and it may involve cholinergic systems since it is enhanced by atropine and inhibited by carbachol. Moreover, CPZMI is a potent inhibitor of QNB binding⁷⁶⁷ and is, therefore, presumably a muscarinic agonist or antagonist. Others, however, say that the reaction produced by CPZMI is not antagonized by pretreatment with anticholinergics, diazepam, diphenhydramine, haloperidol, atropine, propranolol, apomorphine or amphetamine. Treatment with CPZMI (unlike treatment with CPZ) does not alter striatal DA or serum prolactin levels and CPZMI has no effect on ³H-spiroperidol binding to striatal membranes suggesting that its action is not through a DA system.⁷⁶⁸

Unilateral electrolytic destruction of the ventral tegmental area of Tsai (VTA) in cats led to the appearance of torticollis rotatory head postures associated with a marked drop of 5HT in the ipsilateral caudate. Excitotoxic lesions of the VTA did not produce such abnormal postures, suggesting they might depend upon lesions of axons of passage in the VTA. The authors suggested descending tracts from the interstitial nucleus of Cajal (INC) may be important^{769,770} and electrolytic or kainic acid lesions of that nucleus cause frontal torticollis (head tilt) in monkeys and cats.^{771,772} Fukushima-Kudo et al.⁷⁷³ said that the dorsiflexion of the neck and impairment of vertical eye movement seen in cats with INC lesions is very similar to that seen in progressive supranuclear palsy. Moreover, they claimed that a retrospective analysis of previous clinical-pathological data indicates that the dorsiflexion of the neck in progressive supranuclear palsy correlates better with ICN than with basal ganglia lesions.

Jacquet and Abrams⁷⁷⁴ said that postural asymmetry and a movement disorder are produced in rats after unilateral microinjection of ACTH₁₋₂₄ or ACTH N-terminal fragments, but not ACTH₁₋₃₉ into rat brainstem. Jacquet⁷⁷⁵ suggested a role for an

abnormal (mutated) ACTH peptide in dystonia. Sandyk and Consroe⁷⁷⁶ proposed that enhanced release of such a peptide may be important in trauma-induced dystonia.

Marked postural asymmetries of a transient or permanent nature have been induced, respectively, by GABA infusions into, or kainic acid lesions of, the nucleus fastigii but not adjacent sites.⁷⁷⁷

Whether or not such postural asymmetries in animals have any resemblance to dystonia in humans remains open to question. However, the involvement of brainstem nuclei in many such reports suggests the importance of pathological examination of brainstem systems in dystonia. Particularly important ones may be those involving acetylcholine, glycine or various peptides.

However, horizontal head asymmetry has also been reported following electrolytic or 6-hydroxydopamine-induced lesions of the nigrostriatal tract in cats⁷⁷² or marmosets⁷⁷⁸ and an extreme torsion dystonia plus barrel rotation are seen in rats following injections of tetanus toxin into the basal ganglia.⁷⁷⁹ It may be of some interest in relation to the last report that the dystonic reaction sometimes seen early during treatment with neuroleptics has been called "pseudotetanus".^{780,781} Injection of GABA antagonists in or near the zona incerta of monkeys is reported to induce torticollis and circling behavior in contrast to the types of movement disorders produced by similar infusions into the subthalamus (chorea or hemiballismus), lateral segment of the globus pallidus (choreoathetoid) or putamen (myoclonic).⁷⁸²

8. SUMMARY

Both the pharmacological and pathological data suggest that the dystonias may be a group of disorders with multiple etiologies. Knowledge in this field would be immeasurably advanced if a genetic linkage or a consistent regional or chemical brain pathology could be identified for any single subtype. Both kinds of advance are required before the specific etiology can be identified. The problem in trying to identify disturbances in a disease where no obvious neuronal degeneration can be found is rendered extremely complex by the large numbers of chemically distinct, but functionally interrelated, neurotransmitter systems in the brain. The problem is well exemplified by the relatively little progress that has been made in understanding the etiologies of the psychoses despite the many years of intense research effort. An additional difficulty in the dystonia field is the relative scarcity of postmortem tissue available for examination. It thus seems incumbent upon researchers in the field to garner whatever clues they may from the available literature. Each reader of the literature will probably form his own opinion as to the most fruitful brain regions and chemical avenues for research. This review seems to suggest, however, that the following brain regions may deserve the closest scrutiny for possible detection of a lesion:

- basal ganglia - including the zona incerta - with particular emphasis on the putamen (see sections 2, 4, 7, Table 3)
- red nucleus and surround (see sections 2, 4, 5, 7)
- vestibular nuclei (see sections 2, 3, 7)
- nucleus of Cajal (see sections 2, 3, 7)
- nucleus fastigii (see sections 2, 3, 7)
- parabrachial area (see sections 2, 3, 7)

sensorimotor cortex (see section 2)

Other regions worth attention are the spinal cord, premotor area, motor cortex and thalamus.

It is even more difficult to decide on the types of chemical or histochemical assays that should receive priority. Recent work indicating that immunohistochemical staining for the immune complex glycoprotein HLA-DR can readily reveal areas of active neuronal degeneration, not detected by the usual histological methods, in a number of progressive neurological diseases⁷⁸³ suggests that such staining should be tried in dystonic brains. The hints in the literature that dystonic symptoms may be provoked or exacerbated by autoimmune processes (Sections 1b, 1Bb, 4c) would be further reason to undertake such staining. It is this literature which has already led Sandyk et al.⁷⁸⁴ to suggest that hypothalamic dysregulation of immune responses might be of fundamental importance in focal dystonia.

Immunohistochemical staining for the astrocyte marker, glial fibrillary acidic protein (GFAP), can easily be done at the same time as staining for HLA-DR and, while the latter reveals regions of active degeneration at the time of death, the former can reveal areas of past neuronal loss.

Much of the progress in the biochemical pathology of various diseases has been achieved by focusing on particular neurotransmitter systems. While the interesting observations on possible abnormalities in noradrenaline (see Section 4a) deserve attempted confirmation, the paucity of data on any other system suggests that the focus should be also on these rather than just the aromatic monoamines. Certainly the pharmacological activity of anticholinergics indicates that the cholinergic system, both presynaptic and postsynaptic, should be explored as thoroughly as possible with particular emphasis upon brainstem cholinergic systems. Brainstem cholinergic systems in the human are difficult to assess quantitatively but both biochemical techniques for ChAT and the modified histochemical method for acetylcholinesterase⁷⁸⁵ could be used as presynaptic indices, while radioautographic binding methods for cholinergic receptors should be attempted. Nicotinic sites are probably more important to assess than muscarinic sites because of the relatively heavy concentration of the former in regions such as the substantia nigra.

Glutamate/aspartate and GABA systems deserve attention because of their enormous importance in motor control; in these amino acid systems the techniques available for studying the postsynaptic binding sites are far more applicable to human postmortem tissue than are indices for the presynaptic systems.

The peptide neurotransmitters offer a vast and almost untouched field for exploration with reference to dystonia. The problem is in choosing the peptides worth particular attention. One possible group might be the tachykinins, including substance P. Substance P probably has an important role in the basal ganglia, as well as a cotransmitter role in brainstem cholinergic projections.⁷⁸⁶ There is a probability also that it innervates the red nucleus (unpublished observations). Another choice might be neurotensin because of the abundant evidence that this peptide strongly modulates the activity of both basal ganglia and limbic dopaminergic systems. Thyrotropin-releasing factor (TRH) might be of interest because of the frequent interrelation between thyroid disorders and dystonic symptoms (Section 4f). TRH also appears in the basal ganglia. The rat

“models” of dystonia indicate that the σ_h binding sites should be examined, particularly those in the region of the red nucleus. The reports of abnormal levels of SOM in ventricular CSF from dystonic patients would also promote this peptide into the ranks deserving priority. Fortunately, the availability of immunohistochemical procedures for these peptides means that several can be examined in a single brain but a major difficulty in such work is studying sufficient human postmortem controls and dystonic cases to ensure that differences are not just reflections of variations in tissue stainability.

In the meantime, new drugs are being developed, particularly ones which interact with peptide and the glutamate/aspartate systems. It is important that these be tested in dystonics not helped by presently available drugs. Such clinical trials may not only bring better immediate relief to present sufferers but provide the clues which basic researchers need to focus their investigations. Because of the probability that dystonia is not a homogeneous disease, care should be taken in both the clinical trials and basic research to define as clearly as possible the type(s) of dystonia involved.

ACKNOWLEDGEMENT

This review was undertaken on behalf of the Dystonia Medical Research Foundation. We would like to thank particularly Mr. Samuel Belzberg, President of the Foundation, and Dr. C.E. Markham, Scientific Director, for their advice and encouragement.

REFERENCES

1. Fahn S, Marsden CD, Calne DB, eds. Dystonia 2. *Adv Neurol* 1988; 50 (in press).
2. Jankovic J, Tolosa E, eds. Facial Dyskinesias. *Adv Neurol* 1988; 49: 1-538.
3. Jankovic J, Fahn S. Dystonic syndromes. In: Parkinson's Disease and Movement Disorders, Jankovic J, Tolosa E, eds., Urban and Schwarzenberg, Baltimore, Maryland, 1988.
4. Koller WC. Adult-onset foot dystonia. *Neurology* 1984; 34: 703.
5. Arvidson B. Transient foot dystonia in an adult woman. *Neurology* 1985; 35: 615.
6. Sandyk R. Adult-onset focal dystonia. *Neurology* 1985; 35: 137.
7. Jankovic J, Orman J. Blepharospasm: demographic and clinical survey of 250 patients. *Ann Ophthalmol* 1984; 161: 371-6.
8. Elston JS. Blepharospasm and Meige syndrome: a review of diagnostic, aetiological and treatment approaches (letter). *J Psychosom Res* 1986; 30: 103.
9. Corbin D, Williams AC. Stridor during dystonic phases of Parkinson's disease. *J Neurol Neurosurg Psychiatry* 1987; 50: 821-2.
10. Corbin D, Williams A, Johnson AP. Dystonia complicated by respiratory obstruction. *J Neurol Neurosurg Psychiatry* 1987; 50: 1707.
11. Rosenberg RN, Nyhan WL, Coutinho P, Bay C. Joseph's disease: an autosomal dominant neurological disease in the Portuguese of the United States and the Azores Islands. *Adv Neurol* 1978; 21: 33-57.
12. Paping RHL, Annyas AA, Mouij JJA, Penning L. Nasopharyngeal torticollis (Grisel's syndrome). *Ned Tijdschr Geneeskde* 1985; 129: 1787-90.
13. Disertori B, Ducati A, Piazza M. Spasmodic torticollis, substantiating Manto syndrome, of possible toxic aetiology, with alterations of brainstem acoustic evoked potentials (BAEPs). *Ann dell'ospedale Maria Vittoria di Torino* 1982; 25: 3-20.
14. Disertori B, Ducati A, Piazza M, Pavani M. Brainstem auditory evoked potentials in a case of "Manto syndrome" or spasmodic torticollis with thoracic outlet syndrome. *Ital J Neurol Sci* 1982; 3: 359-63.

15. Berardelli A, Rothwell JL, Day BL, Marsden CD. Pathophysiology of blepharospasm and oromandibular dystonia. *Brain* 1985; 108: 593-608.
16. Marsden CD, Sheehy MP. Spastic dysphonia, Meige disease and torsion dystonia. *Neurology* 1982; 32: 1202.
17. Faulstich ME, Carnrike CLM, Williamson DA. Blepharospasm and Meige syndrome: a review of diagnostic, aetiological and treatment approaches. *J Psychosom Res* 1985; 29: 89-94.
18. Garcia-Albea E, Franch O, Munoz D, Ricoy JR. Bruegel's syndrome, report of a case with postmortem studies. *J Neurol Neurosurg Psychiatry* 1981; 44: 437-40.
19. Golper LAC, Nutt JG, Rau MT, Coleman RD. Focal cranial dystonia. *J Speech Hearing Disorders* 1983; 48: 128-34.
20. Jankovic J, Ford J. Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. *Ann Neurol* 1983; 13: 402-11.
21. Martinelli P, Gabellini AS. Essential tremor and buccolingual dyskinesias. *Acta Neurol Scand* 1982; 66: 705-8.
22. Jankovic J, Nutt JG. Blepharospasm and cranial-cervical dystonia (Meige's syndrome): familial occurrence. *Adv Neurol* 1988; 49: 117-23.
23. Tolosa ES. Clinical features of Meige's disease (idiopathic orofacial dystonia). *Arch Neurol* 1981; 38: 147-51.
24. Anon. Overuse syndrome in musicians. *Med J Aust* 1987; 146: 393-4.
25. Fry JH. Overuse syndrome in musicians - 100 years ago: an historical review. *Med J Aust* 1986; 145: 620-5.
26. Lederman RJ. Overuse syndrome in musicians. *Med J Aust* 1987; 146: 390.
27. Hall T. Overuse syndrome in musicians. *Med J Aust* 1987; 146: 390.
28. Pratt RR. Overuse syndrome in musicians. *Med J Aust* 1987; 146: 390.
29. Chamagne P. Functional cramps or functional dystonias in writers and musicians. *Ann Chir Main* 1986; 5: 148-152.
30. Yassa R. The Pisa syndrome: a report of two cases. *Brit J Psychiatry* 1984; 146: 93-5.
31. Ekblom K, Lindholm H, Ljunberg L. New dystonic syndrome associated with butyrophenone therapy. *Neurology* 1972; 202: 94-103.
32. Saxena S. Tardive dystonia and Pisa syndrome. *Brit J Psychiatry* 1986; 149: 524.
33. Rosenfeld DB, Miller RH, Jankovic J. Spasmodic dysphonia: a neurolaryngeal movement disorder. *Am Acad Neurol* 1984; PP96.
34. Rosenfeld DB, Miller RH, Jankovic J, Nudelman H. Persistence of spasmodic dysphonia symptoms following recurrent laryngeal nerve section: an electrodiagnostic evaluation. *Am Acad Neurol* 1984; PP356.
35. Schaefer SD. Neuropathology of spasmodic dysphonia. *Laryngoscope*. 1983; 93: 1183-1204.
36. Hudgson P. Writer's cramp. *Br Med J [Clin Res]* 1983; 286: 585-6.
37. Marsden CD. Writer's cramp. *Br Med J [Clin Res]* 1983; 286: 1057.
38. Sheehy MP, Marsden CD. Writers' cramp - a focal dystonia. *Brain* 1982; 105: 461-80.
39. Fahn S. Torsion dystonia: clinical spectrum and treatment. *Seminars in Neurol* 1982; 2: 316-22.
40. Eldridge R. The torsion dystonias: literature review and genetic and clinical studies. *Neurology* 1970; 20: 1-78.
41. Eldridge R, Gottlieb R. The primary hereditary dystonia: genetic classification of 768 families and revised estimate of gene frequency, autosomal recessive form, and selected bibliography. *Adv Neurol* 1976; 14: 457-474.
42. Alter M, Kahana E, Feldman S. Differences in torsion dystonia among Israeli ethnic groups. *Adv Neurol* 1976; 14: 115-120.
43. Korczyn AD, Kahana E, Zilber N, Streifler M, Carasso R, Alter M. Torsion dystonia in Israel. *Ann Neurol* 1980; 8: 387-91.
44. Zilber N, Korczyn A, Kahana E, Fried K, Alter M. Inheritance of idiopathic torsion dystonia among Jews. *J Med Genet* 1984; 21: 13-20.
45. Nutt JG, Muenter MD, Melton J, et al. Epidemiology of dystonia in Rochester, Minnesota. *Adv Neurol* 50 1988; (in press).
46. Marsden CD, Lieberman AN. Involuntary movement disorders: treatment and prevention. *Clin Neuropharmacol* 1986; 9(Suppl 2): S1-S121.
47. Obeso JA, Rothwell JC, Lang AE, Marsden CD. Myoclonic dystonia. *Neurology* 1983; 33: 825-30.
48. Lang AE. Dopaminergic agonists in the treatment of dystonia. *Clin Neuropharmacol* 1985; 8: 38-57.
49. Eldridge R, Ince SI, Chernow B, Milstein S, Lake CR. Dystonia in 61-year-old identical twins: observations over 45 years. *Ann Neurol* 1984; 16: 356-8.
50. Wachtel RCD, Batshaw ML, Eldridge R, Jankel W, Cataldo M. Torsion dystonia. *John Hopkins Medical J* 1982; 151: 355-9.
51. Eldridge R, Koerber T. Torsion dystonia: autosomal recessive form. *In: Genetic Disorders Among Ashkenazi Jews*, Goodman RM, Motulsky AG, eds., Raven Press, NY, 1979; pp 231-51.
52. Johnson W, Schwartz G, Barbeau A. Studies on dystonia musculorum deformans. *Arch Neurol* 1962; 7: 301-18.
53. Zeman W, Dyken P. Dystonia musculorum deformans. *In: Handbook of Clinical Neurology*, vol 6, Vinken PJ, Bruyn GW eds., Elsevier/North Holland Biomedical Press, Amsterdam, 1981; pp 517-43.
54. Eldridge R. Inheritance of torsion dystonia in Jews. *Ann Neurol* 1981; 10: 203-4.
55. Batshaw ML, Wachtel R, Eldridge R. Letter to the Editor. *New Eng J Med* 1985; 313: 1088.
56. Bressman SB, de Leon D, Brin MF. Inheritance of primary torsion dystonia among Ashkenazi Jews. *Neurology* 1987; 37(Suppl 1): 187.
57. Oswald A, Silber M, Goldblatt J. Autosomal recessive idiopathic torsion dystonia in kindred of mixed ancestry. *S Afr Med* 1986; 79: 18-20.
58. Lisker R, Mutchinick O, Reyes ME, Santos MA, Flores T, Ramos GG. Autosomal recessive inheritance in a Mexican family with torsion dystonia. *Rev Invest Clin (Mex)* 1984; 36: 265-8.
59. Bressman SB, Fahn S, Falk C, Allen FH Jr, Suci-Foca N. Genetic linkage analysis in primary torsion dystonia. *Neurology* 1984; 34: 1490-1493.
60. Breakefield XO, Bressman SB, Kramer PL, et al. Linkage analysis in a family with dominantly inherited torsion dystonia: exclusion of the pro-opiomelanocortin and glutamic acid decarboxylase genes and other chromosomal regions using DNA polymorphisms. *J Neurogenet* 1986; 3: 159-75.
61. Harris EG. Conference report. The torsion dystonias: a summary of the Third Dystonia Workshop, Vancouver, B.C., 1980. *Can J Neurol Sci* 1981; 8: 255-7.
62. Martinez-Martin P, Pareja FB. Familial writer's cramp. *J Neurol Neurosurg Psychiatry* 1985; 48: 4.
63. Nutt JG, Hammerstad JP. Blepharospasm and oromandibular dystonia (Meige's syndrome) in sisters. *Ann Neurol* 1981; 9: 189-91.
64. Theau D, Missoum A. Syndrome dystonique severe traité avec succes par la bromocriptine et syndromes d'ataxie-télangiectasie dans une meme famille. *Arch Fr Pediatr* 1986; 43: 535-8.
65. Jankovic J, Penn AS. Severe dystonia and myoglobinuria. *Neurology* 1982; 32: 1195-7.
66. Rosenbaum F, Jankovic J. Focal task-specific tremor and dystonia. *Neurology* 1988; 38: 522-7.
67. Bunday S, Harrison MJG, Marsden CD. A genetic study of torsion dystonia. *J Med Genet* 1975; 12: 12.
68. Kiwak KJ. Establishing an etiology for torticollis. *Postgrad Medicine* 1984; 75: 126-34.
69. Lee MC. Spasmodic torticollis and other idiopathic torsion dystonias. *Postgrad Med* 1984; 75: 139-45.
70. Naber D, Weinberger DR, Bullinger M, Polsby M, Chase TN. Spasmodic torticollis. A study of symptoms, course, family history and psychopathology. *Nervenarzt* 1986; 57: 238-43.
71. Gauthier S. Idiopathic spasmodic torticollis: pathophysiology and treatment. *Can J Neurol Sci* 1986; 13: 88-90.
72. Martinelli P, Gabellini AS, Gulli MR, Lugaresi E. Different clinical features of essential tremor: a 200-patient study. *Acta Neurol Scand* 1987; 75: 106-11.

73. Mart'inez-Mart'ın P. Epidemiological aspects of essential tremor. *Arch Neurol (Madr)* 1985; 48: 189-95.
74. Bolton PS. Torticollis: a review of etiology, pathology, diagnosis and treatment. *J Manipulative Physiol Therapies* 1985; 8: 29-32.
75. Gilmore R. Movement disorders in the elderly. *Geriatrics* 1984; 39: 65-8, 72-6.
76. Segawa M, Ohmi K, Ito S, et al. Childhood basal ganglia disease with remarkable responses to L-DOPA, "hereditary basal ganglia disease with marked diurnal fluctuation". *Therapy* 1971; 24: 667-72.
77. Segawa M, Hosaka A, Miyagawa F, et al. Hereditary progressive dystonia with marked diurnal fluctuation. *Adv Neurology* 1976; 14: 215-33.
78. Haidvogel M, Stogmann W. Hereditäre progressive Dystonie mit Tageschwankungen. Jahrestag für Österreichischen Gesellschaft für Kinderheilkunde, Millstatt, 1976; 24, 9 (abstract).
79. Ouvrier RA. Progressive dystonia with marked diurnal fluctuation. *Ann Neurol* 1978; 4: 412-7.
80. Chan-Lui WY, Low LCK. Progressive dystonia with marked diurnal fluctuation in a Chinese family. *Aust Paediatr J* 1984; 20: 143-146.
81. Chan-Lui WY, Low LCK. A patient with myasthenia gravis and progressive dystonia with marked diurnal fluctuation. *Dev Med Child Neurol* 1984; 26: 665-668.
82. Bertelsmann FW, Smit LME. Progressive dystonia with marked diurnal fluctuation. *Clin Neurol Neurosurg* 1985; 87: 123-126.
83. Gordon N. Fluctuating dystonia and allied syndromes. *Neuropediatrics* 1982; 13: 152-4.
84. Deonna T. Dopa-sensitive progressive childhood dystonia with diurnal fluctuations. (Segawa type and possible variants). Results of a correspondence workshop of the E.F.C.N.S. Meeting of the E.F.C.N.S. Noordwijkerhout 1983.
85. Schenk E, Kruschke U. Familial progressive Dystonie mit Tageschwankungen - Erfolgreiche Behandlung mit L-dopa. *Klin Wschr* 1975; 53: 779-780.
86. Yamamura Y, Sobne I, Ando K, Iida M, Yanagi T, Kono C. Paralysis agitans of early onset with marked diurnal fluctuation of symptoms. *Neurology* 1978; 23: 239-44.
87. Sunohara N, Mano Y, Ando K, Satoyoshi E. Idiopathic dystonia-parkinsonism with marked diurnal fluctuation of symptoms. *Ann Neurol* 1985; 17: 39-45.
88. Aggarwal R, Bagga A, Kalra V. Progressive dystonia with marked diurnal variation. *Indian J Pediat* 1984; 51: 747-749.
89. Kumamoto I, Nomoto M, Yoshidome H, Osame M, Igata A. Five cases of dystonia with marked diurnal fluctuation and special reference to homovanillic acid in CSF. *Rinsho Shinkeigaku (Clinical Neurology)* 1984; 24: 697-702.
90. Deonna T, Ferreria A. Idiopathic fluctuating dystonia: a case of foot dystonia and writer's cramp responsive to L-dopa. *Dev Med Child Neurol* 1985; 27: 814-821.
91. Costeff H, Gadoth N, Mendelson L, Harel S, Lavie P. Fluctuating dystonia response to levodopa. *Arch Dis Childhood* 1987; 62: 801-4.
92. Nygaard TG, Marsden D. Dopa-responsive dystonia: long-term treatment response and prognosis. *Neurology* 1988; 38(Suppl 1): 130.
93. Fink JK, Baron N, Cohen W, Lovenberg W, Burns RS, Hallett M. Dystonia with marked diurnal variation associated with bipterin deficiency. *Neurology* 1988; 38: 707-11.
94. Nygaard T, Duvoisin R. Hereditary dystonia-parkinsonism syndrome of juvenile onset. *Neurology* 1986; 36: 1424-8.
95. Deonna T. DOPA-sensitive progressive dystonia of childhood with fluctuations of symptoms - Segawa's syndrome and possible variants. *Neuropediatrics* 1986; 17: 81-85.
96. Lance JW. Sporadic and familial varieties of tonic seizures. *J Neurol Neurosurg Psychiatry* 1963; 26: 51-9.
97. Lance JW. Familial paroxysmal dystonic choreoathetosis and its differentiation from related syndromes. *Ann Neurol* 1977; 2: 283-95.
98. Mount LA, Reback S. Familial paroxysmal choreoathetosis: preliminary report on a hitherto undescribed clinical syndrome. *Arch Neurol Psychiatry* 1940; 44: 841-7.
99. Forssman H. Hereditary disorder characterized by attacks of muscular contractions, induced by alcohol amongst other factors. *Acta Med Scand* 1961; 170: 517-33.
100. Kurlan R, Shoulson I. Familial paroxysmal dystonic choreoathetosis and response to alternate-day oxazepam therapy. *Ann Neurol* 1983; 13: 456-7.
101. Richards RN, Barnett HJM. Paroxysmal dystonic choreoathetosis: a family study and review of literature. *Neurology* 1968; 18: 461-9.
102. Mayeux R, Fahn S. Paroxysmal dystonic choreoathetosis in a patient with familial ataxia. *Neurology* 1982; 32: 1184-6.
103. Graff-Radford NR. A recessively inherited ataxia with episodes of dystonia. *J Neurol Neurosurg Psychiatry* 1986; 49: 591-4.
104. Plant GT, Williams AC, Earl CJ, Marsden CD. Familial paroxysmal dystonia induced by exercise. *J Neurol Neurosurg Psychiatry* 1984; 47: 275-9.
105. Willemse J. Benign idiopathic dystonia with onset in the first year of life. *Dev Med Child Neurol* 1986; 28: 355-60.
106. Deonna T, Martin D. Benign paroxysmal torticollis in infancy. *Arch Dis Child* 1981; 56: 956-959.
107. Hanukoglu A, Somekh E, Fried D. Benign paroxysmal torticollis in infancy. *Clin Ped* 1984 23: 272-4.
108. Dunn DW. Paroxysmal dystonia. *Am J Dis Child* 1981; 135: 381.
109. De Benedetto F. Il torcicollo parossistico benigno nell'infanzia. *Min Ped* 1980; 9: 647.
110. Militerni R, Tripodi V, D'Argenzio G, Quinto AM. A case of paroxysmal torticollis. *Pediatrics* 1983; 91: 265-7.
111. Casteels-Van Daele M. Benign paroxysmal torticollis in infancy. *Arch Dis Childhood* 1982; 57: 638-642.
112. Lugaresi F, Cirignotta F, Montagna P. Nocturnal paroxysmal dystonia. *J Neurol Neurosurg Psychiatry* 1986; 49: 375-80.
113. Crowell JA, Anders TF. Hypnogenic paroxysmal dystonia. *J Amer Acad Child Psychi* 1985; 24: 353-358.
114. Lee BI, Lesser RP, Pippenger CE, et al. Familial paroxysmal hypnogenic dystonia. *Neurology* 1985; 35: 1357-60.
115. Berger HJC, Berendsen-Versteeg TMC, Joosten EMG. Hypnogenic, paroxysmal dystonia: epilepsy or a new syndrome? *Ned Tijdschr Geneesk* 1984; 128: 1697-1698.
116. Godbout R, Montplaisir J, Rouleau I. Hypnogenic paroxysmal dystonia: epilepsy or sleep disorder. A case report. *Clin Electroencephalog* 1985; 16: 136-42.
117. Lugaresi E, Cirignotta F. Hypnogenic paroxysmal dystonia: epileptic seizure or a new syndrome. *Sleep* 1981; 4: 129-38.
118. Healton EB, Brust JC, Kerr DL, Resor S, Pern A. Presumably Azorean disease in a presumably non-Portuguese family. *Neurology* 1980; 30: 1084-9.
119. Goto I, Tobimatsu S, Ohta M, Hoisokawa S, Shibasaki H, Kuroiwa Y. Dentatorubropallidolysian degeneration: clinical, neuroophthalmologic, biochemical and pathologic studies on autosomal dominant form. *Neurology* 1982; 32: 1395-9.
120. Hotson JR, Langston EB, Louis AA, Rosenberg RN. The search for a physiologic marker of Machado-Joseph disease. *Neurology* 1987; 37: 112-6.
121. Sachdev HS, Forno LS, Kane CA. Joseph disease: a multisystem degenerative disorder of the nervous system. *Neurology* 1982; 32: 192-5.
122. Grossman A, Rosenberg RN, Warmouth L. Glutamate and malate dehydrogenase activities in Joseph disease and olivopontocerebellar atrophy. *Neurology* 1987; 37: 106-111.
123. Luchins DJ, Goldman M. High-dose bromocriptine in a case of tardive dystonia. *Biol Psychiatry* 1985; 20: 179-81.
124. Watts RWE, Harkness RA, Spellacy E, Taylor NF. Lesch-Nyhan syndrome: growth delay, testicular atrophy and a partial failure of the 11 β -hydroxylation of steroids. *J Inher Metab Dis* 1987; 10: 210-23.
125. Watts RWE, Spellacy E, Gibbs DA, Allsop J, McKeran RO, Slavin GE. Clinical, post-mortem, biochemical and therapeutic observations on the Lesch-Nyhan syndrome with particular reference to the neurological manifestations. *QJ Med* 1982; 51: 43-78.
126. Craig IW, Goodfellow PN. Molecular genetics of the X chromosome and X-linked diseases. *Lab Invest* 1986; 54: 241-253.
127. Goeminne L. A new probable X-linked inherited syndrome: congenital torticollis, multiple keloids, cryptorchidism and renal

- dysplasia. *Acta Henet Med Gemellol* 1968; 17: 439-467.
128. Zuffardi O, Fraccaro M. The locus for torticollis, keloids, cryptorchidism and renal dysplasia (31430 McKusick) is at Xq28, distal to the G6PD locus. *Hum Genet* 1982; 62: 280-1.
 129. Chance PF, Murray JC, Bird TD, Kochin RS. Genetic linkage relationships of Charcot-Marie-Tooth disease (HMSN-Ib) to chromosome 1 markers. *Neurology* 1987; 37: 325-329.
 130. Leblhuber F, Reisecker F, Mayr WR. Genetic linkage studies in hereditary motor and sensory neuropathies. *J Neurol* 1986; 233: 317-9.
 131. Philippart M, Brown WJ. Dystonia and lactic acidosis: new features of Rett's syndrome. *Ann Neurol* 1984; 16: 387.
 132. The Rett Syndrome Criteria Work Group. Diagnostic criteria for Rett syndrome. *Ann Neurol* 1988; 23: 425-8.
 133. DeGennaro LJ, McCaffery CA, Kirchgessner CU, Yang-Feng TL, Francke U. Molecular analysis of synapsin I, a candidate gene for Rett syndrome. *Brain Dev* 1987; 9: 469-74.
 134. Torch WC, Humphreys HK. Pharmacological therapy of Hallervorden-Spatz syndrome: two cases responsive to benzotropine. *Ann Neurol* 1986; 20: 445.
 135. Kessler C, Schwechheimer K, Reuther R, Born JA. Hallervorden-Spatz syndrome restricted to the pallidal nucleus. *J Neurol* 1984; 231: 112-6.
 136. Sethi KD, Adams RJ, Loring DW, ElGammal T. Clinical, neuropsychological and magnetic resonance imaging in Hallervorden-Spatz syndrome. *Ann Neurol* 1987; 22: 146-7.
 137. Tennison MB, Bouldin TW, Whaley RA. Mineralization of the basal ganglia detected by CT in Hallervorden-Spatz syndrome. *Neurology* 1988; 38: 154-155.
 138. Swaiman KF, Smith SA, Trock GL, Siddiqui AR. Sea-blue histiocytes, lymphocytic cytosomes, movement disorder and ⁵⁹Fe-uptake in basal ganglia: Hallervorden-Spatz disease or ceroid storage disease with abnormal isotope scan. *Neurology* 1983; 33: 301-5.
 139. Di Rocco M. Dystonia and calcification of the basal ganglia: another case. *Neurology* 1986; 36: 306.
 140. Alberca R, Rafel E, Chinchon I, Vadillo J, Navarro A. Late onset Parkinsonian syndrome in Hallervorden-Spatz disease. *J Neurol Neurosurg Psychiatry* 1987; 50: 1665-8.
 141. Perry TL, Norman MG, Yong VW, Whiting S, Crichton JU, Hansen S, Kish SJ. Hallervorden-Spatz disease: cysteine accumulation and cysteine dioxygenase deficiency in the globus pallidus. *Ann Neurol* 1985; 18: 482-9.
 142. Jankovic J, Kirkpatrick JB, Blomquist KA, Langlais PJ, Bird ED. Late-onset Hallervorden-Spatz disease presenting as familial parkinsonism. *Neurology* 1985; 35: 227-34.
 143. Walters GF, Brucher JM, Martin JJ, Ceuterick C, Pilz P, Freund M. Leigh's syndrome - several nosological entities with an identical histopathological complex? *Neuropath Appl Neurobiol* 1986; 1: 95-107.
 144. Gallego J, Obeso JA, Delgado G, Villanueva JA. Leigh disease with torsion dystonia as the sole clinical manifestation. *Arch Neurol* 1986; 49: 73-8.
 145. Rondot P, de Recondo J, Davous P, Fredy D, Rous F. Rigidite extra-pyramidale avec dystonie, atrophie optique et atteinte bilaterale du putamen chez un adolescent. Forme juvenile de la maladie de Leigh. *Rev Neurol (Paris)* 1982; 128: 143-8.
 146. Campistol J, Cusi V, Vernet A, Fernandez-Alvarez E. Dystonia as a presenting sign of subacute necrotizing encephalomyelopathy in infancy. *Eur J Pediatr* 1986; 144: 589-591.
 147. Burton K, Farrell K, Li D, Calne DB. Lesions of the putamen and dystonia: CT and magnetic resonance imaging. *Neurology* 1984; 34: 962-965.
 148. Bianco F, Floris R, Pozzassere G, Rizzo PA. Subacute necrotizing encephalopathy (Leigh's disease): clinical correlations with computerized tomography in the diagnosis of the juvenile and adult forms. *Acta Neurol Scand* 1987; 75: 214-217.
 149. Marsden CD, Lang AE, Quinn NP, et al. Familial dystonia and visual failure with striatal CT lucencies. *J Neurol Neurosurg Psychiatry* 1986; 49: 500-9.
 150. Kissel JT, Kolkin S, Chakeres D, Boesel C, Weiss K. Magnetic resonance imaging in a case of autopsy-proved adult subacute necrotizing encephalomyelopathy (Leigh's disease). *Arch Neurol* 1987; 44: 563-6.
 151. van Erven PMMM, Gabreels FJM, Ruitenbeek W, Renier WO, Lamers KJB, Sloof JL. Familial Leigh's syndrome: association with a defect in oxidative metabolism probably restricted to brain. *J Neurol* 1987; 234: 215-9.
 152. Di Mauro S, Zeviani M, Servidei S, et al. Cytochrome oxidase deficiency: clinical and biochemical heterogeneity. *Ann NY Acad Sci* 1986; 488: 19-32.
 153. Miyabayashi S, Ito T, Abukawa D, et al. Immunochemical study in three patients with cytochrome c oxidase deficiency presenting Leigh's encephalomyelopathy. *J Inher Metab Dis* 1987; 10: 289-92.
 154. Ushiyama M, Hanyu N, Ikeda S, Yanagisawa N. A case of type III (adult) GM1-gangliosidosis that improved markedly with trihexyphenidyl. *Rinsho Shinkeigaku* 1986; 26: 221-7.
 155. Nakano T, Ikeda S, Kondo K, Yanagisawa N, Tsuji S. Adult GM1-gangliosidosis: clinical patterns and rectal biopsy. *Neurology* 1985; 35: 875-80.
 156. Takamoto K, Beppu H, Hirose K, Uono M. Juvenile beta-galactosidase deficiency - a case with mental deterioration, dystonic movements, pyramidal symptoms, dysostosis and cherry red spot. *Rinsho Shinkeigaku* 1980; 20: 339-45.
 157. Oates CE, Bosch EP, Hart MN. Movement disorders associated with chronic G₂ gangliosides. *Eur Neurol* 1986; 25: 154-9.
 158. Meek D, Wolfe LS, Andermann E, Andermann F. Juvenile progressive dystonia: a new phenotype of GM₂ gangliosidosis. *Ann Neurol* 1984; 15: 348-52.
 159. Hardie RJ, Young EP, Morgan-Hughes JA. Hexosaminidase A: deficiency presenting as juvenile progressive dystonia. *J Neurol Neurosurg Psychiatry* 1988; 51: 446-7.
 160. Halperin JJ, Williams RS, Kolodny EH. Microcephaly vera, progressive motor neuron disease and nigral degeneration. *Neurology* 1982; 32: 317-20.
 161. Elwes R, Saunders M. Generalised dystonia, whispering dysphonia and Wilson's disease in members of the same family. *J Neurol Neurosurg Psychiatr* 1986; 49: 107.
 162. Bodensteiner JB, Goldblum RM, Goldman AS. Progressive dystonia masking ataxia in ataxia-telangiectasia. *Arch Neurol* 1980; 37: 464-5.
 163. Ferrannini E, Perniola T, Krajewska G, Serlenga L, Trizio M. Schwartz-Jampel syndrome with autosomal-dominant inheritance. *Eur Neurol* 1982; 21: 137-46.
 164. Yatziv S, Russell A. An unusual form of metachromatic leukodystrophy in three siblings. *Clin Genet* 1981; 19: 222-7.
 165. Lang AE, Clarke JTR, Resch L, Strasberg P, Skomorowski MA, O'Connor P. Progressive long-standing "pure" dystonia: a new phenotype of juvenile metachromatic leukodystrophy (MLD). *Neurology* 1985; 35 (Suppl 1): 194.
 166. Poll-The BT, Aicardi J, Girot R, Rosa R. Neurological findings in triosephosphate isomerase deficiency. *Ann Neurol* 1985; 17: 439-43.
 167. Davous P, Rondot P. Homocystinuria and dystonia. *J Neurol Neurosurg, Psychiatry* 1983; 46: 283.
 168. Hagberg R, Hambræus L, Bensch K. A case of homocystinuria with a dystonic neurological syndrome. *Neuropadiatrie* 1970; 1: 337-43.
 169. Hellstrom B. Progressive dystonia and dyskinesia in childhood. A review of some recent advances. *Acta Paediatr Scand* 1982; 71: 177-81.
 170. Amir N, El-Peleg O, Shalev RS, Christensen E. Glutaric aciduria type I: clinical heterogeneity and neuroradiologic features. *Neurology* 1987; 37: 1654-7.
 171. Leibel RL, Shih VE, Goodman SI, et al. Glutaric acidemia: a metabolic disorder causing progressive choreoathetosis. *Neurology* 1980; 30: 1163-8.
 172. Aicardi J, Goutieres F. A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. *Ann Neurol* 1984; 15: 49-54.
 173. Korf B, Wallman JK, Levy HL. Bilateral lucency of the globus pallidus complicating methylmalonic acidemia. *Ann Neurol* 1986; 20: 364-6.
 174. Tahmouh AJ, Alpers DH, Feigin RD, Armbrustmacher V, Prensky AL. Hartnup disease. *Arch Neurol* 1976; 33: 797-807.

175. Darras BT, Gilmore HE. Focal intermittent dystonia in Hartnup disease. *Ann Neurol* 1985; 18: 397-8.
176. Breen LA, Schochet SS Jr. Adult dystonic lipidosis. *Neurology* 1984; 34: 128-9.
177. Longstreth WT, Daven JR, Farrell DF, Bolen JW, Bird TD. Adult dystonic lipidosis: clinical, histologic, and biochemical findings of a neurovisceral storage disease. *Neurology* 1982; 32: 1295-9.
178. Martin JJ, Lowenthal A, Ceuterick C, Vanier MT. Juvenile dystonic lipidosis (variant of Niemann-Pick disease type C). *J Neurol Sci* 1984; 66: 33-45.
179. Miyajima H, Nishimura Y, Mizoguchi K, Sakamoto M, Shimizu T, Honda N. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. *Neurology* 1987; 37: 761-7.
180. Starosta-Rubinstein S, Young AB, Kluin K, et al. Clinical assessment of 31 patients with Wilson's disease. Correlations with structural changes on magnetic resonance imaging. *Arch Neurol* 1987; 44: 365-70.
181. Hawkins RA, Mazziotta JC, Phelps ME. Wilson's disease studied with FDG and positron emission tomography. *Neurology* 1987; 37: 1707-11.
182. Parker N. Hereditary whispering dysphonia. *J Neurol Neurosurg Psychiatry* 1985; 48: 218-24.
183. Hirabayashi S-i, Kanda H, Kurata S, Yanagisawa N. Effects of trihexyphenidyl in a patient with symptomatic dystonia secondary to Wilson's disease. *Brain & Devel* 1985; 7: 230.
184. Brewer GJ, Terry CA, Aisen AM, Hill GM. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. *Arch Neurol* 1987; 44: 490-3.
185. Fazio C, Agnoli A, Perissinotti E. Dystonia attitudinale e torcicollo spastico associati ad un aumento dell'cupruria. *Minerva Med* 1968; 59: 3359-68.
186. Agnoli A, Casacchia M, Fieschi C. Aspetti clinici della degenerazione epatolenticolare. Studio del "turnover" del rame in alcune sindromi extrapiramidali. *Recent Progr Med (Roma)* 1970; 49: 385-98.
187. van Bogaert L. Etudes anatomocliniques sur des dystonies de torsion d'origine hepatolenticulaire et d'origine abiotrophique dans la meme famille. *Monatschr Psychiat Neurol* 1947; 114: 331-56.
188. De Lellis M, Rosini MP, Frascarelli M, Palladini G. Un caso di spasmo di torsione. Studio morfologico e biochimico. *Acta Neurol* 1976; 31: 100-103.
189. Pall HS, Williams AC, Blake DR, Winyard P, Chirico S, Brailsford S. Movement disorder associated with abnormal copper metabolism and decreased blood antioxidants. *J Neurol Neurosurg Psychiatry* 1987; 50: 1234-5.
190. Rust RS, Noetzel MJ, Rosenblum JL, Rothbaum RJ, Keating JP. An unusual movement disorder associated with tyrosinosis and elevated cerebrospinal fluid catecholamines. *Ann Neurol* 1985; 18: 399.
191. Kristensen MO. Progressive supranuclear palsy — 20 years later. *Acta Neurol Scand* 1985; 71: 177-89.
192. Rafal RD, Friedman JH. Limb dystonia in progressive supranuclear palsy. *Neurology* 1987; 37: 1546-9.
193. Leger JM, Girault JA, Bolgert F. Isolated dystonia of an upper limb as the first sign of Steele-Richardson-Olszewski disease. *Rev Neurol* 1987; 143: 140-2.
194. Janati A. Progressive supranuclear palsy: report of a case with torticollis, blepharospasm and dysfluency. *Am J Med Sci* 1986; 292: 391-2.
195. Sieradzan K, Kwieciniski H, Sawicka E. Progressive supranuclear palsy with lower motor neuron involvement. *J Neurol* 1987; 234: 247-250.
196. Tanner CM, Goetz CG, Klawans HL. Multi-infarct PSP. *Neurology* 1987; 37: 1819.
197. Moses H, Zee D. Multi-infarct PSP. *Neurology* 1987; 37: 1819.
198. Sandyk R. Excessive yawning and progressive supranuclear palsy. *Int J Neurosci* 1987; 34: 123-4.
199. Wimalaratna HSK, Capildeo R. Is yawning a brainstem phenomenon? *Lancet* 1988; 1: 300.
200. Foster NL. Progressive supranuclear palsy and hyperkalemic periodic paralysis. *Arch Neurol* 1980; 37: 461-2.
201. Lees AJ, Hardie RJ, Stern GM. Kinesigenic foot dystonia as a presenting feature of Parkinson's disease. *J Neurol Neurosurg Psychiatry* 1984; 47: 885.
202. Poewe WH, Lees AJ, Stern GM. Dystonia in Parkinson's disease: clinical and pharmacological features. *Ann Neurol* 1988; 23: 73-78.
203. Katchen M, Duvoisin RC. Parkinsonism following dystonia in three patients. *Movement Disorders* 1986; 1: 151-7.
204. Poewe WH, Lees AJ, Stern GM. Dystonia in Parkinson's disease: clinical and pharmacological features. *Ann Neurol* 1988; 23: 73-8.
205. Frankel M, Cummings JL. Neuro-ophthalmic abnormalities in Tourette's syndrome: functional and anatomic implications. *Neurology* 1984; 34: 359-61.
206. Feinberg TE, Shapiro AK, Shapiro E. Paroxysmal myoclonic dystonia with vocalizations: new entity or variant of preexisting syndromes? *Neurol Neurosurg Psychiatry* 1986; 49: 52-7.
207. De Reuck J, Van Landegem W. The posterior crico-arytenoid muscle in two cases of Shy-Drager syndrome with laryngeal stridor. *J Neurol* 1987; 234: 187-190.
208. Berger JR, Sheremata WA, Melamed E. Paroxysmal dystonia as the initial manifestation of multiple sclerosis. *Arch Neurol* 1984; 41: 747-750.
209. Jankovic J, Patel SC. Blepharospasm associated with brainstem lesions. *Neurology* 1983; 33: 1237-40.
210. Grafton ST, Bahlis F, Bell KR. Acquired dystonia following central pontine myelinolysis. *Neurology* 1987; 37 (Suppl 1): 276.
211. Schwartz M, Selhorst J, Ochs A, et al. Oculomasticatory myorhythmia: a unique movement disorder occurring in Whipple's disease. *Ann Neurol* 1986; 20: 677-83.
212. Ferrarini G, Greco G, Guidetti D, Bragaglia MM, Zucco R, Baratti M. Paraneoplastic myelo-radiculo-neuropathy with dystonic manifestations. *Riv Neurobiol* 1984; 30: 555-61.
213. Piper HF. Nystagmus and torticollis in albinism. *Klin Mbl Augenheilk* 1980; 176: 782-91.
214. Baraitser M. A new camptodactyly syndrome. *J Med Genet* 1982; 19:40-43.
215. Aver'ianov IuN, Il'ina NA, Nechkina NP, Sokolina NA, Potomskaia LZ. Ophthalmoplegia-plus (multisystem mitochondrial cytopathy) in childhood. *Zh Nevropatol Psikiatr* 1983; 83: 1624-8.
216. Novotny EJ Jr, Singh G, Wallace DC, et al. Leber's disease and dystonia: a mitochondrial disease. *Neurology* 1986; 36: 1053-60.
217. Browne JL, Hart RR. Exacerbation of tardive dyskinesia by Joseph disease. *J Clin Psychiatry* 1986; 47: 315-316.
218. Roytta M, Olsson I, Sowander P, Svendsen P. Infantile bilateral striatal necrosis: clinical and morphological report of a case and a review of the literature. *Acta Neuropathol (Berl)* 1981; 55: 97-103.
219. Goutieres F, Aicardi J. Acute neurological dysfunction associated with destructive lesions of the basal ganglia in children. *Ann Neurol* 1982; 12: 328-32.
220. Paterson D, Carmichael EA. A form of familial cerebral degeneration chiefly affecting the lenticular nucleus. *Brain* 1924; 47: 207-31.
221. Miyoshi K, Matsuoka T, Mizushima A. Familial holotopistic striatal necrosis. *Acta Neuropathol (Berl)* 1969; 13: 240.
222. Roessmann U, Schwartz JF. Familial striatal degeneration. *Arch Neurol* 1973; 29: 314-7.
223. Pebenito R, Ferretti C, Chandry RR, Woodrow PK. Idiopathic torsion dystonia associated with lesions of the basal ganglia. *Clin Pediatr* 1984; 23: 232-5.
224. Lang AE, Quinn NP, Marsden CD. Hereditary generalized dystonia with symmetrical striatal lucencies: a probable form of Leigh's disease. *Neurology* 1984; 34 (suppl 1): 236.
225. Bargeton-Farkas E, Cochard AM, Brissaud HE, Robain O, LeBalle JC. Encephalopathie infantile familiale avec necrose bilaterale et symmetrique des corps stries. *J Neurol Sci* 1964; 1: 429-445.
226. Tudehope DI, Burns YR, O'Callaghan M, Mohay H. Minor neurological abnormalities during the first year of life in infants of birth weight less than 1500 g. *Aust Paediatr J* 1981; 17: 265-8.
227. Burke RE, Fahn S, Gold AP. Delayed-onset dystonia in patients

- with "static" encephalopathy. *J Neurol Neurosurg Psychiatry* 1980; 43: 789-797.
228. Obeso JA, Vaamonde J, Barraquer-Bordas L. Delayed onset dystonia. *J Neurol Neurosurg Psychiatry* 1985; 48: 1190-1.
229. Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. *Neurology* 1985; 35: 73-7.
230. Treves T, Korczyn AD. Progressive dystonia and paraparesis in cerebral palsy. *Eur Neurol* 1986; 25: 148-53.
231. Kyllerman M. Reduced optimality in pre- and perinatal conditions in dyskinetic cerebral palsy - distribution and comparison to controls. *Neuropediatrics* 1983; 14: 29-36.
232. Kyllerman M, Bager B, Bensch J, Bille B, Olow I, Voss H. Dyskinetic cerebral palsy. I. Clinical categories, associated neurological abnormalities and incidences. *Acta Paediatr Scand* 1982; 71: 543-50.
233. Boiten J, Hageman G, de Graaff R. The conservative treatment of patients presenting with Grisel's syndrome. *Clin Neurol Neurosurg* 1986; 88: 95-9.
234. Pinelli G, Piantanida M, Roffo A, Baldini A, Bonioli E. Grisel's syndrome in paediatric age. *Min Ped* 1981; 33: 39-41.
235. Stevanovic L, Weber S. Retropharyngeal abscess as a cause of cervical spine syndrome. *Schweiz Rundschau Med* 1986; 75: 585-9.
236. Neng T, Yi C, Xiu-Bao Z, Zhi-Jiao Q. Acute infectious torticollis. *Neurology* 1983; 33: 1344-6.
237. Fox GN. Acute infectious torticollis in the United States. *Neurology* 1985; 35: 774.
238. Komandenko NI, Grabchuk MA, Komandenko AN. The questions of etiology, pathogenesis, a clinic and treatment of spastic torticollis and other extrapyramidal disorders. *Zh Nevropatol Psikhiatr* 1985; 85: 1783-6.
239. Gollomp SM, Fahn S. Transient dystonia as a complication of varicella. *J Neurol Neurosurg Psychiatry* 1987; 50: 228-9.
240. Knecht JG. Sydenham's chorea. A case report of neurologic sequelae in the foot. *J Amer Podiatry Assoc* 1983; 73: 581-5.
241. Massey EW, Allen NB, Cole TB. Essential blepharospasm and Sjogren's syndrome. *Am Acad Neurol* 1984; PP95.
242. Jankovic J, Patten BM. Blepharospasm and autoimmune diseases. *Movement Disorders* 1987; (in press).
243. Kurlan R, Jankovic J, Rubin A, Patten B, Griggs R, Shoulson J. Coexistent Meige's syndrome and myasthenia gravis. A relationship between blinking and extraocular muscle fatigue? *Arch Neurol* 1987; 44: 1057.
244. Nath A, Jankovic J, Pettigrew LC. Movement disorders and AIDS. *Neurology* 1987; 37: 37-41.
245. Diamond EL, Trobe JD, Belar CD. Psychological aspects of essential blepharospasm. *J Nerv Ment Dis* 1984; 172: 749-56.
246. Wolintz AH, Miller CF. Stress and visual function. *Mt Sinai J Med* 1987; 54: 78-85.
247. Rentrop E, Straschill M. Effect of emotional factors on the occurrence of idiopathic spasmodic torticollis. *Z Psychosom Med Psychoanal* 1986; 32: 44-59.
248. Yonchev V, Yonchev A. The functional conditions of the extrapyramidal system and neuroleptic acute dystonias. *Folia Medica* 1984; 26: 25-8.
249. Schott GD. Induction of involuntary movements by peripheral trauma: an analogy to causalgia. *Lancet* 1986; 712-5.
250. Schott GD. The relationship of peripheral trauma and pain to dystonia. *J Neurol Neurosurg Psychiatry* 1985; 48: 698-701.
251. Lesser RP, Fahn S. Dystonia: a disorder often misdiagnosed as a conversion reaction. *Am J Psychiatry* 1978; 135: 349-452.
252. Batshaw ML, Wachter RC, Decker AW. Munchausen's syndrome simulating torsion dystonia. *New Engl J Med* 1985; 312: 1437-1439.
253. Lang AE. Munchausen's syndrome simulating torsion dystonia. *N Engl J Med* 1985; 313: 1088.
254. Zeman W. Pathology of the torsion dystonias (dystonia musculorum deformans). *Neurology* 1970; 20: 79-88.
255. Zweig RM, Hedreen JC, Jankel WR, Casanova MF, Whitehouse PJ, Price DL. Pathology in brainstem regions of individual with primary dystonia. *Neurology* 1988; 38: 702-6.
256. Hornykiewicz O, Kish S, Becker L, Farley I, Shannak K. Brain neurotransmitters in dystonia musculorum deformans. *New Engl J Med* 1986; 315: 347-53.
257. Jankovic J, Svendsen CN. Brain neurotransmitters in dystonia. *N Engl J Med* 1987; 316: 278-279.
258. Quattrini A, Cinti F, Cianci F, Orteni A, Paggi A, Silvestri R. Clinical and CT aspects of torsion dystonias. *Riv Pat Nerv Ment* 1981; 102: 181-91.
259. Friedman JH, Chiucchini MAJI, Tucci JR. Idiopathic hypoparathyroidism with extensive brain calcification and persistent neurologic dysfunction. *Neurology* 1987; 37: 307-9.
260. Lucci B, Zucco R. Striopallidodentate calcifications. Report of two cases. *Riv Patol Nerv Ment* 1981; 102: 1-11.
261. Micheli F, Parda MMF, Parera IC, Giannula R. Spasmodic paroxysmal dystonic choreoathetosis associated with basal ganglia calcifications. *Ann Neurol* 1986; 20: 750.
262. Yamamoto K, Kawazawa S. Basal ganglion calcification in paroxysmal dystonic choreoathetosis. *Ann Neurol* 1987; 22: 556.
263. Caraceni T, Broggi G, Avanzini G. Familial idiopathic basal ganglia calcification exhibiting "dystonia musculorum deformans" features. *Europ Neurol* 1974; 12: 351-359.
264. Saint-Hilaire M-H, Burke RE, Fahn S, Bressman SB. Delayed onset dystonia following prenatal or childhood anoxia: natural history and treatment. *Neurology* 1988; 38 (Suppl 1): 130.
265. Inbody S, Jankovic J. Hyperkinetic mutism: bilateral ballism and basal ganglia calcification. *Neurology* 1986; 36: 825-7.
266. Andrew J, Fowler C, Harrison MJG. Hemi-dystonia due to focal basal ganglia lesion after head injury and improved by stereotaxic thalamotomy. *J Neurol Neurosurg Psychiatry* 1982; 45: 276.
267. Hirase T, Kawasaki S, Araki S. Familial dystonia with atrophy of the putamen and caudate nuclei detected by CT scan - biochemical study of catecholamine metabolism. *Rinsho Shinkeigaku* 1983; 23: 585-91.
268. Mills KLG, Scotland TR, Wardlaw D, Wytch R. Rapid development of basal ganglia calcification caused by anoxia. *J Neurol Neurosurg Psychiatry* 1988; 51: 449-50.
269. Keane JR, Young JA. Blepharospasm with bilateral basal ganglia infarction. *Arch Neurol* 1985; 42: 1206-8.
270. Maki Y, Akimoto H, Enomoto T. Injuries of basal ganglia following trauma in children. *Child's Brain* 1980; 7: 113-23.
271. Pauranik A, Verma A, Maheshwari MC. Reversible movement disorder in a patient with post traumatic basal ganglia haematoma. *J Neurol Neurosurg Psychiatry* 1987; 50: 1076-7.
272. Altrocchi PH, Forno LS. Spontaneous oral-facial dyskinesia: neuropathology of a case. *Neurology* 1983; 33: 802-5.
273. Williams AC, Owen C, Heath DA. A compulsive movement disorder with cavitation of caudate nucleus. *J Neurol Neurosurg Psychiatry* 1988; 51: 447-8.
274. Daras M, Georgakopoulos T, Avdelidis D. Late onset posthemiplegic dystonia in systemic lupus erythematosus. *J Neurol Neurosurg Psychiatry* 1988; 51: 151-2.
275. De Lellis M, Rosini MP, Frascarelli M, Palladini G. Un caso di spasmo di torsione. Studio morfologico e biochimico. *Acta Neurologica* 1976; 31: 100-103.
276. Messimy R, Diebler C, Metzger J. Dystonie de torsion du membre superieur gauche probablement consecutive a un traumatisme cranien. *Neurol (Paris)* 1977; 133: 199-206.
277. LeWitt PA, Martin SD. Dystonia and hypokinesia with putaminal necrosis after methanol intoxication. *Clin Neuropharmacol* 1988; 11: 161-7.
278. Berkovic SF, Karpatis G, Carpenter S, Lang AE. Progressive dystonia with bilateral putaminal hypodensities. *Arch Neurol* 1987; 44: 1184-1187.
279. D'Alessandro R, Tinuper P, Lozito A, Sacquegna T, Cortelli P, Pazzaglia P. CT scan in a case of progressive generalized dystonia with amyotrophic paraplegia. *Ital J Neurol Sci* 1983; 3: 335-337.
280. Brett EM, Hoare RD, Sheehy MP, Marsden CD. Progressive hemidystonia due to focal basal ganglia lesions after mild head trauma. *J Neurol Neurosurg Psychiatry* 1981; 44: 460.
281. Traub M, Ridley A. Focal dystonia in association with cerebral infarction. *J Neurol Neurosurg Psychiatry* 1982; 45: 1073-4.
282. Demierre B, Rondot P. Dystonia caused by putamino-capsulo-

- caudate vascular lesions. *J Neurol Neurosurg Psychiatry* 1983; 46: 404-9.
283. Russo LS Jr. Focal dystonia and lacunar infarction of the basal ganglia. *Arch Neurol* 1983; 40: 61-2.
284. Grimes JD, Hassan MN, Quarrington AM, D'Alton J. Delayed-onset posthemiplegic dystonia: CT demonstration of basal ganglia pathology. *Neurology* 1982; 32: 1033-5.
285. Fross RD, Martin WRW, Li D, et al. Lesions of the putamen: their relevance to dystonia. *Neurology* 1987; 37: 1125-9.
286. Serby M, Goodgold A. Tardive dyskinesia-like disorder due to basal ganglia irradiation. *J Clin Psychopharmacol* 1986; 6: 122.
287. Narbona J, Obeso JA, Tunon T, Martinez-Lage JM, Marsden CD. Hemi-dystonia secondary to localised basal ganglia tumour. *J Neurol Neurosurg Psychiatry* 1984; 47: 704-9.
288. Franke A, Neu I. A case of torsion dystonia after carbon monoxide poisoning. *Nervenarzt* 1977; 48: 345-7.
289. Anegawa T, Harada K, Akiguchi I, Kameyama M. Two cases of posthemiplegic dystonia and contralateral striatal low density area on CT caused by inflammatory vasculitis. *Rinsho Shinkeigaku* 1986; 26: 180-3.
290. Eaton JM. Hemidystonia due to subdural hematoma. *Neurology* 1988; 38: 507.
291. Friedman DI, Jankovic J, Rolak LA. Arteriovenous malformation presenting as hemidystonia. *Neurology* 1986; 36: 1590-3.
292. Glatt SL, Nausieda PA. Posthemiplegic dystonia: radioautographic and pharmacologic analysis. *Am Acad Neurol* 1984; PP354.
293. Kaste M, Iivanainen M, Juntunen J, Setale A. Brain involvement in spasmodic torticollis. *Acta Neurol Scand* 1981; 63: 373-80.
294. Chopra JS, Radhakrishnan K, Sridharan R. Meige's syndrome: clinical, pharmacological and radiological observations. *Clin Neurol Neurosurg* 1981; 83: 145.
295. van Hoof JJM, Horstink MWI, Berger HJC, van Spaendonck KPM, Cools AR. Spasmodic torticollis: the problem of pathophysiology and assessment. *J Neurol* 1987; 234: 322-7.
296. Obeso JA, Martinez Vila E, Delgado G, Vaamonde J, Maravi E, Martinez Lage JM. Delayed onset following hemiplegic migraine. *Headache* 1984; 24: 266-8.
297. Rasmussen K, Fabian RH. Posttraumatic focal dystonia. *Am Acad Neurol* 1984; PP170.
298. Powers JM. Blepharospasm due to unilateral diencephalon infarction. *Neurology* 1985; 35: 283-4.
299. Solomon GE, Engel M, Hecht HL, Rapoport AR. Progressive dyskinesia due to internal cerebral vein thrombosis. *Neurology* 1982; 32: 769-72.
300. Rousseaux M, Combelles G, Petit H. Bilateral internuclear ophthalmoplegia, ataxia and dystonia with post-traumatic pontine hematoma. *Rev Otoneuroophthalmol* 1984; 56: 57-62.
301. Diel HW, Pulst St-M, Engelhardt P, Mehraein P. Paraneoplastic brainstem encephalitis with acute dystonia and central hypoventilation. *J Neurol* 1982; 227: 229-238.
302. Gimenez-Roldan S, Barraquer-Bordas LL. Torsion dystonia: historical evolution with a note on the Spanish contribution. *Arch Neurobiol (Madr)* 1986; 49: 99-112.
303. Marsden CD, Obeso JA, Zarranz JJ, Lang AE. The anatomical basis of symptomatic hemidystonia. *Brain* 1985; 108: 463-83.
304. Jankovic J. Blepharospasm with basal ganglia lesions. *Arch Neurol* 1986; 43: 866-7.
305. Quinn N, Bydder G, Leenders N, Marsden CD. Magnetic resonance imaging to detect deep basal ganglia lesions in hemidystonia that are missed by computerized tomography. *Lancet ii* 1985; 1007-8.
306. Larsen TA, Dunn HG, Jan JE, Calne DB. Dystonia and calcification of the basal ganglia. *Neurology* 1985; 35: 533-7.
307. Mas J-L, Launay M, Derouesne C. Hemiballism and CT-documented lacunar infarct in the lenticular nucleus. *J Neurol Neurosurg Psychiatry* 1987; 50: 104-5.
308. Gross M. Giant middle cerebral aneurysm presenting as hemiparkinsonism. *J Neurol Neurosurg Psychiatry* 1987; 50: 1075-84.
309. House A, Hodges J. Persistent denial of handicap after infarction of the right basal ganglia: a case study. *J Neurol Neurosurg Psychiatry* 1988; 51: 112-5.
310. Bronstein AM, Rudge P. Vestibular involvement in spasmodic torticollis. *J Neurol Neurosurg Psychiatry* 1986; 49: 290-5.
311. Diamond SG, Markham CH, Baloh RW. Ocular counterrolling abnormalities in spasmodic torticollis. *Arch Neurol* 1988; 45: 164-9.
312. Dawson DM, Feudo P, Zubick HH, Rosenberg R, Fowler H. Electro-oculographic findings in Machado-Joseph disease. *Neurology* 1982; 32: 1272-6.
313. Day TJ, Lefroy RB, Mastaglia FL. Meige's syndrome and palatal myoclonus associated with brain stem stroke. A common mechanism? *J Neurol Neurosurg Psychiatry* 1986; 49: 1324-5.
314. Lang AE, Sharpe JA. Blepharospasms associated with palatal myoclonus and communicating hydrocephalus. *Neurology* 1984; 34: 1522.
315. Anon. Blepharospasm associated with palatal myoclonus and communicating hydrocephalus (letter). *Neurology* 1984; 34: 1522-4.
316. Sandyk R, Gillman MA. Blepharospasm associated with palatal myoclonus and communicating hydrocephalus. *Neurology* 1984; 34: 1522-3.
317. Jankovic J. Blepharospasm associated with palatal myoclonus and communicating hydrocephalus. *Neurology* 1984; 34: 1523.
318. Scherokman B, Husain F, Cuetter A, Jabbari B, Maniglia E. Peripheral dystonia. *Arch Neurol* 1986; 43: 830-2.
319. Al-Kawi MXZ. Focal dystonia in spinal stenosis. *Arch Neurol* 1987; 44: 692-3.
320. K'omar J, Szegwari M. Peripheral neurologic background of writer's cramp: type with median nerve lesion. *Nervenarzt* 1983; 54: 322-5.
321. Witt TN, Jager M. Congenital subluxation of the metacarpophalangeal joint of the thumb as the cause of writer's syndrome. *Z Orthop* 1984; 122: 37-9.
322. Canale ST, Griffin DW, Hubbard CN. Congenital muscular torticollis. *J Bone Joint Surg* 1982; 64: 810.
323. Morrison DL, MacEwen GD. Congenital muscular torticollis: observations regarding clinical findings, associated conditions, and results of treatment. *J Ped Orthoped* 1982; 2: 500-5.
324. Nemet J, Godel V, Baruch E, Lazar M. Pitfall of acquired ocular torticollis. *J Ped Ophthal Strabismus* 1980; 17: 310-1.
325. Sty JR, Wells RG, Schroeder BA. Congenital muscular torticollis: computed tomographic observations. *Am J Dis Child* 1987; 141: 243-4.
326. Dyck P. Spasmodic torticollis and neurovascular compression. *J Neurosurg* 1986; 64: 686-687.
327. Girodias J-B, Duhaime M, Marton D, Berner M, Boisvert J. Calcification d'un disque intervertebral: cause inhabituelle de torticollis chez l'enfant. *L'Union Med du Can* 1980; 109: 1078-80.
328. Pagni CA, Naddeo M, Faccani G. Spasmodic torticollis due to neurovascular compression of the 11th nerve. *J Neurosurg* 1985; 63: 789-91.
329. Shima F, Fukui M, Matsubara T, et al. Spasmodic torticollis caused by vascular compression of the spinal accessory root. *Surg Neurol* 1986; 26: 431-4.
330. Freckmann N, Hagenah R. Relationship between the spinal accessory nerve and the posterior root of the first cervical nerve in spasmodic torticollis and common autopsy cases. *Zentralbl Neurochir* 1986; 47: 134-8.
331. Rubin SE, Wagner RS. Ocular Torticollis. *Survey Ophthalmology* 1986; 30: 366-76.
332. Samat HB, Morrissy RT. Idiopathic torticollis: sternocleidomastoid myopathy and accessory neuropathy. *Muscle Nerve* 1981; 4: 374-80.
333. Hadari A, Azizi E, Lernau O, Nissan S. Sandifer's syndrome - a rare complication of hiatal hernia. A case report. *Z Kinderchir* 1984; 39: 202-3.
334. Taboas-Perez RA, Rivera-Reyes L. Head tilt: a revisit to an old sign of posterior fossa tumors. *Assoc Med Puerto Rico Bol* 1987; 76: 62-5.
335. Kiwak KJ, Deray MJ, Shields WD. Torticollis in three children with syringomyelia and spinal cord tumor. *Neurology* 1983; 33: 946-8.
336. Maxwell RE. Surgical management of torticollis. *Postgrad Med* 1984; 75: 147-55.

337. Robb JE, Southgate GW. An unusual case of torticollis. *J Pediatr Orthop* 1986; 6: 469.
338. Dubouset J. Torticollis in children caused by congenital anomalies of the atlas. *J Bone Joint Surgery* 1986; 68A: 178.
339. Bagolini B, Campos EC, Chiesi C. Plagiocephaly causing superior oblique deficiency. *Arch Ophthalmol* 1982; 100: 1093-6.
340. Wang FM. Plagiocephaly and torticollis. *J Pediatrics* 1981; 99: 164.
341. Junck L, Gilman S, Hichwa RD, Young AB, Markel DS, Ehrenkauf RLE. PET studies of local cerebral glucose metabolism in idiopathic torsion dystonia. *Neurology* 1986; 36(Suppl 1): 182.
342. Tempel LW, Perlmutter JS. Abnormal cerebral blood flow response to vibrotactile stimulation in dystonics. *Neurology* 1988; 38(Suppl 1): 131.
343. Stoessl AJ, Martin WRW, Clark C, et al. PET studies of cerebral glucose metabolism in idiopathic torticollis. *Neurology* 1986; 36: 653-7.
344. Perlmutter JS, Raichle ME. Pure hemidystonia with basal ganglion abnormalities on positron emission tomography. *Ann Neurol* 1984; 15: 228-33.
345. Jankel WR, Allen RP, Niedermeyer E, Kalsher MJ. Polysomnographic findings in dystonia musculorum deformans. *Sleep* 1983; 6: 281-5.
346. Jankel WR, Niedermeyer E, Graf M, Kalsher M. Polysomnography of torsion dystonia. *Arch Neurol* 1984; 41: 1081-1083.
347. Jankel WR, Niedermeyer E, Graf M, Kalsher MJ. Case report: polysomnographic effects of thalamotomy of torsion dystonia. *Neurosurg* 1984; 14: 495-8.
348. Wein A, Golubev V. Polygraphic analysis of sleep in dystonia musculorum deformans. *Waking & Sleeping* 1979; 3: 41-50.
349. Narayan TM, Ludwig C, Sato S. A study of multimodality evoked responses in idiopathic spasmodic torticollis. *Electroencephalog Clin Neurophysiol* 1986; 63: 239-41.
350. Zeithofer J, Brainin M, Reiser TH. BAEP abnormalities in tardive dyskinesia. *J Neurol* 1984; 231: 266-8.
351. Golubev VL. Facial paraspasm. *Zh Nevropatol Psikhiatr* 1986; 86: 504-9.
352. Jacome DE, Risko M. Photic induced-driven PLEDs in paroxysmal dystonic choreoathetosis. *Clin Electroenceph* 1984; 15: 153.
353. Quinn NP, Marsden CD. Dominantly inherited myoclonic dystonia with dramatic response to alcohol. *Am Acad Neurol* 1984; PP7.
354. Karson CN, Burns RS, LeWitt PA, Foster NL, Newman RP. Blink rates and disorders of movement. *Neurology* 1984; 34: 677-8.
355. Tatton WG, Bedingham W, Verrier MC, Blair RDG. Characteristic alterations in responses to imposed wrist displacements in parkinsonian rigidity and dystonia musculorum deformans. *Can J Neurol Sci* 1984; 11: 281-7.
356. Rothwell JC, Obeso JA, Day BL, Marsden CD. Pathophysiology of dystonias. In: JE Desmedt, ed. *Motor Control Mechanisms in Health and Disease*, Raven Press, NY, 1983; pp 851-63.
357. Fasshauer K. Klinische und elektromyographische Verlaufsuntersuchungen beim Torticollis spasmodicus. *Nervenarzt* 1983; 54: 535-9.
358. Marsden CD. The pathophysiology of movement disorders. *Neurol Clin* 1984; 2: 435-59.
359. Thompson PD, Dick JPR, Day BL, et al. Electrophysiology of the corticomotoneurone pathways in patients with movement disorders. *Movement Disorders* 1986; 1: 113-7.
360. Stejskal L, Tomanek Z. Postural laterality in torticollis and torsion dystonia. *J Neurol Neurosurg Psychiatry* 1981; 41: 1029-34.
361. Corbin DOC, Williams AC, White AC. Tardive dystonia: which way do schizophrenics twist? *Lancet* 1987; i: 268-9.
362. Wolfson LI, Sharpless NS, Thal LJ, Waltz JM, Shapiro K. Decreased ventricular fluid norepinephrine metabolite in childhood-onset dystonia. *Neurology* 1983; 33: 369-72.
363. Tabaddor K, Wolfson LI, Sharpless NS. Diminished ventricular fluid dopamine metabolites in adult-onset dystonia. *Neurology* 1978; 28: 1254-8.
364. Tabaddor K, Wolfson LI, Sharpless NS. Ventricular fluid homovanillic acid and 5-hydroxyindoleacetic acid concentrations in patients with movement disorders. *Neurology* 1978; 28: 1249-53.
365. Barkhatova VP, Kandel EI, Demina EG. Approaches to the study of cerebral dopamine metabolism in certain extrapyramidal diseases. *Neurosci Behav Physiol* 1985; 15: 132-9.
366. West KA, Edvinson L, Nielsen KC, et al. Concentration of acid monoamine metabolites in ventricular CSF of patients with posterior fossa tumours. In: Brock M, Dietz H, eds. *Intracranial Pressure: Experimental and Clinical Aspects*. Springer-Verlag, Berlin, 1972; pp. 331-7.
367. Curzon G, Kantamaneni BD, Bartlett JR, et al. Transmitter precursors and metabolites in human ventricular cerebrospinal fluid. *J Neurochem* 1976; 26: 613-5.
368. Stahl SM, Faull KF, Barchas JD, Berger PA. CSF monoamine metabolites in movement disorders and normal aging. *Arch Neurol* 1985; 42: 166-9.
369. Busard HLSM, Renier WO, Gabreels FJM, Horstink MWJM, Rotteveel JJ. Sporadic distal dystonia: a clinical study of seven juvenile cases. *Clin Neurol Neurosurg* 1983; 85: 23-9.
370. Chase TN, Gordon EK, Ng LKY. Norepinephrine metabolism in the central nervous system of man: studies using 3-methoxy-4-hydroxyphenylethylene glycol levels in cerebrospinal fluid. *J Neurochem* 1973; 21: 581-7.
371. Lal S, Allen J, Etienne P, Sourkes TL, P Humphreys. Dopaminergic function in Gilles de la Tourette's syndrome, Sydenham's chorea and torsion dystonia. *Clin Neurol Neurosurg* 1976; 79: 66-9.
372. Fahn S. Systemic therapy of dystonia. *Can J Neurol Sci* 1987; 14: 528-32.
373. Willemsse J, Van Nieuwenhuizen O, Gooskens RH, Westenberg HGM. Treatment of non-fluctuating progressive dystonia a neuropharmacological approach. *Neuropediatrics* 1984; 15: 208-10.
374. Sunohara N, Mukoyama M, Mano Y, Satoyoshi E. Action-induced rhythmic dystonia: an autopsy case. *Neurology* 1984; 34: 321-7.
375. Shimoyamada Y, Yoshikawa A, Kashii H, Kihira S, Koike M. Hereditary progressive dystonia - an observation of the catecholamine metabolism during L-DOPA therapy in a 9-year old girl. *No To Hattatsu* 1986; 18: 505-9.
376. Abbott RJ, Currie S, Howe JG, Sumner DW. Cerebrospinal fluid γ -aminobutyric acid in spasmodic torticollis. *Ann Neurol* 1983; 13: 342.
377. Perry TL, Hansen S, Quinn N, Marsden CD. Concentration of GABA and other amino acids in CSF from torsion dystonia patients. *J Neurochem* 1982; 39: 1188-91.
378. Thal LJ, Sharpless NS, Rosenbaum D, Davies P, Amin IM, Waltz JM. Ventricular fluid somatostatin concentration decreases in childhood-onset dystonia. *Neurology* 1985; 35: 1742-6.
379. Cramer H, Wolf A, Rissler K, Weigel K, Osterlag C. Ventricular somatostatin-like immunoreactivity in patients with basal ganglia disease. *J Neurol* 1985; 232: 219-22.
380. Cullis PA, Townsend L, LeWitt P, Pomara N, Reitz D. Electrophoresis and immunoblot of cerebrospinal fluid proteins in spasmodic torticollis. *Movement Disorders* 1986; 1: 179-186.
381. LeWitt PA, Newman RP, Miller LP, Lovenberg W, Eldridge R. Treatment of dystonia with tetrahydrobiopterin (letter). *N Engl J Med* 1983; 308: 157-8.
382. LeWitt PA, Miller LP, Levine RA, et al. Tetrahydrobiopterin in dystonia: identification of abnormal metabolism and therapeutic trials. *Neurology* 1986; 36: 760-4.
383. Smith I, Leeming RJ, Cavanagh NP, Hyland K. Neurological aspects of biopterin metabolism. *Arch Dis Child* 1986; 61: 130-7.
384. Williams A, Eldridge R, Levine R, Lovenberg W, Paulson G. Low CSF hydroxylase cofactor (tetrahydrobiopterin) levels in inherited dystonia. *Lancet* ii 1979; 410-1.
385. Williams AC, Levine RA, Chase TN, Lovenberg W, Calne DB. CSF hydroxylase cofactor levels in some neurological diseases. *J Neurol Neurosurg Psychiatry* 1980; 43: 735-8.
386. Tanaka K, Yoneda M, Nakijima T, Miyatake T, Owada M. Dihydrobiopterin synthesis defect: an adult with diurnal fluctuation of symptoms. *Neurology* 1987; 37: 519-22.
387. Mehta BC, Srinivas HV, Taly AB. Dystonia musculorum deformans

- mans with hyperuricaemia study of a family. *Clin Neurol Neurosurg* 1982; 84: 29-36.
388. Coleman M. Effect of nicotinamide administration in a patient with an extrapyramidal movement disorder and hyperuricemia: a double-blind crossover study. *Adv Neurol* 1976; 14: 297-302.
 389. Wooten GF, Eldridge R, Axelrod J, Stern RS. Elevated plasma dopamine-beta-hydroxylase activity in an autosomal dominant torsion dystonia. *N Engl J Med* 1973; 288: 284-7.
 390. Ziegler MG, Lake CR, Eldridge R, Kopin JJ. Plasma norepinephrine and dopamine-beta-hydroxylase in dystonia. *Adv Neurol* 1976; 14: 307-15.
 391. Ebstein RP, Freedman LS, Lieberman A, et al. A familial study on serum dopamine-beta-hydroxylase levels in torsion dystonia. *Neurology* 1974; 24: 684-7.
 392. Menkes JH, Wetterberg L, Ross SB, et al. Catecholaminergic activity in idiopathic torsion dystonia. *Neurology* 1987; 37: 779-83.
 393. Korczyn AD, Rabinowitz R, Kahana E, Streifler M, Carasso R, Alter M. Dopamine- β -hydroxylase (DBH) in idiopathic torsion dystonia. *J Neurol Sci* 1982; 53: 91-3.
 394. Friedman H, Mendlewicz J. Plasma dopamine-beta-hydroxylase activity in spasmodic torticollis. *Neuropsychobiology* 1981; 7: 238-42.
 395. Korczyn AD, Lazarovits J, Dvilanski A, Eshel Y, Nathan I. 5-Hydroxytryptamine in platelets of torsion dystonia patients. *Acta Neurol Scand* 1985; 71: 171-3.
 396. Maltese WA, Bressman S, Fahn S, DeViVivo DC. Acetylcholinesterase activity in patients with torsion dystonia. *Arch Neurol* 1985; 42: 154-5.
 397. Pratty JS, Ananth J, O'Brien JE. Relationship between dystonia and serum calcium levels. *J Clin Psychiat* 1986; 47: 418-9.
 398. Borisova TV. Exchange of microelements in patients with hereditary extrapyramidal diseases. *Zh Nevropatol Psikhiatr* 1978; 78: 217-21.
 399. Gannushkina IV, Zhirnova JG, Toropova NG, Toporkina TD, Markova ED. Quantitative evaluation of the T- and B- systems of immunity in various hereditary diseases of the nervous system. *Zh Nevropatol Psikhiatr* 1981; 81: 1009-13.
 400. Moore AP, Behan PO, Behan WMH. Lymphocyte subset abnormalities in patients with spasmodic torticollis. *Acta Neurol Scand* 1986; 74: 371-8.
 401. Korein J, Willoughby E, Pollack MS, Levidow L, Dupont B. Human leucocyte antigen in torticollis and other idiopathic dystonic symptoms. *Ann Neurol* 1981; 10: 573-5.
 402. Mosunova TG. The change of catecholamines in extrapyramidal disorders in children. *Zh Nevropatol Psikhiatr* 1977; 77: 1466-9.
 403. Iwanowa-Smolenskja JA, Barchatowa WP. Characteristics of central neurotransmitter metabolism in hereditary extrapyramidal disorders. *Neurol Neurochir Pol* 1981; 15: 377-80.
 404. Dadali EL. Catecholamine excretion in various forms and at various stages of deforming myodystonia. *Sov Med* 1980; 41: 5.
 405. Iadgarov IS. Circadian rhythm of catecholamine excretion: effect of L-DOPA in various diseases of the nervous system. *Zh Nevropatol Psikhiatr* 1983; 83: 1792-6.
 406. Mel'nichuk PV, Khokhlov AP, Khailova IM. Pathogenesis of hyperkinesias in children. *Neurosci Behav Physiol* 1984; 14: 241-5.
 407. Breakefield XO, Braverman M, Riker DK, Giller EL Jr. Catechol-O-methyltransferase activity in cultured human skin fibroblasts from controls and patients with dystonia musculorum deformans. *J Neurosci Res* 1981; 6: 349-360.
 408. Edelstein SB, Costa MRC, Castiglione CM, Breakfield XO. Monoamine oxidase activity in fibroblasts from control individuals and patients with inherited neurologic disease. In: Usdin E, Kopin JJ, Barchas J eds. *Catecholamines: Basic and Clinical Frontiers*. Pergamon Press, New York 1979; pp 210-12.
 409. Maltese WA, De Vivo DC. Cholesterol and phospholipids in cultured skin fibroblasts from patients with dystonia. *Ann Neurol* 1984; 16: 250-2.
 410. Thomas RA, Gordon AS, Diamond I. Phosphoprotein phosphatase activity in normal and dystonic human fibroblast plasma membranes (41082). *Proc Soc Exper Biol Med* 1981; 166: 405-12.
 411. Korein J. Iris pigmentation (melanin) in segmental dystonic syndromes including torticollis. *Trans Amer Neurol Assoc* 1980; 105: 361-4.
 412. Korein J. Iris pigmentation (melanin) in idiopathic dystonic syndromes including torticollis. *Ann Neurol* 1981; 10: 53-5.
 413. Korein J. Reply to the authors. *Ann Neurol* 1982; 12: 586.
 414. Lang AE, Ellis C, Kingon H, Marsden CD. Iris pigmentation in idiopathic dystonia. *Ann Neurol* 1982; 12: 585-6.
 415. Nutt JG, Carter J, DeGarmo P, Hammerstad JP. Meige syndrome and thyroid dysfunction. *Neurology* 1984; 34 (Suppl 1): 222.
 416. Lang AE. Familial Meige syndrome and thyroid dysfunction. *Neurology* 1985; 35: 138.
 417. Mehta AB, Marsden CD. Latent idiopathic torsion dystonia provoked by thyrotoxicosis. *J Neurol Neurosurg Psychiatry* 1981; 44: 93-4.
 418. Anon. The management of dystonias. *Lancet* 1985; ii: 321-322.
 419. Poewe WH, Lees AJ. The pharmacology of foot dystonia in Parkinsonism. *Clin Neuropharmacol* 1987; 10: 47-56.
 420. Rondot P, Ziegler M. Dystonia-L-Dopa responsive or juvenile Parkinsonism? *J Neural Transm* 1983; (Suppl 19): 273-81.
 421. Burns RS, LeWitt PA, Ebert MH, Pakkenberg H, Kopin JJ. The clinical syndrome of striatal dopamine deficiency: parkinsonism induced by MPTP. *New Engl J Med* 1985; 312: 1418-21.
 422. Klawans HL, Paleologos N. Dystonia-Parkinson syndrome: differential effects of levodopa and dopamine agonists. *Clin Neuropharm* 1986; 9: 298-302.
 423. LeWitt PA, Burns RS, Newman RP. Dystonia in untreated Parkinsonism. *Clin Neuropharmacol* 1986; 9: 293-7.
 424. Burke RE, Fahn S. Double-blind evaluation of trihexyphenidyl in dystonia. *Adv Neurol* 1983; 37: 189-192.
 425. Fahn S. High dosage anticholinergic therapy in dystonia. *Neurology* 1983; 33: 1255-61.
 426. Burke RE, Fahn S, Marsden CD. Torsion dystonia: A double-blind, prospective trial of high-dosage trihexyphenidyl. *Neurology* 1986; 36: 160-4.
 427. Marsden CD, Marion M-H, Quinn N. The treatment of severe dystonia in children and adults. *J Neurol Neurosurg Psychiatry* 1984; 47: 1166-73.
 428. Pakkenberg H, Pedersen B. Medical Treatment of dystonia. In: Casey DE, Chase TN, Christensen AV, Gerlach J, eds. *Dyskinesia - Research and Treatment*, Springer-Verlag, Berlin 1985; pp. 111-7.
 429. Boyson SJ. Bethanechol for anticholinergic side effects. *Ann Neurol* 1988; 23: 422-3.
 430. Lang AE. High dose anticholinergic therapy in adult dystonia. *Can J Neurol Sci* 1986; 13: 42-6.
 431. Lang AE, Sheehy MP, Marsden D. Anticholinergics in adult-onset dystonia. *Can J Neurol Sci* 1982; 9: 313-8.
 432. Lang AE, Sheehy MP, Marsden CD. Acute anticholinergic action in focal dystonia. *Adv Neurol* 1983; 37: 193-9.
 433. Burke RE, Fahn S. Pharmacokinetics of trihexyphenidyl after short-term and long-term administration to dystonic patients. *Ann Neurol* 1985; 18: 35-40.
 434. Burke RE, Fahn S. Serum trihexyphenidyl levels in the treatment of torsion dystonia. *Neurology* 1985; 35: 1066-9.
 435. Campanella G, Roy M, Barbeau A. Drugs affecting movement disorders. *Ann Rev Pharmacol Toxicol* 1987; 27: 113-36.
 436. Castaigne P, Rondot P, Ribadeau Dums JL, Said G. Affection extrapyramidale evoluant chez deux freres: effets remarquables du traitement par la L-dopa. *Rev Neurol* 1971; 124: 162-6.
 437. Sabouraud O, Allani H, Pinel J-F, Menault F. Familial dystonia transformed by bromocriptine. *Nouv Presse Med* 1978; 7: 3370.
 438. Micheli F, Pardal MF, de Arbelaz R, Lehkuniec E, Giannaula R. Paroxysmal dystonia responsive to anticholinergic drugs. *Clin Neuropharmacol* 1987; 10: 365-9.
 439. Lang AE. Dopamine agonists in the treatment of dystonia. *Clin Neuropharmacol* 1985; 8: 38-57.
 440. Eldridge R, Kanter W, Coerber T. Levodopa in dystonia. *Lancet* ii 1973; 1027-8.
 441. Allen N, Knopp W. Hereditary parkinsonism-dystonia with sustained control by L-DOPA and anticholinergic medication. *Adv Neurol* 1976; 14: 201-13.
 442. Balottin U, Lanzi G, Zambrino CA. A case of dystonia musculo-

- rum deformans susceptible to the L-Dopa therapy. *Riv Neurobiol* 1981; 27: 584-90.
443. Bondarenko ES, Malyshev IuI. Experience with L-DOPA treatment of children with dystonia musculorum deformans and dystonic hyperkinesia in infantile cerebral palsy. *Zh Nevropatol Psikhiatr* 1985; 85: 1471-5.
444. Casey DE. Pharmacology of blepharospasm-ommandibular dystonia syndrome. *Neurology* 1980; 30: 690-5.
445. Garcia-Albea E, Munoz D, Mateos F, Martinez P, Golzueta G. Syndrome de Brueghel. Aportacion de un caso. *Rev Clin Exp* 1979; 153: 69-70.
446. Garg BP. Dystonia musculorum deformans. Implications of therapeutic response to levodopa and carbamazepine. *Arch Neurol* 1982; 39: 376-7.
447. Ignatowicz R, Michalowicz R, Kmiec T. Problemy etiopatogenetyczne i kliniczne dystonii torsyjnej u dzieci. *Wiadomosci Lekarske* 1983; 36: 1197-1200.
448. Katsukawa K, Hosokawa K, Sano Y, Otsuka R. Remarkable effect of haloperidol in torsion dystonia: a case report. *Rinsho Shinkeigaku* 1976; 16: 351-6.
449. Marsden CD, Lang AE, Sheehy MP. Pharmacology of cranial dystonia. *Neurology* 1983; 33: 1100-1.
450. Muenter MD, Gomez MR, Gordon H, Sharpless NS. L-Dopa-responsive dystonia musculorum deformans with on-off effect. *Neurology* 1982; 32: A112.
451. Patti F, Marano P, Nicoletti F, Giammona G, Nicoletti Fr. Generalized and focal dystonic symptoms: possible therapy with salmon calcitonin. *Eur Neurol* 1985; 24: 386-91.
452. Richards CL, Bedard PJ, Fortin G, Malouin F. Quantitative evaluation of the effects of L-DOPA in torsion dystonia: a case report. *Neurology* 1983; 33: 1083-7.
453. Schenk E, Kruschke U. Familiare progressive Dystonie mit Tagesschwankungen. Erfolgreiche Behandlung mit L-DOPA. *Klin Wochenschr* 1975; 53: 779-80.
454. Stahl SM, Davis KL, Berger PA. The neuropharmacology of tardive dyskinesia, spontaneous dyskinesia, and other dystonias. *J Clin Psychopharmacol* 1982; 2: 321-8.
455. Stahl SM, Yesavage JA, Berger PA. Pharmacologic characteristics of Meige dystonia: differentiation from tardive dyskinesia. *J Clin Psychiatry* 1982b; 43: 445.
456. Stahl SM, Berger PA, Newman RP, LeWitt P. Reply from the authors. *Neurology* 1984a; 34: 135.
457. Still CN, Herberg K-P. Long-term levodopa therapy for torsion dystonia. *Southern Med J* 1976; 69: 564.
458. Tolosa ES, Chi-Wan L. Meige disease: striatal dopaminergic preponderance. *Neurology* 1979; 29: 1126-30.
459. Winkelmann W. Long-term treatment with L-DOPA in a case of torsion dystonia. *J Neurol* 1975; 208: 319-23.
460. Bassi S, Ferrarese C, Frattola L, Sbacchi M, Trabucchi M. Lisuride in generalised dystonia and spasmodic torticollis. *Lancet* ii 1982; 514.
461. Bosio A, Bassi S, Govoni S, et al. Lisuride in extrapyramidal disorders: A possible mechanism of action. *Adv Neurol* 1984; 40: 523-6.
462. Esperanca P, Castro-Caldas A. Improvement of Meige syndrome with lisuride. *Acta Med Port* 1985; 6: 187-9.
463. Frattola L, Albizzati MG, Bassi S, Ferrarese C, Trabucchi M. "On-off" phenomena, dyskinesias and dystonias. Comparison of lisuride versus apomorphine acute treatment. *Acta Neurol Scand* 1982; 66: 227-36.
464. Leiguarda RC, Pardo MF, Micheli F. Reply from the authors. *Neurology* 1984; 34: 136.
465. Micheli F, Pardo MMF. Responses to lisuride in Meige's disease and chorea. *Neurology* 1986; 36: 445.
466. Micheli F, Pardo MMF, Leiguarda RC. Beneficial effects of lisuride in Meige disease. *Neurology* 1982; 32: 432-4.
467. Obeso JA, Luquin MR. Bromocriptine and lisuride in dystonias. *Neurology* 1984; 34: 135.
468. Nutt JG, Hammerstad J, Carter J, deGarmo P. Lisuride treatment of focal dystonias. *Neurology* 1985; 35: 1242-3.
469. Quinn NP, Lang AE, Sheehy MP, Marsden CD. Lisuride in dystonia. *Neurology* 1985; 35: 766-9.
470. Frattola L, Albizzati MG, Bassi S, Spano PF, Trabucchi M. Treatment of dyskinetic and dystonic disorders with CF 25-397: clinical and pharmacological aspects. *Adv Biochem Psychopharmacol* 1980; 23: 381-6.
471. Gautier JC, Awada A. Dystonia musculorum deformans. Effet favorable de la bromocriptine. *Rev Neurol (Paris)* 1983; 139: 449-50.
472. Girotti F, Scigliano G, Nardocci N, et al. Idiopathic dystonia: neuropharmacological study. *J Neurol* 1982; 227: 239-47.
473. Newman RP, LeWitt PA, Shults C, et al. Dystonia: Treatment with bromocriptine. *Clin Neuropharmacol* 1985; 8: 328-33.
474. Stahl SM, Berger PA. Bromocriptine in dystonia. *Lancet* ii: 1981; 745.
475. Stahl SM, Berger PA. Bromocriptine, physostigmine and neurotransmitter mechanisms in the dystonias. *Neurology* 1982; 32: 889-90.
476. Greene P, Fahn S. Tardive complications in patients with idiopathic dystonia treated with dopamine blocking agents. *Neurology* 1988; 38(Suppl 1): 131.
477. Couch JR. Dystonia and tremor in spasmodic torticollis. *Adv Neurol* 1976; 14: 245-58.
478. Gilbert GJ. The medical treatment of spasmodic torticollis. *Arch Neurol* 1972; 27: 503-6.
479. Gollomp SM, Fahn S, Burke RE, Reches A, Ilson J. Therapeutic trials in Meige syndrome. *Adv Neurol* 1983; 37: 207-10.
480. Nakajima Y, Kondo T, Narabayashi H. Long-term evaluation of tiapride in patients with various forms of dyskinesias. *No To Shinkei* 1985; 37: 1013-9.
481. Ransmayr G, Kleedorfer B, Dierckx RA, Poewe W, Kemmler GW, Gerstenbrand F. Pharmacological study in Meige's syndrome with predominant blepharospasm. *Clin Neuropharmacol* 1988; 11: 68-76.
482. Sechi GP, deMontis G, Rosati G. Relationship between Meige syndrome and alpha-methyl-dopa-induced parkinsonism. *Neurology* 1985; 35: 1668-9.
483. Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. *Neurology* 1982; 32: 1335-46.
484. Coats ME. Meige's disease and a positive treatment response with deanol. *Milit Med* 1985; 150: 152-3.
485. Hughes EC, Brackmann DE, Weinstein RC. Seventh nerve spasm: effect of modification of cholinergic balance. *Otolaryngol Head Neck Surg* 1980; 88: 491-9.
486. Skarf B, Sharpe JA. Choline for blepharospasm. *N Engl J Med* 1987; 305: 957-8.
487. Lees A. Hemidystonia relieved by nicotine. *Lancet* ii 1984; 871.
488. Duvoisin RC. Meige syndrome: relief on high-dose anticholinergic therapy. *Clin Neuropharmacol* 1983; 6: 63-6.
489. Fisher CM. Letter to the Editor. *Neurology* 1983; 33: 1101.
490. Hashimoto T, Shindo M, Yanagisawa N. Treatment of dystonia with high-dosage trihexyphenidyl. *Clin Neurol* 1984; 24: 769-77.
491. Jabbari B, Scherokman BJ, Gunderson CH, Miller JA. Effectiveness of high doses of trihexyphenidyl in movement disorders: a preliminary report. *Am Acad Neurol* 1984; PP14.
492. H'ipola D, Mateo D, Gim'enez-Rold'an S. Meige's syndrome: acute and chronic responses to clonazepam and anticholinergics. *Eur Neurol* 1984; 23: 474-8.
493. Nutt JG, Hammerstad JP, Carter JH, deGarmo P. Meige syndrome: treatment with trihexyphenidyl. *Adv Neurol* 1983; 37: 201-5.
494. Nutt JG, Hammerstad JP, deGarmo P, Carter J. Cranial dystonia: double-blind crossover study of anticholinergics. *Neurology* 1984a; 34: 215-7.
495. Ravits J, Hallett M, Baker M, Wilkins D. Primary writing tremor and writer's cramp response to anticholinergics. *Neurology* 1985; 35: 1387-91.
496. Tanner CM, Glantz RH, Klawans HL. Meige disease; acute and chronic cholinergic effects. *Neurology* 1982; 32: 783-5.
497. Scherokman B, Jabbari B, Gunderson CH, Miller JM, Rappaport HL. Trihexyphenidyl and torticollis. *Neurology* 1986; 36: 1626.
498. Tanner CM, Glantz RH, Klawans HL. Reply from the authors. *Neurology* 1983; 33: 1101.
499. Wolf ME, Koller WC. Tardive dystonia: treatment with tri-

- hexyphenidyl. *J Clin Psychopharmacol* 1985; 5: 247-8.
500. Brantley PJ, Carnrike CL Jr, Faulstich ME, Barkemeyer CA. Blepharospasm: a case study comparison of trihexyphenidyl (Artane) versus EMG biofeedback. *Biofeedback Self Regul* 1985; 10: 173-80.
 501. Koller WC, Biary N. Lithium ineffective in dystonia. *Ann Neurol* 1983; 13: 579-80.
 502. Lippmann S, Kareus J. Lithium for spasmodic torticollis. *Am J Psychiatry* 1983; 140: 946.
 503. Marti-Masso JF, Obeso JA, Carrera N, Astudillo W, Martinez Lage JM. Lithium therapy in torsion dystonia. *Ann Neurol* 1982; 11: 106-7.
 504. Quinn N, Marsden CD. Lithium for painful dystonia in Parkinson's disease. *Lancet* 1986; 1377.
 505. Yung CY. A review of clinical trials with lithium in neurology. *Pharmacol Biochem Behav* 1984; 21(Suppl 1): 57-64.
 506. Lang AE, Marsden CD. Alpha-methyl-paratyrosine and tetrabenazine in movement disorders. *Clin Neuropharmacol* 1982; 5: 375-87.
 507. Asher SW, Aminoff MJ. Tetrabenazine and movement disorders. *Neurology* 1981; 31: 1051-4.
 508. Jankovic J. Treatment of hyperkinetic disorders with tetrabenazine: a double-blind crossover study. *Ann Neurol* 1982; 11: 41-7.
 509. Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. *Adv Neurol* 1983; 37: 277-89.
 510. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics and other dyskinesias. *Neurology* 1988; 38: 391-4.
 511. Schumm F, Dichgans J, Zeller E. Spontaneous oral dyskinesia. Successful treatment with tetrabenazine. *Arch Psychiatr Nervenkr* 1981; 230: 315-23.
 512. Korein J, Lieberman A, Kupersmith M, Levidow W. Effect of L-glutamine and isoniazid on torticollis and segmental dystonia. *Ann Neurol* 1981; 10: 247-50.
 513. Ziegler DK. Prolonged relief of dystonic movements with diazepam. *Neurology* 1981; 31: 1457-8.
 514. Lal S, Young SN, Kiely ME, Hoyte K, Baxter DW, Sourkes TL. Effect of L-tryptophan on spasmodic torticollis. *Can J Neurol Sci* 1981; 8: 305.
 515. Meinck HM, Conrad B. Neuropharmacological investigations in the stiff-man syndrome. *J Neurol* 1986; 233: 340-7.
 516. ten Houten R, Lakke PWF, de Jong P, van Weerden TW, van Burg W, Wesseling H. Spasmodic torticollis: treatment with Tizanidine. *Acta Neurol Scand* 1984; 70: 373-6.
 517. Baumann L, Baumann J. Betrachtungen zu einem Fall von Torsion Dystonie. *Acta Neurol Scand* 1963; 39: S14: 221-225.
 518. De Andrade LA, Bertolucci PM. Treatment of Meige disease with a GABA receptor agonist. *Arq Neuropsiquiatr* 1985; 43: 260-6.
 519. Sandyk R, Gillman MA. Baclofen in hemifacial spasm. *Intern J Neurosci* 1987; 33: 261-4.
 520. Rosse RB, Allen A, Lux WE. Baclofen treatment in a patient with tardive dystonia. *J Clin Psychiatry* 1986; 47: 474-5.
 521. Auff E, Holzner F, Wessely P. Further therapeutic possibilities with valproic acid (Convulex). *Wien Med Wochenschr* 1985; 135: 421-3.
 522. Snoek JW, Van Weerden TW, Teelken AW, Van Den Burg W, Flakke JPW. Meige syndrome: double-blind crossover study of sodium valproate. *J Neurol Neurosurg Psychiatry* 1987; 50: 1522-5.
 523. Sandyk R. Beneficial effect of sodium valproate and baclofen in spasmodic torticollis. *S Afr Med J* 1984; 65: 62-3.
 524. Sandyk R. Blepharospasm - successful treatment with baclofen and sodium valproate. A case report. *S Afr Med J* 1983; 64: 955-6.
 525. Sandyk R. Treatment of writer's cramp with sodium valproate and baclofen. *S Afr Med J* 1983; 63: 702-3.
 526. Brennan MJW, Ruff P, Sandyk R. Efficacy of a combination of sodium valproate and baclofen in Meige's disease (idiopathic orofacial dystonia). *Br Med J* 1982; 285: 853.
 527. Carella F, Girotti F, Scigliano G, Caraceni T, Joder-Ohlenbusch AM, Schechter PJ. Double-blind study of oral gamma-vinyl GABA in the treatment of dystonia. *Neurology* 1986; 36: 98-100.
 528. Stahl SM, Thornton JE, Simpson ML, Berger PA. Gamma-vinyl-GABA in tardive dyskinesia and other movement disorders. *Am Acad Neurol* 1984; PP40.
 529. Stahl SM, Thornton JE, Simpson ML, Berger PA, Napoliello MJ. Gamma-vinyl-GABA treatment of tardive dyskinesia and other movement disorders. *Biol Psychiatry* 1985; 20: 888-93.
 530. Mondrup K, Dupont E, Braendgaard H. Progabide in the treatment of hyperkinetic extrapyramidal movement disorders. *Acta Neurol Scand* 1985; 72: 341-3.
 531. Koller WC, Rubino R, Gupta S. Pharmacologic probe with progabide of GABA mechanisms in essential tremor. *Arch Neurol* 1987; 44: 905-6.
 532. Nishikawa T, Tanaka M, Tsuda A, Koga I, Uchida Y. Clonidine therapy for tardive dyskinesia and related syndromes. *Clin Neuropharmacol* 1984; 7: 239-45.
 533. Bailie GR, Nelson MV, Kranzelok EP, Lesar T. Unusual treatment response of a severe dystonia to diphenhydramine. *Ann Emerg Med* 1987; 16: 705-8.
 534. Sandyk R, Snider SR, Consroe P, Elias SM. Cannabidiol in dystonic movement disorders. *Psychiatry Res* 1986; 18: 291.
 535. Consroe P, Sandyk R, Snider S. Open label evaluation of cannabidiol in dystonic movement disorders. *Int J Neurosci* 1986; 30: 277-82.
 536. Biary N, Koller W. Reply from the authors. *Neurology* 1986; 36: 303.
 537. Biary N, Koller W. Effect of alcohol on dystonia. *Neurology* 1985; 35: 239-40.
 538. Gillman MA. Alcohol improves dystonia: opioid system involvement. *Neurology* 1986; 36: 303.
 539. Gillman MA. Analgesic (sub anesthetic) nitrous oxide interacts with the endogenous opioid system: a review of the evidence. *Life Sci* 1986; 39: 1209-21.
 540. Gillman MA, Sandyk R. Nitrous oxide ameliorates spasmodic torticollis. *Eur Neurol* 1985; 24: 292-3.
 541. Krishnan KR. Treatment of spasmodic torticollis with ethyl chloride. *J Clin Psychopharmacol* 1982; 2: 286.
 542. Sandyk R. Writer's cramp and the endogenous opioid system. *Clin Neuropharmacol* 1986; 9: 98-99.
 543. Barrow N, Childs A. An anti-tardive dyskinesia effect of verapamil. *Am J Psychiatry* 1986; 143: 1485.
 544. Ross JL, MacKenzie TB, Hanson DR, Charles CR. Diltiazem for tardive dyskinesia. *Lancet* 1987; 268.
 545. Falk WE, Wojick JD, Gelenberg AJ. Diltiazem for tardive dyskinesia and tardive dystonia. *Lancet* 1988; ii: 824-5.
 546. Bouchier-Hayes T. Chlormezanone in low back pain and wry neck - an "analgesic sparing" effect. *Br J Clin Prac* 1984; 38: 259-262.
 547. Special Issue Excitatory amino acids in the brain - focus on NMDA receptors. *Trends Neurosci* 1987; 10: 263-345.
 548. Olney JW, Price MT, Labruyere J, et al. Anti-parkinsonian agents are phencyclidine agonists and N-methyl-aspartate antagonists. *Eur J Pharmacol* 1987; 142: 319-20.
 549. Jayne D, Lees AJ, Stern GM. Remission in spasmodic torticollis. *J Neurol Neurosurg Psychiatry* 1984; 47: 1236-7.
 550. Lowenstein DH, Aminoff MJ. The clinical course of spasmodic torticollis. *Neurology* 1988; 38: 530-2.
 551. Friedman A, Fahn S. Spontaneous remissions in spasmodic torticollis. *Neurology* 1986; 36: 398-400.
 552. Brin M, Fahn S, Moskowitz CB, et al. Localized injections of botulinum toxin for the treatment of focal dystonia. *Adv Neurol* 1988; 50: 599-608.
 553. Frueh BR, Felt DP, Wojno TH, Musch DC. Treatment of blepharospasm with botulinum toxin. *Arch Ophthalmol* 1984; 102: 1464-8.
 554. Carruthers J, Stubbs HA. Botulinum toxin for benign essential blepharospasm, hemifacial spasm and age-related lower eyelid entropion. *Can J Neurol Sci* 1987; 14: 42-5.
 555. Mauriello JA Jr, Coniaris H. Use of botulinum in the treatment of 100 patients with blepharospasm. *NJ Med* 1987; 84: 43-4.
 556. Mauriello JA. Blepharospasm, Meige syndrome and hemifacial spasm: treatment with botulinum toxin. *Neurology* 1985; 35: 1499-1500.
 557. Tsui JKC, Stoessl AJ, Eisen A, Calne S, Calne DB. Double-blind

- study of botulinum toxin in spasmodic torticollis. *Lancet* ii 1986; 245-7.
558. Tsui JK, Eastmann E, Mak E, Calne S, Calne DB. Botulinum toxin in writer's cramp: a pilot study. *Ann Neurol* 1987; 22: 147.
 559. Cremonesi E, Murata KN. Infiltration of a neuromuscular relaxant in diagnosis and treatment of torticollis. *Anesth Analg* 1986; 65: 1077-8.
 560. Dieckmann G, Veras G. Bipolar spinal cord stimulation for spasmodic torticollis. *Appl Neurophysiol* 1985; 48: 339-346.
 561. Waltz JM, Davis JA. Cervical cord stimulation in the treatment of athetosis and dystonia. *Adv Neurol* 1983; 37: 225.
 562. Fahn S. Lack of benefit from cervical cord stimulation for dystonia. *New Engl J Med* 1985; 313: 1229.
 563. Sold-Darseff J, Leydhecker W. Acupuncture for pain in the cranial region and for blepharospasm without organic cause. *Klin Monatsbl Augenheilkd* 1986; 189: 167-9.
 564. Lee EH, Kang YK, Bose K. Surgical correction of muscular torticollis in the older child. *J Pediatr Orthop* 1986; 6: 585-9.
 565. Zervas NT. Long-term review of dentatectomy in dystonia musculorum deformans and cerebral palsy. *Acta Neurochirurgica* 1977; S24: 49-51.
 566. Cooper IS. Dystonia: Surgical approaches to treatment and physiologic implications. In: *Yahr MD, ed. The Basic Ganglia*, Raven Press, NY 1976; pp 369-383.
 567. Kandel EI. Stereotaxic method of treating extrapyramidal spastic torticollis. *Zh Vopr Neurokhir* 1984; 6: 28-34.
 568. Vasin NY, Medzhidov MR, Shabalov VA. Stereotaxic destruction of the interstitial nucleus of cajal in torticollis spastica. *Zh Vopr Neurokhir* 1985; 4: 3-7.
 569. Andrew J, Fowler CJ, Harrison MJG. Stereotaxic thalamotomy in 55 cases of dystonia. *Brain* 1983; 106: 981-1000.
 570. Starikov AS. Effect of destruction of the ventrolateral nucleus of the thalamus on the motor analyzer. *Zh Vopr Neurokhir* 1981; 5: 45-51.
 571. Namba S, Wani T, Masaoka T, Nakamura S, Nishimoto A. Long-term follow-up study of spasmodic torticollis. *No Shinkei (Brain & Nerve)* 1986; 38: 121-8.
 572. Jorgenson C, Porphyris H. Idiopathic spasmodic torticollis. *J Neurosurg Nursing* 1985; 17: 169-74.
 573. Van Waveren LEAK. Cause and treatment of spasmodic torticollis. *Acta Neurochir* 1982; 61: 127-37.
 574. Ortiz A. Neuropharmacological profile of Meige's disease: overview and a case report. *Clin Neuropharmacol* 1983; 6: 297-304.
 575. Husain A, Chapel J, Malek-Ahmad P. Methylphenidate, neuroleptics and dyskinesia-dystonia. *Can J Psychiatry* 1980; 25: 254-8.
 576. Dahiya U, Noronha P. Drug-induced acute dystonic reactions in children. Alternatives to diphenhydramine therapy. *Postgrad Med* 1984; 75: 286-290.
 577. Cohen GH, Casta A, Sapire DW, Talabi A. Decorticate posture following "cardiac cocktail". *Ped Cardiol* 1982; 2: 251-253.
 578. Prusiński A, R'ozniecki J, Durko A, Gluszczyńska A, Kozubski W, Swatko A. Acute dystonic reactions after administration of neuroleptics and other drugs. *Wien Lek* 1985; 38: 347-51.
 579. Anon. Acute dystonia with fatal outcome. A possible adverse drug reaction in the simultaneous administration of chlorpromazine and metoclopramide. *Ugeskr Laeger* 1986; 148: 2357-8.
 580. Stallworth HF. Acute dystonia secondary to illicit phenothiazine usage: a report of two cases. *J Kentucky Med Assoc* 1981; 79: 83-4.
 581. Lew T-L, Tollefson G. Chlorpromazine-induced neuroleptic malignant syndrome and its responses to diazepam. *Biol Psychiatry* 1983; 18: 1441-5.
 582. Wood GM, Waters AK. Prolonged dystonic reaction to chlorpromazine in myxoedema coma. *Postgrad Med J* 1980; 56: 192-3.
 583. Ayers JL, Dawson KP. Acute dystonic reactions in childhood to drugs. *NZ Med J* 1980; 92: 464-465.
 584. Korcyn AD, Goldberg GJ. Intravenous diazepam in drug-induced dystonic reactions. *Br J Psychiatry* 1972; 121: 75-7.
 585. Town IG. Haloperidol: neuroleptic malignant syndrome. *New Zealand Med J* 1982; 95: 199.
 586. Gross ML. Acute dystonia as idiosyncratic reaction to haloperidol. *Lancet* ii 1980; 479-80.
 587. Logan FA, Herrington RN, Mackie MMS, Rubin PC. Pimozide: adverse reaction and prolonged half-life. *Brit J Psychiatry* 1982; 140: 433-4.
 588. Khanderia U. Recurrent dystonic reactions induced by thiethylperazine. *Drug Intell Clin Pharm* 1985; 19: 550-1.
 589. Vlachos P. Dystonic reactions following thiethylperazine in children. *Toxicol Letters* 1982; 13: 183-4.
 590. Darwish H, Grant R, Haslam R, Roth S. Promethazine-induced acute dystonic reactions. *Am J Dis Child* 1980; 134: 990-991.
 591. Shannon M. Paroxysms, obtundation in a healthy toddler. *Hospital Practice* 1986; 21: 159-60.
 592. Dick DJ, Saunders M. Persistent involuntary movements after treatment with flupenthixol. *Br Med J* 1981; 282: 1756.
 593. Casteels-Van Daele M, Dobosz-Cyklis R, Van de Casseye W, Verbeeck P, Wijndaele L. Refusal of further cancer chemotherapy due to antiemetic drug. *Lancet* i 1984; 57.
 594. Grimes JD, Hassan MN, Preston DN. Adverse neurologic effects of metoclopramide. *CMA Journal* 1982; 126: 23-5.
 595. Gupte S. Dystonic reactions following metoclopramide therapy. *Indian J Pediatr* 1982; 50: 291-2.
 596. Cowan AN. Acute dystonic reaction to Maxolon (metoclopramide). *Med J Aust* 1982; 2: 215.
 597. Aasen J, Slaastad RA. Akutt dystoni forarsaket av metoklopramid (Primperan). *Tidsskr Nor Laegeforen* 1982; 102: 916-7.
 598. Casteels-Van Daele M. Metoclopramide poisoning in children. *Arch Dis Childhood* 1981; 56: 405-7.
 599. Wandless I, Evans JG, Jackson M. Fever associated with metoclopramide-induced dystonia. *Lancet* i 1980; 1255-6.
 600. Low LCK, Goel KM. Metoclopramide poisoning in children. *Arch Dis Child* 1980; 55: 310-2.
 601. Debontridder O. Dystonic reactions after domperidone. *Lancet* ii 1980; 1259.
 602. Madej TH. Domperidone - an acute dystonic reaction. *Anaesthesia* 1985; 40: 202.
 603. Shafrir Y, Levy Y, Steiner R. Acute dystonic reaction due to domperidone in an infant. *Harefuah* 1986; 110: 237-8.
 604. Rose TE, Averbuch SD. Acute dystonic reaction due to benzquinamide. *Ann Intern Med* 1975; 83: 231-2.
 605. Yassa R, Nair V, Dimitry R. Prevalence of tardive dystonia. *Acta Psychiatr Scand* 1986; 73: 629-33.
 606. Gospe SM Jr, Jankovic J. Drug-induced dystonia in neuronal ceroid-lipofuscinosis. *Pediatr Neurol* 1986; 2: 236-7.
 607. Burke RE, Reches A, Traub MM, Ilson J, Swash M, Fahn S. Tetrabenazine induces acute dystonic reaction. *Ann Neurol* 1985; 7: 200-2.
 608. Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH. Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. *Neurology* 1981; 31: 1022-6.
 609. Sandyk R, Gillman MA. Nomifensine exacerbates orofacial dyskinesia in hypothyroidism. *Neurology* 1985; 35: 282.
 610. Finder E, Lin K, Ananth J. Dystonic reaction to amitriptyline. *Am J Psychiatry* 1982; 139: 1220.
 611. Kramer MS, Marcus DJ, DiFerdinando J, Dewey D. Atypical acute dystonia associated with trazodone treatment. *J Clin Psychopharmacol* 1986; 6: 117-8.
 612. Gardos G. Undiagnosed dystonic reaction secondary to amoxapine. *Psychosomatics* 1984; 25: 68-9.
 613. Steele TE. Adverse reactions suggesting amoxapine-induced dopamine blockade. *Am J Psychiatry* 1982; 139: 1500-1.
 614. Hunt-Fugata AK, Zander J, Lesar TS. Adverse reactions due to dopamine blockade by amoxapine. A case report and review of the literature. *Pharmacotherapy* 1984; 4: 35-9.
 615. Jacome D. Carbamazepine-induced dystonia. *JAMA* 1979; 241: 2263.
 616. McMahon T. Dyskinesia associated with amoxapine withdrawal and use of carbamazepine and antihistamines. *Psychosomatics* 1986; 27: 145.
 617. Martin'on JM, Docampo G, Martin'on JA, Viso JA, Pena J. Dystonia por carbamacepina. *An Esp Pediat* 1980; 13: 789-92.
 618. Bradbury AJ, Bentick B, Todd PJ. Dystonia associated with car-

- bamazepine toxicity. *Postgrad Med J* 1982; 58: 525-526.
619. Reynolds EH, Trimble MR. Adverse neuropsychiatric effects of anticonvulsant drugs. *Drugs* 1985; 29: 570-81.
620. Lazaro RP. Involuntary movements induced by anticonvulsant drugs. *Mt Sinai J Med (NY)* 1982; 49: 274-81.
621. Choonara IA, Rosenbloom L. Focal dystonic reaction due to phenytoin. *Dev Med Child Neurol* 1984; 26: 677-680.
622. Corey A, Koller W. Phenytoin-induced dystonia. *Ann Neurol* 1983; 14: 92-93.
623. Gladhuc EG, Devivo DC, Volpe JJ. Phenytoin induced dystonia and choreoathetosis in two retarded epileptic children. *Neurol* 1976; 26: 498-498.
624. Francis DA. Benzodiazepines and spasmodic torticollis. *Arch Neurol* 1983; 40: 325.
625. Kaplan SR, Murkofsky O. Oral-buccal dyskinesic symptoms associated with low dose benzodiazepine treatment. *Am J Psychiatry* 1978; 135: 1558-9.
626. Demetropoulos S, Schauben JL. Acute dystonic reactions from "street Valium". *J Emerg Med.* 1987; 5: 293-7.
627. Lavenstein BL, Cantor FK. Acute dystonia: an unusual reaction to diphenhydramine. *JAMA* 1976; 236: 291.
628. Smith RE, Domino EF. Dystonic and dyskinesic reactions induced by HI antihistaminic medication. *In: Fann WE, Smith RC, Davis JM, et al., eds. Tardive Dyskinesia: Research and Treatment, SP Medical and Scientific Books, NY 1980; pp 325-32.*
629. Casteels-Van Daele M, Eggermont E, Casaer P, Van de Casseye W, De Boeck K. Acute dystonic reactions and long-lasting impaired consciousness associated with oxatomide in children. *Lancet i*; 1986; 1204-5.
630. Thatch BT, Chase TN, Bosma JF. Oral dyskinesia associated with prolonged use of antihistaminic decongestants. *N Engl J Med* 1975; 293: 486-7.
631. Papini M, Martinetti MG, Pasquinelli A. Tradodone symptomatic extrapyramidal disorders of infancy and childhood. *Ital J Neurol Sci* 1982; 3: 161-2.
632. Joske DJL. Dystonic reaction to azatadine. *Med J Australia* 1984; 141: 449.
633. Powers JM. Decongestant-induced blepharospasm and orofacial dystonia. *JAMA* 1982; 247: 3244-5.
634. Kaeser HE. Parkinson therapy 1985. *Schweiz Med Wochenschr* 1986; 116: 801-4.
635. Lewith GT, Davidson F. Dystonic reactions to dimotapp elixir. *J R. Coll Gen Pract* 1981; 31: 241.
636. Nausieda PA, Weiner WJ, Klawans HL. Dystonic foot response of Parkinsonism. *Arch Neurol* 1980; 37: 132-6.
637. Felser JM, Orban DJ. Dystonic reaction after ketamine abuse. *Ann Emerg Med* 1982; 673-5.
638. Goetting MG. Acute lithium poisoning in a child with dystonia. *Pediatrics* 1985; 76: 978-80.
639. Srikanth S, Khanna S, Channabasavanna SM. Writer's cramp associated with lithium. *Clin Neuropharmacol* 1988; 11: 189-90.
640. Susman VL, Addonizio G. Reinduction of neuroleptic malignant syndrome by lithium. *J Clin Psychopharmacol* 1987; 7: 339.
641. Arjona JAM, Garcia CA, Hoenigsfeld LC, Pareja FB. Early morning dystonia: a complication of levodopa therapy in Parkinson's disease. Report of 4 cases. *Med Clin* 1984; 83: 47-49.
642. Molina Arjona JA, Arnal Garc'ia C, Calandra Hoenigsfeld L, Bernejo Pareja F. Early morning dystonia: a complication of levodopa therapy in Parkinson's disease. Presentation of 4 cases. *Med Clin (Barc)* 1984; 83: 47-9.
643. Peir'o Grasa A, Grau-Veciana JM. Secondary effects of prolonged levodopa therapy in Parkinson's disease. *Med Clin (Barc)* 1985; 85: 88-91.
644. Lees AJ, Stern GM. Bromocriptine in treatment of levodopa-induced end-of-dose dystonia. *Lancet ii* 1980; 215-6.
645. Umez-Eronini EM, Eronini EA. Chloroquine-induced involuntary movements. *Br Med J i* 1977; 945-6.
646. Howrie DL, Rowley AH, Krenzelok EP. Benzotropine-induced acute dystonic reaction. *Ann Emerg Med* 1986; 15: 141-3.
647. Shafirir Y, Levy Y, Beharab A, Nitzam M, Steinerz R. Acute dystonic reaction to bethanechol - a direct acetylcholine receptor agonist. *Dev Med Child Neurol* 1986; 28: 646-8.
648. Quinn NP. Dystonia in epidemic ergotism. *Neurology* 1983; 33: 1267.
649. DiMonda V, Fazzari G, Callea L, Almici G. On a case of dystonia from manganism: therapeutic considerations. *Acta Bio-Med* 1979; 50: 317-20.
650. Hicks CB, Abraham K. Verapamil and myoclonic dystonia. *Ann Intern Med.* 1985; 103: 154.
651. de Medina A, Biasini O, Rivera A, Sampera A. Nifedipine and myoclonic dystonia. *Ann Intern Med* 1986; 104: 125.
652. Rosin MA. Chlozoxazone-induced spasmodic torticollis. *JAMA* 1981; 246: 2575.
653. Nakano T, Kondo K, Oguchi K, Yanagisawa N, Nakano T. A late onset case of paroxysmal dystonic choreoathetosis induced by caffeine and aminophylline. *Rinsho Shinkeigaku* 1983; 23: 199-202.
654. Salminen L, Jantti V, Gronross M. Blepharospasm associated with tegafur combination chemotherapy. *Am J Ophthalmol* 1984; 97: 649-50.
655. Rupniak NMJ, Jenner P, Marsden CD. Acute dystonia induced by neuroleptic drugs. *Psychopharmacology* 1986; 88: 403-19.
656. Sramek JJ, Simpson GM, Morrison RL, Heiser JF. Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study. *J Clin Psychiatry* 1986; 47: 305-9.
657. Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. *Acta Psychiat Scand* 1987; 73: 337-47.
658. Pearlman CA. Neuroleptic malignant syndrome: a review of the literature. *J Clin Psychopharmacol* 1986; 6: 257-73.
659. Friedman JH, Davies R, Wagner RL. Neuroleptic malignant syndrome: a six-month prospective study in a state psychiatric hospital. *Neurology* 1988; 38(Suppl 1): 179.
660. Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. *Br Med J [Clin Res]* 1985; 291: 930-2.
661. Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions to prochlorperazine and haloperidol in the United Kingdom. *Q J Med* 1986; 59: 549-56.
662. Keepers GA, Casey DE. Prediction of neuroleptic-induced dystonia. *J Clin Psychopharmacol* 1987; 7: 342-5.
663. Swett C. Drug-induced dystonia. *Am J Psychiatry* 1975; 132: 532-4.
664. Chiles JA. Extrapyramidal reactions in adolescents treated with high-potency antipsychotics. *Am J Psychiatry* 1978; 135: 239-40.
665. Keepers GA, Casey DE. Clinical management of acute neuroleptic-induced extrapyramidal syndromes. *Current Psychiat Therap* 1986; 23: 139-57.
666. Boyer WF, Bakalar NH, Lake CR. Anticholinergic prophylaxis of acute haloperidol-induced acute dystonic reactions. *Clin Psychopharmacol* 1987; 7: 164-6.
667. Winslow RS, Stillner V, Coons DJ, Robinson MW. Prevention of acute dystonic reactions in patients beginning high-potency neuroleptics. *Am J Psychiatry* 1986; 143: 706-10.
668. Manos N, Lavrentiadis G, Gkiouzevas J. Evaluation of the need for prophylactic antiparkinsonian medication in psychotic patients treated with neuroleptics. *J Clin Psychiatry* 1986; 47: 114-6.
669. McEvoy JP, Simpson GM. Dystonia, neuroleptic dose, and anticholinergic drugs. *Am J Psychiatry* 1987; 144: 393.
670. Kumor K et al. Haloperidol-induced dystonia in cocaine addicts. *Lancet ii* 1986; 1341-2.
671. Freed E. Alcohol-triggered neuroleptic-induced tremor, rigidity and dystonia. *Med J Aust* 1981; 44-5.
672. Sovner N, McGorrill S. Stress as a precipitant of neuroleptic-induced dystonia. *Psychosomatics* 1982; 23: 707-9.
673. Malen RL. The role of psychological factors in reversible drug-related dystonic reactions. *Mt Sinai J Med* 1976; 43: 56-70.
674. Flaherty JA, Lahmeyer HW. Laryngeal-pharyngeal dystonia as a possible cause of asphyxia with haloperidol treatment. *Am J Psychiatry* 1978; 135: 1414-5.
675. McDanal CE Jr. Brief letter on case of laryngeal-pharyngeal dystonia induced by haloperidol, relieved by benzotropine. *Am J Psychiatry* 1981 138: 1262-3.
676. Menuck M. Laryngeal-pharyngeal dystonia and haloperidol. *Am J*

- Psychiatry 1981; 138: 394-5.
677. Ravi SD, Borge GF, Roach FL. Neuroleptics, laryngeal-pharyngeal dystonia, and acute renal failure. *J Clin Psychiatry* 1982; 43: 300.
678. Holmes VF, Adams F, Fernandez F. Respiratory dyskinesia due to antiemetic therapy in a cancer patient. *Cancer Treatment Reports* 1987; 71: 415.
679. Corre KA, Niemann JT, Bessen HA. Extended therapy for acute dystonic reactions. *Ann Emerg Med* 1984; 13: 194-197.
680. Gardos G. Dystonic reaction during maintenance antipsychotic therapy. *Am J Psychiatry* 1981; 138: 114-5.
681. Keegan DL, Rajput AH. Drug induced dystonia tarda: treatment with L-dopa. *Dis Nerv Syst* 1973; 38: 167-9.
682. Bartels M, Riffel B, Stohr M. Tardive dystonie: Eine seltene Nebenwirkung nach Neuroleptika-langzeitbehandlung. *Nervenarzt* 1982; 53: 674-6.
683. Peatfield RC, Spokes EGS. Phenothiazine-induced dystonias. *Neurology* 1984; 34: 260.
684. Guy N, Raps A, Assael M. The Pisa syndrome during maintenance antipsychotic therapy. *Am J Psychiatry* 1986; 143: 1492.
685. Gimenez-Roldan S, Mateo D, Bartolome P. Tardive dystonia and severe tardive dyskinesia. *Acta Psychiatr Scand* 1985; 71: 488-94.
686. Friedman JH, Kucharski LT, Wagner RL. Tardive dystonia in a psychiatric hospital. *J Neurol Neurosurg Psychiatry* 1987; 50: 801-3.
687. Kwentus JA, Schulz SC, Hart RP. Tardive dystonia, catatonia, and electroconvulsive therapy. *J Nerv Mental Dis* 1984; 172: 171-3.
688. Weiner WJ, Nausieda PA, Glantz RH. Meige syndrome (blepharospasm-ommandibular dystonia) after long-term neuroleptic therapy. *Neurology* 1981; 31: 1555-6.
689. Dilsaver SC, Domino L, Greden JF. Meige's syndrome of tardive dyskinesia? *J Clin Psychopharmacol* 1985; 5: 362-4.
690. Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. *Movement Disorders* 1986; 1: 193-208.
691. Murray JB. Neuroleptic malignant syndrome. *J Gen Psychiatry* 1987; 114: 39-46.
692. Verhoeven WMA, Elderson A, Westenberg HGM. Neuroleptic malignant syndrome: successful treatment with bromocriptine. *Biol Psychiatry* 1985; 20: 680-4.
693. Martin DT, Swash M. Muscle pathology in the neuroleptic malignant syndrome. *J Neurol* 1987; 235: 120-1.
694. Anon. 5-HT₃ receptor antagonists: a new class of antiemetics. *Lancet* 1987; ii: 1470-1.
695. Allan SG, Leonard RCF, Cornbleet MA, Smyth JF. Dystonic reactions due to metoclopramide. *Lancet* 283, Feb 4 1984.
696. Arrowsmith J, Gams RA. Dystonia with droperidol therapy. *New Engl J Med* 1981; 305: 227.
697. Terrin BN, McWilliams NB, Maurer HM. Side effects of metoclopramide as an antiemetic in childhood cancer chemotherapy. *J Pediatrics* 1984; 104: 138-40.
698. Bateman DN, Craft AW, Nicholson E, Pearson ADJ. Dystonic reactions and the pharmacokinetics of metoclopramide in children. *Br J Clin Pharmacol* 1983; 15: 557-9.
699. Pollera CF, Cognetti F, Nardi M, Mazza D. Sudden death after acute dystonic reaction to high-dose metoclopramide. *Lancet* ii 1984; 460-1.
700. Hotson JR, Langston EB, Langston JW. Saccade responses to dopamine in human MPTP-induced parkinsonism. *Ann Neurol* 1986; 20: 456-63.
701. Marsden CD, Jenner P. The pathophysiology of extrapyramidal side effects of neuroleptic drugs. *Psychol Med* 1980; 10: 55-72.
702. Korczyn AD. The pathophysiology of dystonia. *J Neural Transm* 1978; 42: 245-50.
703. Parkes JD, Bedard P, Marsden CD. Chorea and torsion in Parkinsonism. *Lancet* 1976; i: 155.
704. Hallett M. Bromocriptine for levodopa-induced end-of-dose dystonia. *Lancet* 1981; i: 616.
705. Weiner WJ, Nausieda PA. Meige's syndrome during long-term dopaminergic therapy in Parkinson's disease. *Arch Neurol* 1982; 39: 451-2.
706. Wakayama Y, Nakashima Y, Tanaka K, Mano Y, Ando K. Parkinson's disease with diphasic dyskinesia and early-morning dystonia. *Arch Neurol* 1982; 39: 531.
707. Rondot P, Bianco C, de Recondo J. Ageing and Parkinson's disease. *Gerontology* 1986; 32(suppl 1): 102-5.
708. Quinn NP, Lang AE, Koller WC, Marsden CD. Painful Parkinson's disease. *Lancet* 1986; i: 708.
709. Kidron D, Melamed E. Forms of dystonia in patients with Parkinson's disease. *Neurology* 1987; 37: 1009-11.
710. Curtis L, Lees A-J, Stern G-M, Marmot M-G. Effect of L-dopa on course of Parkinson's disease. *Lancet* ii 1984; 211-2.
711. Friedman A, Markowa E. Involuntary movements as a complication of the treatment of extrapyramidal disorders with L-DOPA. *Neurol Neurochir Pol* 1981; 15: 437-40.
712. Mendez JS, Cotzias GC, Mena I, Parpavasiliou PS. Diphenylhydantoin: blocking of levodopa effects. *Arch Neurol* 1975; 32: 44-6.
713. Chadwick D, Reynolds EH, Marsden CD. Anticonvulsant-induced dyskinesias: a comparison with dyskinesias induced by neuroleptics. *J Neurol Neurosurg Psychiatry* 1976; 39: 1210-8.
714. Goni M, Jimenez M, Feijoo M. Parkinsonism induced by phenytoin. *Clin Neuropharmacol* 1985; 8: 383-4.
715. Akindele MO, Odejide AO. Amodiaquine-induced involuntary movements. *Br Med J* ii 1976; 214-5.
716. Bhargava RK, Parakh LK, Hakim A, Gori MN, Bhardari NC. Extra-pyramidal syndrome after antimalarials. *J Assoc Physicians India* 1973; 21: 969-73.
717. Singhi S, Singhi P, Singh M. Chloroquine-induced involuntary movements. *Br Med J* 1977; ii: 520.
718. Bowen WD, Walker JM, Yashar AG, Matsumoto RR, Walker FO, Lorden JF. Altered haloperidol-sensitive σ receptors in the genetically dystonic (dt) rat. *Eur J Pharmacol* 1988; 147: 153-4.
719. Gundlach AL, Largent BL, Snyder SH. Autoradiographic localization of sigma receptor binding sites in guinea pig and rat central nervous system with (+)-[³H]3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. *J Neurosci* 1986; 6: 1757-70.
720. Weber E, Sonders M, Quaram M, McLean S, Pou S, Keanna JFW. 1,3-Di(2-[5-³H]tolyl)guanidine: a selective ligand that labels σ type receptors for psychomimetic opiates and antipsychotic drugs. *Proc Natl Acad Sci USA* 1986; 83: 8784.
721. Walker JM, Matsumoto RR, Bowen WD, Gans DL, Jones KD, Walker FO. Evidence for a role of haloperidol-sensitive σ "opiate" receptors in the motor effects of anti-psychotic drugs. *Neurology* 1988; 38: 961-5.
722. McKeon TW, Lorden JF, Oltmans GA, Beales M, Walkley SU. Decreased catalepsy response to haloperidol in the genetically dystonic (dt) rat. *Brain Res* 1984; 308: 89-96.
723. McKeon TW, Lorden JF, Beales M, Oltmans GA. Alterations in the noradrenergic projection to the cerebellum of the dystonic (dt) rat. *Brain Res* 1986; 366: 89-97.
724. Lorden JF, McKeon TW, Baker HJ, Cox N, Walkley SU. Characterization of the rat mutant dystonic (dt): a new animal model of dystonia musculorum deformans. *J Neurosci* 1984; 4: 1925-32.
725. Oltmans G, Beales M, Lorden J. Glutamic acid decarboxylase activity in micropunches of the deep cerebellar nuclei of the genetically dystonic (dt) rat. *Brain Res* 1986; 385: 148-51.
726. Oltmans GA, Beales M, Lorden JF, Gordon JH. Alterations in cerebellar glutamic acid decarboxylase (GAD) activity in a genetic model of torsion dystonia (rat). *Exp Neurol* 1984; 85: 216-22.
727. Lorden JF, Oltmans GA, McKeon TW, Lutes J, Beales M. Decreased cerebellar 3',5'-cyclic guanosine monophosphate levels and insensitivity to harmaline in the genetically dystonic rat (dt). *J Neurosci* 1985; 5: 2618-25.
728. Lutes J, Lorden JF, Oltmans GA. Effects of clonidine on the motor syndrome of the genetically dystonic rat. *Soc Neurosci Abstr* 1985; 11: 670.
729. Duchon LW, Strich ST, Falconer DS. Clinical and pathological studies of an hereditary neuropathy in mice (dystonia musculorum). *Brain* 1964; 87: 367-78.
730. Moss TH. Segmental demyelination in the peripheral nerves of mice affected by hereditary neuropathy (Dystonia Musculorum). *Acta Neuropathol* 1981; 53: 51-6.
731. Moss TH, Lewkowicz SJ. A comparative scanning electron

- microscopical study of endoneurial collagen around normal mouse nerve fibres, nerve fibres following crush injury and nerve fibres of the dystonic mouse mutant (dt/dt). *Cell Tissue Res* 1981; 220: 881-7.
732. Hanker JS, Ambrose WW, Yates PE, Koch GG, Carson KA. Peripheral neuropathy in mouse hereditary diabetes mellitus. *Acta Neuropathol (Berl)* 1980; 51: 145-53.
733. Moss TH. Schwann cell involvement in the neurological lesion of the dystonic mutant mouse. *J Neurol Sci* 1981; 49: 207-22.
734. Messer A, Gordon D. Changes in whole tissue biosynthesis of γ -aminobutyric acid (GABA) in basal ganglia of the dystonia (dtALb) mouse. *Life Sci* 1979; 25: 2217-21.
735. Riker DK, Messer A, Roth RH. Increased noradrenergic metabolism in the cerebellum of the mouse mutant Dystonia Musculorum. *J Neurochem* 1981; 37: 649-54.
736. Messer A. Amino acid changes in the mouse mutant dystonia musculorum deformans similar to those in Friedreich's ataxia. *Can J Neurol Sci* 1982; 9: 185-8.
737. Ebendal T, Lundin LG. Nerve growth factor in three neurologically deficient mouse mutants. *Neurosci Lett* 1984; 50: 121-6.
738. Messer A, Strominger NL. An allele of the mouse mutant dystonia musculorum deformans exhibits lesions in red nucleus and striatum. *Neuroscience* 1980; 5: 543-9.
739. Stanley E, Messer A, Strominger NL. Effects of age and strain differences on the red nucleus of the mouse mutant dystonia musculorum. *Anat Rec* 1983; 206: 313-8.
740. Gopalakrishnakone P. Pathological features of idiopathic torticollis in the duck - a model for human disease. *J Comp Path* 1984; 94: 453-62.
741. Gopalakrishnakone P. Animal model of human disease: idiopathic torticollis. Torticollis in white Pekin duck. *Am J Path* 1985; 118: 500-1.
742. Clarke CE, Sambrook MA, Mitchell IJ, Crossman AR. Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). *J Neurol Sci* 1987; 78: 273-80.
743. Kistrup K, Gerlach J. Selective D1 and D2 receptor manipulation in Cebus monkeys: relevance for dystonia and dyskinesia in humans. *Pharmacol Toxicol* 1987; 61: 157-61.
744. Meldrum BS, Anlezark GM, Marsden CD. Acute dystonia as an idiosyncratic response to neuroleptics in baboons. *Brain* 1977; 100: 313-26.
745. Casey DE, Gerlach J, Christensson A. Dopamine, acetylcholine and GABA effects in acute dystonia in primates. *Psychopharmacol* 1980; 70: 83-7.
746. Neale R, Gerhardt S, Liebman JM. Effects of dopamine agonists, catecholamine depletors, and cholinergic and GABAergic drugs on acute dyskinesias in squirrel monkeys. *Psychopharmacol* 1984; 82: 20-6.
747. Murphey DL, Dill RE. Chemical stimulation of discrete brain loci as a method of producing dyskinesia models in primates. *Exp Neurol* 1972; 34: 244-54.
748. Cools AR, Hendriks G, Korten J. The acetylcholine-dopamine balance in the basal ganglia of rhesus monkeys and its role in dynamic, dystonic, dyskinetic, and epileptoid motor activities. *J Neural Transm* 1974; 36: 91-105.
749. Haggstrom JE. Effects of sulpiride on persistent neuroleptic-induced dyskinesia in monkeys. *Acta Psychiatr Scand (Suppl)* 1984; 311: 103-8.
750. Povlsen UJ, Noring U, Laursen AL, et al. Effects of serotonergic and anticholinergic drugs in haloperidol-induced dystonia in cebus monkeys. *Clin Neuropharm* 1986; 9: 84-90.
751. Bedard P, Delean J, Lafleur J, Larochelle L. Haloperidol-induced dyskinesias in the monkey. *Can J Neurol Sci* 1977; 4: 197-201.
752. Paulson GW. Dyskinesias in monkeys. *Adv Neurol* 1973; 1: 647-50.
753. Mones RJ. Experimental dyskinesias in normal rhesus monkeys. *Adv Neurol* 1973; 1: 665-9.
754. Sassin JF. Drug-induced dyskinesia in monkeys. *Adv Neurol* 1973; 1: 47-54.
755. Heintz R, Casey DE. Pargyline reduces/prevents neuroleptic-induced, acute dystonia in monkeys. *Psychopharmacology* 1987; 93: 207-13.
756. Liebman J, Neale R. Neuroleptic-induced acute dyskinesias in squirrel monkeys: correlation with propensity to cause extrapyramidal side effects. *Psychopharmacol* 1980; 68: 25-9.
757. Liebman JM. Tetrabenazine and dystonia in primates. *Ann Neurol* 1986; 19: 203-4.
758. Neale R, Gerhardt S, Fallon S, Liebman JM. Progressive changes in the acute dyskinetic syndrome as a function of repeated elicitation in squirrel monkeys. *Psychopharmacol* 1982; 77: 223-8.
759. Haggstrom JE, Anderson U, Gunne LM. A primate model for tardive dyskinesia: postmortem biochemical findings. In: Perris C, Struwe G, Jansson G, eds., *Developments in Psychiatry*, vol. 5, *Biological Psychiatry*. Elsevier/North Holland, Biomedical Press, Amsterdam, 1981; pp 837-9.
760. Gunne L-M, Barany S. Haloperidol-induced tardive dyskinesia in monkeys. *Psychopharmacology* 1976; 50: 237-40.
761. Cadet JL. Participation of the serotonin₂ receptor in the iminodipropionitrile-induced dyskinetic syndrome. *Exp Neurol* 1988; 99: 589-93.
762. Gray LE Jr, Rogers JM, Kavlock RJ, Ostby JS, Ferrell JM, Gray KL. Prenatal exposure to the fungicide dinocap causes behavioral torticollis, ballooning and cleft palate in mice, but not in rats or hamsters. *Teratogen Carcinogen Mutagen* 1986; 6: 33-43.
763. Cutting W, Furst A, Read D, Read G, Parkman H. Circling syndrome produced by dimethylaminoheptose reductone. *Proc Soc Exp Biol Med* 1960; 104: 381-5.
764. Read D, Furst A, Cutting W. Effect of chlorpromazine and thiouracil on the circling syndrome produced in mice by dimethylaminoheptose reductone. *Stanford Med Bull* 1960; 18: 125-8.
765. Kunstler I, Naumann S, Kaup F-J. Torticollis in cats: etiology, pathology, diagnosis and therapy. *Berl Munch Tierarztl Wochenschr* 1986; 99: 14-9.
766. Burke RE, Fahn S. Electroencephalographic studies of chlorpromazine methiodide and somatostatin-induced barrel rolling in rats. *Exp Neurol* 1983; 179: 704-13.
767. Burke RE, Fahn S. Chlorpromazine methiodide acts at the vestibular nuclear complex to induce barrel rotation in the rat. *Brain Res* 1983; 288: 273-81.
768. Rotrosen J, Stanley M, Kuhn C, Wazer D, Gershon S. Experimental dystonia induced by quaternary-chlorpromazine. *Neurology* 1980; 30: 878-81.
769. Mori K, Shimabukuro H, Yamashiro K, Miyake H, Kawano T. Spasmodic head movements produced by destruction of unilateral ventromedial tegmentum in cats. *Appl Neurophysiol* 1985; 48: 347-50.
770. Arushanyan EB, Dutov AA. Effect of DOPA and haloperidol on experimental mesencephalic torticollis and its modulation by caudate nucleus stimulation. *Farmakol Toksikol* 1983; 46: 24-8.
771. Malouin F, Bedard PJ. Frontal torticollis (head tilt) induced by electrolytic lesion and kainic acid injection in monkeys and cats. *Exp Neurol* 1982; 78: 551-60.
772. Malouin F, Bedard PJ. Evaluation of head motility and posture in cats with horizontal torticollis. *Exp Neurol* 1983; 81: 559-70.
773. Fukushima-Kudo J, Fukushima K, Tashiro K. Rigidity and dorsiflexion of the neck in progressive supranuclear palsy and the interstitial nucleus of Cajal. *J Neurol Neurosurg Psychiatry* 1987; 50: 1197-1203.
774. Jacquet YF, Abrams GM. Postural asymmetry and movement disorder after unilateral microinjection of adrenocorticotropin 1-24 in rat brainstem. *Science* 1982; 218: 175-7.
775. Jacquet YF. "Dystonia"-like postural asymmetry after microinjection of ACTH N-terminal fragments but not after ACTH 1-39 in rat brainstem suggests role of neuropeptide mutation in genetic movement disorders. *Brain Res* 1984; 294: 144-7.
776. Sandyk R, Consroe P. The relationship of peripheral trauma and pain to dystonia. *J Neurol Neurosurg Psychiatry* 1986; 49: 845.
777. Imperato A, Nicoletti F, Diana M, Scapagnini U, Di Chiara G. Fastigial influences on postural tonus as studied by kainate lesions and by local infusion of GABAergic drugs in the rat. *Brain Res* 1984; 295: 51-63.
778. Sambrook MA, Crossman AR, Slater P. Experimental torticollis in the mormoset produced by injection of 6-hydroxydopamine

- into the ascending nigrostriatal pathway. *Exp Neurol* 1979; 63: 583-93.
779. McGeer PL, McGeer EG. Intracerebral injections of kainic acid and tetanus toxin: possible models for the signs of chorea and dystonia. *Adv Neurol* 1978; 21: 331.
780. Stoddart JC. Pseudotetanus. *Anesthesia* 1979; 34: 877-81.
781. D'Angelo LJ, Beary JF III, Stair T. Tetanus mimicking "pseudotetanus". *South Med J* 1984; 77: 1052.
782. Crossman AR, Sambrook MA, Jackson A. Experimental hemichorea/hemiballismus in the monkey. Studies on the intracerebral site of action in a drug-induced dyskinesia brain. *Brain* 1984; 107: 579-96.
783. McGeer PL, Itagaki S, McGeer EG. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. *Acta Neuropath* 1988; (in press).
784. Sandyk R, Iacono RP, Bamford CR. Hypothalamic dysregulation of immune responses in focal dystonia. *Acta Neurol Scand* 1987; 75: 440.
785. Mizukawa K, McGeer PL, Tago H, Peng JH, McGeer EG, Kimura H. The cholinergic system of the human hindbrain studied by choline acetyltransferase immunohistochemistry and acetylcholinesterase histochemistry. *Brain Res* 1986; 379: 39-55.
786. Vincent SR, Satoh K, Armstrong DM, Panula P, Vale W, Fibiger HC. Neuropeptides and NADPH-diaphorase activity in the ascending cholinergic reticular system of the rat. *Neuroscience* 1986; 17: 167-82.